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Background 
Vagus nerve stimulation (VNS) is used to treat medically refractory epilepsy. Despite 
years of basic and clinical research it is still not clear why patients develop epileptic 
seizures and why VNS can reduce these seizures. In this thesis the results of scientific 
experiments aimed at exploring the pathophysiology of epilepsy and at establishing 
the effectiveness of VNS in a clinically relevant animal model for epilepsy are 
described.  
Epilepsy 
Epilepsy is a syndrome that is characterized by recurrent unprovoked seizures which 
are due to occasional, excessive or abnormal synchronous firing of neurons1. Patients 
are diagnosed after clinical observation and electro-encephalographic (EEG) 
recording of brain activity. It is the second most common neurological disorder after 
stroke, affecting approximately 1% of the world’s population2.  
Epileptic seizures that originate in a specific part of the brain are referred to as partial 
seizures while seizures in which both hemispheres participate are referred to as 
generalized seizures. Partial seizures can be subdivided into simple, in which 
consciousness remains unaffected (e.g. clonic  movement in one limb), and complex 
in which consciousness is impaired (e.g. complex partial seizure). Often a partial 
seizure secondarily spreads through the brain evolving into a generalized seizure. 
This is called secondary generalization. 
Pathophysiology of epilepsy 
Interleukin 1 
Why neurons start to fire synchronously in epilepsy patients is not known. The most 
important risk factors for developing epilepsy are febrile seizures (FS)3, brain trauma4 
and stroke5. These conditions are associated with increased levels of the pro-
inflammatory cytokine interleukin-1 beta (IL-1β)6-8. It is thought that IL-1β contributes 
to, or even initiates epileptogenesis9.  
For long it was thought that the brain is deprived of immune cells, being protected 
by the blood brain barrier (BBB). Research over the past twenty years has revealed 
that the brain has an immune system of its own, mainly represented by microglial 
cells. These cells are able to produce IL-1 and other immunological mediators, and do 
so when neurons are threatened, for instance in stroke7, traumatic brain injury8 and 
epilepsy10-12. The seizure-induced IL-1β expression13-17 most likely results from the 
release of heath shock proteins (HSP) during the seizure that activate Toll-like 
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receptors (TLR) which in turn induce IL-1β production via activation of nuclear factor 
kappa B (NFκB)18-20 (Figure 1.1). Activation of NFκB also induces expression of other 
proteins, amongst others the ceramide transporter (CERT, also known as the 
Goodpasture antigen binding protein) a protein involved in intracellular transport of 
ceramide21.  
Besides local seizure-induced IL-1β production it has been shown recently that the 
BBB is leaky in many neurological conditions including epileptic seizures, exposing 
the cells to circulating cytokines as well22,23 (Figure 1.1).  
After entering the central nervous system (CNS) via either the leaky BBB or local 
production, IL-1β can affect functioning of neurons after binding to its receptor (IL-1 
receptor type I, IL-1RI). This is followed by association with an accessory protein (AcP) 
after which intracellular signal transduction cascades are activated. These cascades 
can affect amongst others N-methyl-D-aspartic acid receptor (NMDA-R) 
phosphorylation, IL-6 production, Ca2+ influx, K+ efflux, alpha-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid receptor (AMPA-R) function and the balance 
between gamma-aminobutyric acid (GABA) and glutamate24-32. Some of these IL-1β 
dependent mechanisms bring the neuron in a state more favorable for 
depolarisation, for example NMDA-R phosphorylation29, augmented Ca2+ influx31 and 
restrained K+ efflux33, and may contribute to increased seizure susceptibility and the 
actual development of a subsequent seizure by causing cellular hyperexcitability 
(Figure 1.1). 
Calcium 
In addition to IL-1β, several other mechanisms appear to play a role in seizure 
generation and the pathophysiology of epilepsy. A well-established factor in this 
regard is intracellular free calcium. The process of epileptogenesis, the process that 
transforms a normal brain into a hyperexcitable brain, is characterized by high 
intracellular calcium levels. While irreversible elevations in intracellular free calcium 
levels result in neuronal death, a prolonged but reversibly high intracellular calcium 
concentration can trigger pathological neuronal plasticity, leading to the 
development of epilepsy34 (Figure 1.1).  
Stroke, brain injury and several other conditions associated with epilepsy are 
characterized by high intracellular calcium levels. These high calcium levels are the 
result of excessive release of glutamate, leading to activation of the NMDA-R and 
calcium influx35 (Figure 1.1). Glutamate excitotoxicity occurs in all stroke or traumatic 
brain injury patients, and is unclear why some of them develop epilepsy, while the 
majority does not.  
 Introduction⏐11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Scheme depicting seizure-induced actions of IL-1β in the brain. If a seizure evolves in a status 
epilepticus this can cause glutamate excitotoxicity, that is associated with the release of 
heath shock proteins (HSPs). HSPs are endogenous ligands for the Toll like receptors which in 
turn induce NFκB production. NFκB stimulates the neurons to produce IL-1β. 
Simultaneously, the blood brain barrier becomes disrupted during a seizure and during 
status epilepticus. This leads to entrance of macromolecules and leucocytes from the general 
circulation which either activate microglial IL-1β expression, or express IL-1β themselves.  
 When this seizure-induced IL-1β signal is picked up by IL-1 receptors on neurons, a cascade 
of events is initiated: firstly upregulation of the Src family of kinases occurs, which increase 
the degree of phosphorylation of the NDMA-R, in turn leading to augmented calcium influx. 
This ultimately causes cellular hyperexcitability for as long as the NMDA-R are letting more 
calcium in. In many epilepsy models, especially those that are based on status epilepticus, 
other cascades contribute to hyperexcitability as well. Glutamate excitotoxicity that occurs 
during status epilepticus leads to excess activation of NMDA-R, resulting in massive calcium 
influx into the neurons. Neuronal death occurs if the intracellular calcium concentrations 
remain chronically elevated, while reversible high calcium levels cause sprouting. Neuronal 
death and sprouting lead to network changes, ultimately resulting in network 
hyperexcitability. If both network hyperexcitability and cellular hyperexcitability are present, 
it is likely that network hyperexcitability contributes more to epileptogenesis than cellular 
hyperexcitability caused by IL-1β. When a seizure is less severe with regard to excitotoxicity, 
the contribution of seizure-induced IL-1β may be relatively bigger. 
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Antiepileptic treatment 
The majority of epilepsy patients is seizure free with classic antiepileptic drugs such 
as carbamazepine and valproate, but 25% is medically refractory36,37. For them, 
several treatment options are available. First of all the ketogenic diet can be used to 
treat children with refractory epilepsy, resulting in >50% seizure frequency reduction 
in 38% of children versus in 6% of controls38. Secondly, resective neurosurgery is an 
option in a small number of patients that can be cured from epilepsy by removing 
the part of the brain where the seizures originate without damaging eloquent brain 
areas. In the majority of medically refractory epilepsy patients this is not possible.  
Consequently, there are still many medically refractory epilepsy patients. Scientists 
have been searching for other ways to treat these patients; over the past 25 years this 
has lead to the development of several different antiepileptic drugs such as 
lamotrigine, zonisamide and levetiracetam39-43, but also to neuromodulative 
treatments such as deep brain stimulation44 and VNS. 
Evaluation of the effectiveness of an antiepileptic treatment in general relies on 
seizure-diaries that are kept by patients or caretakers. A patient that has >50% 
reduction in seizure frequency after treatment compared to baseline is generally 
considered a responder.  
Vagus nerve stimulation 
VNS consists of continuous cyclic electrical stimulation of the left vagus nerve in the 
neck. During a <60-minute surgical procedure, a helical electrode (Figure 1.2) is 
wrapped around the nerve and connected to a subcutaneously placed pulse 
generator (Figure 1.3). Actual stimulation (a 30-second train of 30 Hz, 0.25 – 0.5 ms 
block pulses with an intensity of 0.25 - 2.5 mA) is followed by a 5-minute stimulation-
free interval.  
Randomized controlled trials report >50% seizure frequency reduction in 22-39% of 
adult patients within the first three months of treatment45,46. After correcting these 
data for placebo effect and natural course of the disease, >50% seizure frequency 
reduction is reached in 11.7%.  
Stimulation-induced side effects are generally mild, consisting of vocal cord paralysis 
(hoarseness) a strange feeling in the throat (can be painful), neck pain and difficulty 
swallowing47. Surgical complications consist of infection, bleeding, (transient) vocal 
cord paralysis, and Horner’s syndrome. Hardware failure can occur as well, most often 
lead damage48,49. VNS does not have the negative effects on mood, cognition and 
behavior often found after antiepileptic drug treatment. VNS on the contrary even 
appears to have a positive effect on mood in epilepsy patients50. This observation 
was followed by studies on VNS in depressive patients but a true antidepressant 
effect has not been established51. Behavioral function also appears to improve after 
VNS52.  
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The vagus nerve 
The vagus nerve is the 10th cranial nerve, and mainly known by its parasympathetic 
function. Besides this efferent visceromotor function, that is carried out by only 20% 
of the vagus nerve fibers, the nerve contains efferent motor fibers, afferent 
exteroceptive sensory fibers, afferent viscerosensory fibers, and afferent taste fibers. 
The majority of nerve fibers (90% of the afferents and 70% of the efferents) are 
unmyelinated C-fibers53.  
The efferent parasympathetic fibers that innervate organs in the thoracic and 
abdominal cavity, originate in the visceromotor dorsal nucleus of the vagus nerve 
(DMV). The efferent motor fibers that innervate muscles of the larynx and pharynx, 
originate in the nucleus ambiguus (AMB). The afferent viscerosensory and pure 
sensory fibers end in the nucleus of the solitary tract (NTS), while the afferent 
exteroceptive sensory fibers end in the spinal trigeminal nucleus (Table 1.1).  
Fibers originating in or projecting to the AMB, DMV and NTS, respectively, unite 
dorsally from the olivary nucleus and leave/enter the brain stem between the olivary 
nucleus and the cerebellar peduncle. Just prior to leaving the skull through the 
jugular foramen, the superior ganglion of the vagus nerve is found, containing the 
cell bodies of the exteroceptive nerve fibers. These fibers transmit sensory 
information from the infratentorial dura mater and skin of the external acustic 
meatus and part of the concha of the ear to the spinal trigeminal nucleus. The vagus 
nerve subsequently exits the skull via the jugular foramen, together with the 
glossopharyngeal and accessory nerves and sigmoid and inferior petrosal sinusses. 
Immediately outside the skull the nodose ganglion is found, containing cell bodies of 
the viscerosensory and pure sensory fibers that transmit information from the organs 
and larynx/pharynx to the NTS (Figure 1.4).  
The vagus nerve subsequently courses between the internal and communal carotid 
artery and the internal and communal jugular vein in the neck where it gives off four 
(groups of) branches. 1) The motor fibers that innervate the pharyngeal muscles as 
well as sensory fibers that originate in the pharynx mucosa and in trachea, 
esophagus and epiglottis constitute the pharyngeal branches. 2) The motor fibers 
that innervate the m. cricothyroideus and the sensory fibers that originate in the 
laryngeal mucosa constitute the superior laryngeal nerve. 3) The recurrent laryngeal 
nerve that contains fibers that innervate all muscles of the larynx except the m. 
cricothyroideus, as well as fibers that transmit sensory information from the mucosa 
of the pharynx below the level of the vocal cords to the NTS. 4) The parasympathetic 
fibers that originate in the DMV course via the superior and inferior cervical cardiac 
branches to the heart. The superior branches leave the vagus nerve at variable levels 
but in general at the level of the parotid gland. They end in a large parasympathetic 
plexus of the heart: the cardiac plexus. One of these branches also contains 
viscerosensible fibers that transmit information regarding the aortic wall-tension and 
can cause blood pressure to fall. The inferior cardiac branches either leave the vagus 
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nerve itself or branch off the recurrent laryngeal nerve and also end in the cardiac 
plexus.  
After these four groups of branches have left the vagus nerve, it loses its character as 
a single nerve and subdivides into a number of plexi and rami: the pulmonal plexus, 
the esophageal plexus, the gastric rami, the hepatic rami, the coeliac rami and the 
renal rami. 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Bipolar electrode used for vagus Figure 1.3 Pulse generator  
 nerve stimulation in humans.   (Courtesy of Cyberonics Inc.) 
 (Courtesy of Cyberonics, Inc.) 
 
Table 1.1 Functions of the vagus nerve. 
Afferents Nucleus Vargus target organs Nerve efferents Nucleus Target organs 
Exteroceptive spinal 
trigeminal 
nucleus 
dura mater posterior fossa  
skin concha ear  
skin meatus acusticus externus 
Motor AMB larynx-pharynx 
muscles 
Viscerosensory NTS organs in thorax and abdomen Visceromotor DMV organs in thorax  
and abdomen 
Sensory NTS pharynx  
epiglottis 
oesophagus 
trachea 
   
 
 
With regard to the mechanisms of action of VNS and to the IL-1β-hypothesis in 
epilepsy, a recently discovered function of the vagus nerve is of particular interest. 
The vagus nerve carries out the cholinergic anti-inflammatory reflex, by which the 
CNS can modulate peripheral IL-1β expression54. Afferent vagus nerve fibers signal 
the CNS when circulating macrophages produce more IL-1β (and other pro-
inflammatory markers). As a result of this afferent vagal signal, the efferent vagus 
nerve is activated. This results in the release of acetylcholine, which immediately 
triggers the α7 subunit of the nicotinic receptor on activated macrophages. These in 
turn decrease peripheral IL-1β production. It is not clear whether activation of the 
afferent vagus nerve induces a similar immunosuppressive effect inside the CNS as 
well. 
 Introduction⏐15 
 
Figure 1.4 Anatomy of the vagus nerve. Netter illustration used with permission of Elsevier, Inc. All 
rights reserved. www.netterimages.com. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vagus Nerve (X): Schema
Glossopharyngeal nerve (IX)
Meningeal branch of vagus nerve
Auricular branch of vagus nerve
Auditory (pharyngotympanic, Eustachian) tube
Levator veli
palatini muscle
Salpingopharyngeus
muscle
Palatoglossus muscle
Palatopharyngeus
muscle
Superior pharyngeal
constrictor muscle
Stylopharyngeus muscle
Middle pharyngeal constrictor muscle
Inferior pharyngeal constrictor muscle
Cricothyroid muscle
Trachea
Esophagus
Right subclavian artery
Right recurrent laryngeal nerve
Heart
Cranial root of
accessory nerve* 
(see next plate)
Posterior nucleus of vagus 
nerve (parasympathetic 
and visceral afferent)
Spinal tract and spinal
nucleus of trigeminal nerve
(somatic afferent)
Solitary tract nucleus (visceral
afferents including taste)
Nucleus ambiguus
(motor to pharyngeal
and laryngeal muscles)
Vagus nerve (X)
Jugular foramen
Superior ganglion of vagus nerve
Inferior ganglion of vagus nerve
Pharyngeal branch of vagus nerve (motor to muscles of
palate and pharynx; sensory to lower pharynx)
Communicating branch of vagus nerve to
carotid branch of glossopharyngeal nerve
Pharyngeal plexus
Superior laryngeal nerve:
Internal branch (sensory and parasympathetic)
External branch (motor to cricothyroid muscle)
Superior cervical cardiac branch of vagus nerve
Inferior cervical cardiac branch of vagus nerve
Thoracic cardiac branch of vagus nerve
Left recurrent laryngeal nerve (motor to muscles of larynx
except cricothyroid; sensory and parasympathetic to
larynx below vocal folds; parasympathetic, efferent, and
afferent to upper esophagus and trachea)
Pulmonary plexus
Hepatic branch of anterior
vagal trunk (in lesser omentum)
Celiac branches from anterior
and posterior vagal trunks
to celiac plexus
Celiac and superior mesenteric
ganglia and celiac plexus
Hepatic plexus
Cardiac plexus
Esophageal plexus
Gallbladder
and bile ducts
Liver
Pyloric branch
from hepatic plexus
Pancreas
Anterior vagal trunk
Gastric branches of anterior vagal trunk
(branches from posterior trunk behind stomach)
Duodenum
Ascending colon
Vagal fibers (parasympathetic motor,
secretomotor, and afferent fibers) accompany
superior mesenteric artery and its branches
usually as far as left colic (splenic) flexure
Small intestine
Cecum
Appendix
Efferent fibers
Afferent fibers
Parasympathetic fibers
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C-fiber activation is not required for obtaining an anticonvulsive effect55. This implies 
that only 14% of vagus nerve fibers, consisting of myelinated A and B fibers that are 
normally involved in mediating reflexes56, are responsible for the anticonvulsive 
effect. 
Animal models for epilepsy 
Animal models are and have been used to test novel antiepileptic drugs and to 
unravel the pathophysiology of epilepsy. Several types of animal models are 
available. They can roughly be divided into seizure models and epilepsy models. 
Seizure models 
Chemical seizure models are models in which a single seizure is induced by 
administration of a chemical substance such as kainate, phenylenetetrazol or 
bicuculline. In electrical seizure models a single seizure is induced by electrical 
stimulation of the brain, for instance through ear-clip electrodes or corneal 
electrodes. Infection induced seizure models are models in which a single seizure is 
provoked using pertussis vaccine or shigella dysenteria toxin. In fever induced 
seizure models lipopolysaccharide is injected to provoke fever followed by 
administration of a subconvulsive dose of kainate to provoke a single seizure. Major 
drawback of the seizure models is the fact that they mimic a single seizure, not 
epilepsy.  
Epilepsy models 
In chemical epilepsy models a status epilepticus is induced by administration of a 
high dose of a chemical substance such as kainate, pilocarpine or bicuculline. 
Spontaneous seizures start to develop later. In this latent period between status 
epilepticus and the first spontaneous seizure, epileptogenesis takes place. Status 
epilepticus can also be provoked by electrical stimulation of the hippocampus or 
amygdala. Similarly to the chemical epilepsy models, in these electrical epilepsy 
models spontaneously recurring seizures start later, after epileptogenesis has taken 
place in the latent period. These models are especially useful to study 
epileptogenesis itself. Major drawback of both electrical and chemical epilepsy 
models is the fact that either the chemical and the status epilepticus themselves can 
cause major neuronal damage by glutamate excitotoxicity that is generally not 
present in the brains of humans with epilepsy.  
In kindling, chemicals or electrical stimulation are used as well but instead of using 
these stimuli to provoke a severe status epilepticus, repetitive subthreshold stimuli 
(either chemical or electrical) are administered at fixed intervals. These stimuli 
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eventually lead to a decreased seizure-threshold which results in the occurrence of a 
seizure upon administration of the (previously subthreshold) stimulus. The 
disadvantages of the kindling models are that there is no seizure-free latent phase to 
study epileptogenesis in, and that most seizures occur after stimulation and not 
spontaneously, as is the case in the human situation. Spontaneous seizures do occur, 
but at a low frequency, generally too low to be useful in an experimental setup to 
evaluate treatment effects.  
A number of genetic epilepsy models are available. Most of them model absence 
epilepsy.  
Exposing rat pups to hyperthermia evokes febrile seizures (FS) in a subpopulation of 
rats. A subpopulation of these FS rats develops spontaneous seizures in later adult 
life. The advantage of this animal model is that it is directly linked to the situation in 
humans, where a significant number of temporal lobe epilepsy (TLE) patients have a 
history of febrile seizures, making FS the most important risk factor for developing 
temporal lobe epilepsy (still the majority of patients that suffer from FS will never 
develop epilepsy). The disadvantage is that a large number of rats is required in order 
to collect a sufficient number of epileptic animals to study treatment effects in. 
Amygdala kindling  
In the experiments that have been carried out for this thesis, the amygdala kindled 
(AK) rat was used57. This is one of the electrical animal models for epilepsy that is 
based on daily subthreshold stimulation of the left basolateral amygdala (Figure 1.5) 
and has been used frequently in the past and present to study the pathophysiology 
of TLE58 and to study treatment effects of novel antiepileptic drugs59. For kindling, 
animals are implanted with an electrode in the left amygdala and connected to an 
external stimulator and a stimulus consisting of 50 Hz, 0.2 ms block pulses with an 
intensity of 400 μA is administered to the amygdala for two seconds. These twice 
daily kindling stimuli provoke seizures of increasing severity, graded on a five-point 
scale first described by Racine (Table 1.2)57. 
 
The kindling model was chosen for a number of reasons. First of all we aimed at a 
model that mimics the clinical features of the most frequently occurring type of 
epilepsy, TLE57. Furthermore, seizures evoked by kindling are often resistant to 
phenytoin, a phenomenon often encountered in human TLE as well60. Thirdly we 
aimed at a model that mimics the histopathological changes seen in TLE61. Fourthly 
we wanted to avoid all models that are associated with major neuronal damage since 
this would interfere with our immunological studies involving IL-1β 62. Since we did 
not have the video/EEG equipment to monitor the animals continuously, 24 hours 
per day, 7 days per week, that is required when animals that have spontaneously 
recurring seizures are used, we chose a model for chronic epilepsy in which all 
seizures are provoked.  
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Figure 1.5 Amygdala kindling: Coronal section of a rat brain (A) showing the location of the electrode 
tip in a microscopic picture of a brain slice in which the basolateral amygdala is visualized 
using hematoxylin-eosin (B). 
 
Table 1.2 Racine’s scale. 
Stage Seizure behavior 
1 mild facial clonus 
2 severe facial clonus 
3 unilateral forelimb clonus 
4 bilateral forelimb clonus, rearing 
5 rearing, loss of balance, falling 
 
Animal models for vagus nerve stimulation 
The first animal study on VNS was published in 1952 63. Between that year and 1997, 
the year of FDA approval, it had been tested in a number of animal studies in which 
single seizures were treated with a short train of VNS, when the animal was 
anesthetized64-68. Only one study dating from this period was conducted in freely 
moving animals suffering from experimental epilepsy69. These studies generally 
confirm the effectiveness of VNS and do not focus on possible mechanism of action.  
The first studies in which the mechanism of action of VNS was explored date from the 
late 1990-s, when Krahl et al. described that the locus coeruleus played a crucial role 
in the anticonvulsant effect of VNS70. The same group showed a couple of years later 
that C-fiber activation was not required for the anticonvulsive effect of VNS55. The 
third paper on this subject from the same period by Zagon and Kemeny focused on 
the hyperpolarizing effect of VNS on cortical neurons as a possible mode of action71.  
Even though more studies on VNS in animal models have been published, all the 
others focus on the effectiveness and not on the mechanism of action72-79; all studies 
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except one using Genetic Absence Epilepsy Rats from Strassbourg (GAERS)76 show 
that VNS is effective in reducing the severity or duration of one or more seizures.  
Apart from the studies in animal models for seizures, a number of papers has been 
published in which VNS was applied in otherwise healthy animals to evaluate the 
effect on the EEG pattern63, cognitive function and memory80-82 or for feasibility 
purposes83. The past five years more scientists have shown interest in the 
anticonvulsive mode of action of VNS, resulting in a number of papers focusing on 
VNS-induced activity in the locus coeruleus84, thalamus85,86, NTS87,88, cortex89,90 and 
hippocampus91,92.  
In the experiments that were carried out for this thesis, VNS was performed using a 
custom-made circular electrode (Figure 1.6) that was wrapped around both left 
carotid artery and vagus nerve of the rats. The lead of the electrode was tunneled 
subcutaneously and fixed to the cranium of the rat with a connector for connecting 
the animal to an external stimulator. 
 
 
 
Figure 1.6 Vagus nerve electrode (photograph by P. Van Venrooij and V. Duysens, developers of the 
electrode at Medtronic Bakken Research Center, Maastricht, The Netherlands). A: lateral 
view; B: ventral view. Green suture is used for surgical placement. 
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Scope and aims of the study 
The aims of the present study were to gain more insight into the pathophysiology of 
epilepsy with regard to both IL-1β and calcium, and to develop a clinically relevant 
animal model in which the mode of action of VNS can be studied. 
Chapters 2, 3 and 4 are dedicated to the pathophysiology of epilepsy while the 
studies regarding VNS are described in Chapters 5, 6 and 7.  
In Chapter 2 the existing literature concerning the role of IL-1 in epilepsy is reviewed. 
Based on these data a hypothesis regarding the involvement of IL-1 in the 
pathophysiology of epilepsy is presented. 
In Chapter 3 the involvement of the immune system in the kindling model is 
investigated. We demonstrate that IL-1β is not chronically expressed in this animal 
model, probably because the model is not associated with neuronal damage.  
Some people develop seizures after stroke or traumatic brain injury, while others do 
not. In a similar way, some rats need a low number of kindling stimuli to develop 
epilepsy while others need many more. Apparently seizure thresholds can vary 
between individuals. In Chapter 4 we demonstrate that polymorphisms in genes that 
are involved in calcium homeostasis may contribute to the individual seizure 
susceptibility in rats. 
In Chapter 5 we demonstrate that VNS affects seizures induced by kindling. This 
means that the VNS-treated kindled rat is a clinically relevant animal model in which 
the mechanism of action of VNS can be studied. The primary and secondary 
projection nuclei of the vagus nerve in the brain stem appear to be involved, as we 
immunohistochemically demonstrate in Chapter 6.  
A rare complication of VNS in humans is Horner’s syndrome. In Chapter 7 we describe 
Horner’s syndrome as a complication of vagus nerve electrode placement in rats.  
Finally, in Chapter 8 a summary of the findings described in this thesis is given, and 
implications of these findings are discussed.    
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Abstract 
Interleukin-1 (IL-1) has a multitude of functions in the central nervous system. Some of them involve 
mechanisms that are related to epileptogenesis. The role of IL-1 in seizures and epilepsy has been 
investigated in both patients and animal models. This review aims to synthesize, based on the currently 
available literature, the consensus role of IL-1 in epilepsy.  
Three lines of evidence suggest a role for IL-1: brain tissue from epilepsy patients and brain tissue from 
animal models shows increased IL-1 expression after seizures, and IL-1 has proconvulsive properties when 
applied exogeneously. However, opposing results have been published as well. More research is needed 
to fully establish the role of IL-1 in seizure generation and epilepsy, and to explore possible new treatment 
strategies that are based on interference with intracellular signaling cascades that are initiated when IL-1 
binds to its receptor.  
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Introduction 
In the last decade, the immune system has attracted the attention of many 
investigators in epilepsy research. This has resulted in a still rapidly growing amount 
of information, on involvement of various immunological factors in seizures and 
epileptogenesis. The pro-inflammatory cytokine interleukin-1 (IL-1) is one of the 
immunological factors receiving much attention in this regard. Data from both 
clinical and preclinical research indicate a role for this cytokine in epilepsy.  
The aim of this review is to establish, based on literature so far available, whether IL-1 
is related to increased seizure susceptibility and plays a key role in epileptogenesis, 
or if it is merely a biochemical epiphenomenon of a seizure. If epileptogenesis 
depends on IL-1, this cytokine is an important target for the development of new 
anti-epileptic or anti-epileptogenic therapies. 
Interleukin-1 
Cytokines, soluble mediators that are produced by virtually all cells of the immune 
system and many other cells, regulate the activity of the immune system. Generally, 
cytokines are synthesized and secreted rapidly in response to an antigenic stimulus. 
They have half-lives in the range of minutes. 
Interleukin-1 beta (IL-1β) belongs to the so-called IL-1 family, which further consists 
of interleukin-1 alpha (IL-1α) and interleukin-1 receptor antagonist (IL-1ra). Recently, 
eight new ligands were added: IL-18 1, IL-33 2 and IL-1F5 - IL-1F10 3. IL-1β is one of the 
pro-inflammatory cytokines. Together with other pro-inflammatory cytokines such as 
tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8), IL-1β 
can induce acute inflammation (cytokine cascade, high fever, C-reactive protein 
(CRP) production) in response to infection. IL-1α and IL-1β exert identical agonist 
actions by binding to a receptor called interleukin-1 receptor type I (IL-1RI). IL-1α has 
lower affinity for this receptor than IL-1β, and mainly regulates intracellular events4. 
After binding its ligand, IL-1RI associates with an accessory protein (AcP) which 
activates intracellular signal transduction cascades. Type II interleukin-1 receptor 
(IL-1RII) binds IL-1α and IL-1β as well, but does not initiate signal transduction 
because it lacks an intracellular domain and is thus referred to as decoy receptor. 
IL-1ra is a highly selective, competitive receptor antagonist that binds to IL-1RI as 
well. Unlike IL-1α and IL-1β, IL-1ra is unable to trigger the association with AcP and 
consequently, signal transduction cannot take place. High molar excess (100- to 
1000- fold) of IL-1ra is needed to counteract the effects of IL-1β.  
Thus, at cellular level, the IL-1 response can be controlled by two mechanisms: 1) the 
ratio of IL-1RI/IL-1RII, and 2) the concentration of IL-1 agonists (IL-1α and IL-1β) 
versus that of IL-1ra. 
Four IL-1 ligands are formed as precursors: pro-IL-1α, pro-IL-1β, pro-IL-18 and 
pro-IL-1ra. Pro-IL-1α and pro-IL-1ra are biologically active, while pro-IL-1β and 
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pro-IL-18 need to be cleaved first. Cleaving takes places by the enzyme caspase-1 
(=interleukin-1 converting enzyme, ICE). 
Interleukin-1 in the central nervous system - Where is it located? 
IL-1 in the central nervous system (CNS) either comes from outside, or is locally 
produced by CNS cells. Systemic IL-1 levels are usually very low, but rapidly increase 
in case of inflammation (e.g. during systemic infection). In this situation, diffusion of 
IL-1 into the CNS occurs at the circumventricular organs (lining the third ventricle) 
that lack a blood-brain barrier (BBB). Diffusion can occur outside these 
circumventricular organs, and despite low systemic IL-1 levels as well, in case of a 
leaky or temporarily opened BBB (e.g. after an epileptic seizure5).  
Low basal expression of IL-1RI is found throughout the CNS, on all CNS cells6. In case 
of neuronal injury, IL-1 is rapidly produced by microglia and other CNS cells7. 
Common neurological and psychiatric conditions, such as stroke8, traumatic brain 
injury9, spinal cord injury10, multiple sclerosis11, Down syndrome and Alzheimer 
disease12 are associated with increased CNS production of IL-1β.  
When IL-1 is expressed in the brain, its signal propagates via 3 pathways, described 
by Vitkovic et al.: 1) extracellular diffusion and circulating cerebrospinal fluid (CSF), 2) 
neuronal projections and 3) gap junctions that connect glial cells13.  
Apart from the presence of IL-1 in the CNS (either from diffusion or local production), 
the CNS can also modulate peripheral IL-1 expression through the cholinergic anti-
inflammatory reflex14. An important structure in this reflex is the vagus nerve: its 
afferent fibers signal the CNS when circulating macrophages produce more IL-1β 
(and other pro-inflammatory markers). As a result of this afferent vagal signal, the 
efferent vagus nerve is activated. This results in the release of acetylcholine which 
immediately triggers the α7 subunit of the nicotinic receptor on activated 
macrophages. These in turn decrease IL-1β production. It is not clear whether 
activation of the afferent vagus nerve induces a similar immunosuppressive effect 
within the CNS as well. 
Interleukin-1 in the central nervous system – What are the effects? 
Il-1β has a multitude of actions in the CNS, summarized by Allan et al.15. Binding of 
IL-1β to the IL-1RI on any of the CNS cell types has both neuroprotective and 
neurotoxic effects. Neuroprotective effects take place when IL-1β is present in low 
concentrations, while under pathological circumstances, when IL-1β levels are 
higher, processes leading to neurotoxicity are facilitated by IL-1β. 
When IL-1β binds the neuronal IL-1RI, it  has many effects on, for instance, N-methyl-
D-aspartic acid receptor (NMDA-R) function, IL-6 production, Ca2+ influx, alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) function 
and the balance between gamma-aminobutyric acid (GABA) and glutamate16-24. 
When excessively activated, these IL-1β effects are generally considered to increase 
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neuronal excitability, and the risk of excitotoxicity. At the cellular level, increased 
neuronal excitability means that less current is needed to depolarize the neuron and 
can be caused by an increased inward current and/or a decreased outward current. 
Experimental evidence has shown that, when hippocampal neurons are held at -
40 mV, and then exposed to NMDA and IL-1β simultaneously, the inward current is 
increased25,26, and the outward current is decreased25, compared with hippocampal 
neurons that are subjected to NMDA alone, or to NMDA, IL-1β and IL-1ra. The 
amplitude of the inward current increases because more Ca2+ can enter the cell via 
both the NMDA-R channel and voltage-dependent Ca2+ channels25. In the presence of 
IL-1β, NMDA-R subunits are phosphorylated which leads to increased Ca2+ influx21. 
The amplitude of the outward current is reduced due to IL-1β-mediated inhibition of 
Ca2+-dependent K+ channels26.  
As mentioned above, activation of neuronal IL-1RI is not always associated with risk 
of excitotoxicity. For instance, IL-1β originating from hippocampal neurons may be 
involved in long-term potentiation (LTP), an experimental correlate of memory 
formation27-29, yet externally applied IL-1β inhibits LTP29,30. 
IL-1β can have both neurotoxic and physiologic effects on glial cells as well. In 
astrocytes22,31-35 and microglia36,37, IL-1RI activation initiates the expression of many 
genes, ultimately resulting in astrogliosis15,20, dampening of the neuroinflammatory 
response, and modulation of BBB permeability38.  
Through binding the IL-1RI on oligodentrocytes, IL-1β appears to have mainly 
neuroprotective effects39 that contribute to myelination and to CNS repair40. 
However, neurotoxic effects of IL-1RI activation on oligodendrocytes have been 
reported as well41,42. 
Apart from these direct effects of IL-1β on the different CNS cell types, pro-
inflammatory cytokines in general influence tryptophan metabolism, ultimately 
leading to an increase of the neurotoxic metabolite quinolinic acid, an NMDA 
receptor agonist43. 
Interleukin-1 & epilepsy 
Based on these findings, IL-1β originating peripherally or in the CNS, can modulate 
neuronal excitability, and thus potentially contribute to seizure development or 
epileptogenesis.  
The aim of the current review is to determine, based on the currently available 
literature, whether IL-1 is involved in the process of epileptogenesis, as was 
suggested recently44, or whether it is merely an epiphenomenon. If IL-1 is related to 
increased seizure-susceptibility and/or to epileptogenesis, the modulation of IL-1 
may play a role in the mechanism of action of some of the currently available anti-
epileptic treatments, such as vagus nerve stimulation (VNS) and ACTH/ 
dexamethasone treatment. Moreover, it may be a potential target for development 
of new anti-epileptic treatment strategies. 
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To establish whether there is evidence for a specific role for IL-1 in increased seizure 
susceptibility and epileptogenesis we reviewed all currently available literature on 
this topic. This review concentrates on data from original papers, directly relevant to 
the topic, published in peer-reviewed journals and written in English. Data were 
obtained after searching Pubmed, The Cochrane Library and Embase using 'epilepsy 
AND IL-1', ‘epilepsy AND interleukin-1’, 'seizures AND IL-1' and ‘seizures AND 
interleukin-1’ as key words and after citation tracking in March 2008.  
The Pubmed search resulted in 101 hits for ‘seizures AND IL-1’, 97 hits for ‘seizures 
AND interleukin-1’, 120 hits for ‘epilepsy AND IL-1’ and 114 hits for ‘epilepsy AND 
interleukin-1’. The Embase search resulted in 22 hits for ‘seizures AND IL-1’, 27 hits for 
‘seizures AND interleukin-1’, 19 hits for ‘epilepsy AND IL-1’ and 26 hits for ‘epilepsy 
AND interleukin-1’. The  Cochrane Library search resulted in 0 hits. After counting out 
overlap, 90 papers were left, 36 of which on human material and 54 on animal 
material. 
In epilepsy patients, plasma interleukin-1 levels show no consistent 
change 
The relation between cytokine levels in the CNS and in plasma, has not been 
established yet. Nevertheless, in search of clinically applicable biochemical markers, 
several scientists have attempted to determine IL-1 levels in plasma and IL-1 
production in whole blood of patients that suffer from CNS disease. Concerning 
seizures and epilepsy, 16 papers have been published on this subject.  
Blood cells of epilepsy patients do not consistently produce more IL-1 in response to 
inflammatory stimulation than blood cells of controls45-49. Moreover, no consistent 
changes have been found in plasma levels of any of the IL-1 family members in 
patients with epilepsy (see Table 2.1), nor in children with febrile seizures (FS)46,49-58.  
Anti-epileptic treatment does not affect IL-1α and IL-1β production by mononuclear 
cells48, nor plasma levels of IL-1β and IL-1ra49. Although no data are available on IL-1 
levels after vagus nerve stimulation (VNS) in epileptic patients, VNS did not affect 
plasma IL-1β levels in depressed patients59. Anti-inflammatory drugs are sometimes 
used to treat (childhood) epilepsy. No data are available on IL-1 changes after such 
treatment. However, recently a systematic review has been published in which no 
evidence was found for the efficacy or safety of corticosteroid treatment for 
childhood epilepsy60.  
Perhaps these results reflect the real situation. On the other hand, differences in 
methods may account for the inconsistent results as well. For example, ELISA kits that 
were used varied in sensitivity and detection levels (see Table 2.1). Other limitations 
are: differences in time interval between FS or epileptic seizure and time of blood 
collection, short half-life of IL-1, small patient number, the use of different controls 
and of different epilepsy syndromes or causes of seizures, the lack of information on 
comorbidity or drug use.  
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Nevertheless, it is important to continue determination of plasma IL-1 levels in 
epilepsy patients. If consistent differences are found between patients and controls, 
between different types of epilepsies or between responders to anti-epileptic 
treatment and non-responders, IL-1 could be used as biochemical marker or 
predictor, e.g. for response to anti-epileptic treatment. 
Interleukin-1 is present in the brain of epilepsy patients, but not in 
cerebrospinal fluid 
The majority of CSF is produced by the choroid plexus (60%), but it also consists of 
fluid derived from the capillary bed (30%), and ‘metabolic water’ (10%). Metabolic 
water contains substances that have not been recaptured following liberation by 
CNS cells. Therefore, the association between CNS cytokine levels and CSF cytokine 
levels is a stronger one than the association between CNS cytokine levels and plasma 
cytokine levels. However, IL-1 determination in CSF is difficult. This is illustrated by 
the fact that of the seven studies published on this subject (summarized in Table 
2.2)51-54,56,57,61, only four report on detectable IL-1β levels51-53. Of these four, three 
studies were unable to find statistically significant differences between patients and 
controls, while one reported on increased IL-1β levels in children with FS53. Reasons 
for these scarce results are similar to the reasons mentioned above on plasma 
studies: ELISA kits that were used varied in sensitivity and detection limit (see Table 
2.2), studies differed in time interval between seizure and time of CSF collection, IL-1 
has a short half life, small patient number, the use of different controls and of 
patients suffering from different epilepsy syndromes, and the lack of information on 
comorbidity or drug use. Moreover, ELISA kits are generally developed for 
determinations in plasma, not in CSF.  
Changes in IL-1 mRNA expression in brain tissue of epilepsy patients gives the most 
direct information on involvement of IL-1 in epilepsy. However, brain tissue is more 
difficult to obtain than CSF or plasma, and therefore even less studies (n=3) have 
been published on this subject62-64.  
These three studies have revealed that several of the IL-1 family members are present 
in epileptic brain tissue in temporal lobe epilepsy (TLE)62,63, chronic focal encephalitis 
(CFE, also known as Rasmussen encephalitis)63, and in epileptogenic cortical 
malformations64. In TLE, the IL-1α positive cells had morphological characteristics of 
microglia and were mainly located adjacent to neurons in layer V of the temporal 
cortex, while in the cortical malformations IL-1 positive astrocytes and neurons were 
found as well. In this last study, the number of IL-1β positive cells was positively 
correlated with seizure frequency, while the number of IL-1ra positive cells was 
negatively correlated with epilepsy duration prior to surgery. These important 
findings were not mentioned in the other two papers. No expression of IL-1β, IL-1RI, 
IL-1RII and IL-1ra was found in perilesional cortex from the same patients or in cortex 
tissue from autopsy specimens.  
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Entrance of IL-1 through a leaky BBB (caused by a recent seizure) may have been the 
source of the increased IL-1α 62 and IL-1β 64. This assumption would be more likely if 
IL-1 was expressed in the parenchyma surrounding blood vessels as well as in 
neurons and astrocytes around blood vessels, similar to the post-seizure localization 
of albumin in the study by Van Vliet et al.5. This was not specifically mentioned in 
these two studies.  
As already addressed by the authors of these papers, it is not clear whether the IL-1 
expression is intrinsic to the lesions or induced by the seizures. The fact that normal 
perilesional cortex samples did not express IL-1 suggests that seizures alone are 
unlikely to be responsible. However, time interval between sample collection and last 
seizure (which is not mentioned) may have been too long for seizure-induced IL-1 to 
be still present.  
Single nucleotide polymorphisms in interleukin-1 genes may be 
associated with epilepsy  
Genes for IL-1α, IL-1β and IL-1ra are all located in a gene cluster on the long arm of 
chromosome 2 (2q12-13 region). Many common polymorphisms in this gene cluster 
have been described, and some of them are associated with increased levels of 
circulating cytokines. Because of the association of FS with inflammation, 
polymorphisms in the IL-1 gene cluster have been studied in relation to FS. Because 
of the suggested association between FS and TLE, the frequency of some of these 
polymorphisms has been investigated in TLE patients as well. All studies that have 
been performed so far, are association studies. Linkage studies have not yet been 
published.  
The polymorphisms that have been studied are: two C-to-T transitions, one at 
position -511 (IL-1B-511, promotor region, designated as rs16944), and one at 
position +3953 (IL-1B+3953, exon 5, designated as rs1143634) of the IL-1β gene, and 
two common polymorphisms, one at position -889 (IL-1A-889) of the IL-1α gene, 
giving rise to alleles 1 and 2, and one in the second intron of the IL-1RN gene 
(encoding IL-1ra). 
No consistent data are available on the frequency of any of these polymorphisms in 
FS46,65-70.  
The studies on these polymorphisms in relation to epilepsy are summarized in Table 
2.3. Kauffman et al.71 recently systematically analyzed the data from the studies on 
the frequency of IL-1B-511 allele 2 (T) in TLE66,69,72-77. They calculated a significantly 
increased risk of developing TLE with hippocampal sclerosis for IL-1B-511 allele 2 
homozygotes71. Interestingly, this polymorphism is associated with increased IL-1β 
expression78. 
The role of polymorphisms in the IL-1A-889 gene, in the IL-1B+3953 gene and in the 
IL-1RN gene in epilepsy is still undetermined72,74,77,79. More studies, in larger patient 
groups with the same genetic background and similar control groups are needed.  
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Interleukin-1 is present in most animal models for seizures and 
epilepsy  
IL-1 mRNA or IL-1 protein expression in the brains of experimental animal models for 
seizures and for epilepsy, has been investigated by a number of groups. The 19 
different animal models that have been used for this, comprise both models for 
seizures and models for epilepsy, in which either chemical, electrical, or other stimuli 
are used to induce seizures. 
Chemically induced seizures are associated with increased CNS IL-1 expression  
The 15 studies in which seizures were induced by administration of a chemical 
substance (often a neurotoxin) are summarized in Table 2.4. They all report about 
increased cerebral levels of IL-1α, IL-1β or IL-1ra80-94. Protein levels as well as mRNA 
expression levels were increased, and in most studies these increases were acute and 
transient. The location of IL-1 expression correlated with the location of neuronal 
injury, with which many of the chemical seizure models are associated. Chronic 
increases were found in trimethyltin (TMT)-induced seizures90 (IL-1α mRNA levels 
remained increased up to eight days after the seizure) and in sarin-induced seizures91 
(IL-1β levels remained increased up to 30 days after the seizure). While it is most likely 
that these long-lasting increases in IL-1α mRNA expression and IL-1β protein levels 
are related to the ongoing neuronal injury associated with TMT and sarin 
intoxication, they may contribute to seizure development as well. 
Electrically-induced seizures are associated with increased CNS IL-1 expression  
More IL-1β mRNA was found in the cortex of rats between four and 12 hours after a 
single seizure induced by electrical stimulation through ear-clip electrodes, than in 
rats that were not stimulated95. No data are available on the cells that expressed IL-1β 
mRNA, nor on associated neuronal injury. Therefore no conclusions on the role of IL-1 
in this type of seizure can be drawn from this single study. 
Infection-induced seizures are associated with increased CNS-IL-1 expression  
Shigella Dysenteriae infection and whole-cell pertussis vaccination are associated 
with seizures and other neurological symptoms in humans. In mice, S. Dysenteriae 
infection and pertussis vaccination are associated with increased sensitivity to 
pentylenetetrazol (PTZ, a GABA antagonist)96 and with seizures97, respectively. Both 
experimental paradigms are associated with increased levels of IL-1β mRNA and 
IL-1β protein in plasma96, hippocampus and hypothalamus97. These studies have not 
clarified what the time span between infection, seizures and IL-1β expression was or 
what cells were involved. Moreover, the increased IL-1β expression may be related to 
the generalized encephalopathy that both experimental conditions are associated 
with. Whether it has contributed to seizure development, can not be concluded from 
these studies.  
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Fever-induced seizures are associated with increased CNS IL-1 expression  
Injection of lipopolysaccharide (LPS, the coating of gram negative bacteria) induces 
fever. If LPS is injected in combination with a low (subconvulsant) dose of kainate 
(KA), approximately 50% of rats show seizures. These rats display significantly higher 
hippocampal and hypothalamic IL-1β protein levels (cell types not mentioned) than 
the rats that do not show seizures within two hours after KA administration, while 
IL-1ra protein levels remain unchanged98. These results suggest that the increased 
IL-1β protein levels are associated with the development of FS because they are most 
pronounced in the hippocampus, the structure thought to be mainly involved. The 
reason for the lack of IL-1ra expression may be related to the relatively short time 
span between FS and measurements; from the other studies in which IL-1ra is 
increased in response to seizures, the earliest IL-1ra responses are often found more 
than two hours after the seizure.  
Chemically induced epilepsies are associated with increased CNS IL-1 expression  
The two chemicals KA and pilocarpine have been used to study IL-1 expression after 
chemically induced epilepsy. The effect of KA-induced epilepsy on the IL-1 system 
was reviewed previously by Oprica et al. in 200399. All KA studies and pilocarpine 
studies report on increased CNS levels of the different IL-1 family members80,83,100-118. 
KA-induced neuronal injury may have been the main cause of all IL-1 expression, 
because IL-1 was mainly found in regions that showed the most extensive neuronal 
injury, such as hippocampus and piriform cortex83,102,105-107,109-112,114,118, and because 
microglia were the main source83,101,104-106,114. In pilocarpine treated rats, IL-1β staining 
paralleled that of fluoro-Jade-B (marker of neuronal degeneration) and was found in 
glial cells as well113.  
Due to the association with chemical-induced neuronal injury, the IL-1 expression 
that was found in these studies can not be directly linked to the development of 
epilepsy itself. Moreover, no IL-1β was found in the latent period after the 
pilocarpine-induced status epilepticus (SE), while during this period,  epileptogenesis 
takes place. This suggests that there is no major role for IL-1 during epileptogenesis 
in this model. Additionally, IL-1β mRNA expression does not appear to be necessary 
for KA-induced seizures, because dexamethasone pretreatment suppressed KA-
induced IL-1β mRNA expression, but not the KA-induced seizure80. 
Not all electrically induced epilepsies are associated with increased CNS IL-1 
expression 
Both seizures induced by amygdala kindling (AK) and spontaneous seizures that 
occur after SE induced by electrical stimulation, are associated with increased 
expression of several of the IL-1 family members119-121. No data are available on the 
morphology of the IL-1 positive cells. Interestingly, in a subgroup of rats that 
received kindling stimuli during the dark period, normal kindling took place but no 
changes in IL-1α mRNA or IL-1β mRNA expression were observed120. This last finding 
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suggests that IL-1 is not necessary for the development of AK seizures. The results 
from these studies are particularly interesting in determining the role of IL-1 
expression in epileptogenesis, because AK is not associated with neuronal injury122.  
SE induced by electrical stimulation of the ventral hippocampus  is associated with 
both acutely and chronically increased levels of IL-1ra and IL-1β121. This chronic 
expression may be related to epileptogenesis, which takes place during this period in 
this model. However, spontaneous recurring seizures after ventral hippocampus 
stimulation induced SE, are associated with neuronal injury and neuronal loss123 and 
the increased IL-1β and IL-1ra protein expression may be related to that as well. This 
is supported by the finding that IL-1β positive cells have glial morphology. Moreover, 
the occurrence of spontaneous epileptic seizures prior to sacrificing the animals is 
not mentioned in the paper; the authors have stated that the rats had not 
experienced a seizure two hours prior to death, but this does not exclude the 
hypothesis that the ‘chronic’ IL-1β expression 60 days after SE is a result of 
spontaneous seizures more that two hours prior to death. 
Not all genetic epilepsies are associated with increased CNS IL-1 expression  
Six to 24 hours after a seizure, hypothalamic IL-1α mRNA expression is increased in 
two strains of audiogenic mice124. This hypothalamic IL-1α mRNA increase resembles 
c-fos activation in one of the strains (Frings mice)125, a finding that supports the 
hypothesis that IL-1α mRNA expression is related to acute neuronal activation 
related to the development of seizures.  
No changes in IL-1 expression were found in two other strains of genetically seizure 
susceptible animals: kindled Wistar audiogenic rats show no increased levels of 
hippocampal IL-1β mRNA126 and the complex partial seizures provoked by tossing of 
the El-mouse are not associated with IL-1β mRNA expression either127. Pretreating the 
El mice with turpentine (as a model for sterile inflammation) leads to increased 
duration of the postconvulsive period and to detectable levels of cortical IL-1β 
mRNA, but did not affect seizures or seizure threshold. Although these results 
suggest that IL-1β mRNA expression is no prerequisite for the development of 
seizures, the time interval at which IL-1β mRNA has been determined is relatively 
long (24 hours). On the other hand, the finding that co-administration of turpentine 
increases cortical IL-1β mRNA as well as the postconvulsive period suggests that 
IL-1β mRNA does contribute to seizure-related processes.  
Conclusion  
All seizure and epilepsy models described above are associated with enhanced 
cerebral IL-1β expression, except a subgroup of rats in one study using the AK 
model120, a subgroup of KA-treated rats that was treated with dexamethasone80, and 
two studies using genetic models126,127. Many of the results are based on experiments 
in only one or two research groups, and have not yet been reproduced by others. 
Nevertheless, from these results it can be concluded that IL-1 is expressed as a result 
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of experimental seizures, especially if these seizures are associated with neuronal 
injury. However, the presence of IL-1 after one or more seizures does not imply that it 
is involved in epileptogenesis. More insight into possible mechanisms may come 
from intervention studies, in which the effect of exogenously applied IL-1β, IL-1ra 
and caspase-1 inhibitors on excitability, seizures and epilepsy has been evaluated. 
These studies are discussed in the following part. 
The effect of interleukin-1 on epilepsy 
Interleukin-1β has both inhibitory and excitatory effects 
All studies on the effect of exogenously applied IL-1β and IL-1ra on excitability, 
seizures or epilepsy are summarized in Table 2.5. Three of them describe inhibitory 
effects of IL-1β on PTZ seizures19 and on seizures provoked by amygdala 
kindling120,128. These findings suggest that IL-1β has anticonvulsive properties, while 
the finding that kindling rate was slowed by IL-1β even suggests that IL-1β has 
antiepileptogenic properties128.  
However, the majority of studies that have evaluated the effect of one of the IL-1 
family members on seizures or epilepsy find either no effect88,129, or a proconvulsive 
effect of IL-1β81,83,97,98,130,131, and an anticonvulsive effect of IL-1ra81,98,121,130 and of 
caspase 1-inhibition97,132.  
Only i.c.v., but not i.h., injections with IL-1ra reduced KA-induced seizures83,129,130. 
Assuming that 40 μg of IL-1ra (the maximal dose used129), is sufficient to block all 
hippocampal IL-1β activity, these results indicate that not only hippocampal, but also 
extrahippocampal IL-1β contributes to KA-induced seizures. On the other hand, an 
other study revealed that i.h. applied IL-1ra effectively blocked bicuculline-induced 
seizures, and that mice overexpressing IL-1ra did not develop seizures after 
bicuculline treatment81. These results suggest that, in bicuculline-induced seizures, 
hippocampal IL-1β alone contributes to the development of seizures. An 
anticonvulsive effect of i.c.v. applied IL-1ra was also found in electrical stimulation-
induced SE rats121. Seizures elicited by whole-cell pertussis vaccine97 and by KA132 
were both suppressed by decreasing IL-1β-activity through caspase-1 inhibition.  
In the majority of studies reporting on anticonvulsive effects of IL-1ra, the 
administration of exogenous IL-1β worsened seizures. This was confirmed in KA-
induced seizures83,130, in bicuculline-induced seizures81,130, in whole-cell pertussis-
vaccine induced seizures97 and in FS98,131. 
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Pharmacological seizure suppression is associated with decreased 
interleukin-1 expression 
In a number of animal studies, summarized in Table 2.6, the effect of antiepileptic 
treatment on IL-1 has been investigated.  
Most of these studies show both seizure suppression and decreased IL-1 expression 
as a result of treatment80,89,107,111,112, often in association with reduced neuro-
degeneration107,111,112. On the contrary, dexamethasone treatment prior to KA 
administration abolished the normally induced IL-1β expression but did not affect 
the KA-induced seizures80. This suggests that IL-1β expression is not necessary for the 
development of KA-induced seizures, a finding in line with the results of Dinkel et 
al.110. They described a KA-induced corticosterone peak which was followed by 
reduced IL-1β expression. As a result, adrenalectomized rats (lacking the KA-induced 
corticosterone peak) had higher IL-1β levels. Despite the increased IL-1β expression, 
adrenalectomized rats showed smaller KA-induced lesions in this study. In contrast 
with the inhibiting effect of a single corticosterone peak on IL-1β expression, 
chronically elevated corticosterone levels were associated with increased IL-1β 
expression and increased KA-induced lesion size. This suggests that chronically 
elevated corticosterone levels worsen KA-induced neurotoxicity due to 
neuroinflammatory changes. This is in line with the findings of Bruccoleri et al., who 
found augmentation of TMT-induced cerebral IL-1α expression after chronic 
dexamethasone pretreatment in mice84.  
In summary, it can be concluded that different anticonvulsive drugs that have been 
studied in this regard, including NMDA antagonists, GABA agonists and 
levetiracetam, decrease both seizure severity and IL-1β expression. The results of 
studies using other types of medication, like dexamethasone or indomethacine, are 
inconsistent. Perhaps this is related to the fact that these last drugs are not 
anticonvulsive drugs, but act on the immune system and only indirectly influence 
seizures.  
Implications 
Clearly, experimental seizures are associated with post-ictally increased IL-1β levels in 
the CNS. However, these seizures are often accompanied by extensive neuronal 
injury, which may account for IL-1 production by microglia7. At the cellular level, Toll-
like receptors (TLRs), activated by seizure-induced heath shock proteins (HSPs), 
induce the activation of nuclear factor kappa B (NFκB), which finally results in IL-1β 
production133-135. Thus, increased CNS levels of IL-1 after experimental seizures may 
be an epiphenomenon of neuronal injury alone, especially when IL-1 is found in the 
structures that are most severely affected. Epilepsies in humans are sometimes 
associated with neuronal injury as well, especially after prolonged SE. This neuronal 
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injury is thought to be the result of excitotoxicity related to massive release of 
glutamate, activation of NDMDA-R and subsequent influx of Ca2+ that causes cell 
death136.  
Even though in these cases IL-1β may be the result of neuronal injury, the cascades of 
events that are initiated when IL-1β binds to IL-1RI, may contribute to increased 
seizure-susceptibility (Figure 2.1). Increased neuronal NFκB activity has indeed been 
found in animal models for epilepsy137-140, and in the glial scar in the hippocampus of 
TLE patients141. As a transcription factor it is involved in many intracellular processes, 
for instance induction of iNOS and subsequent formation of NO, that may contribute 
to seizure generation142-144. Moreover, IL-1β directly increases NMDA-R function, and 
Ca2+ influx, and inhibits K+ efflux, all contributing to increased neuronal excitability 
and thus to seizure susceptibility21-23,25,26.  
Some epilepsies in humans are associated with neuronal injury that is present 
already prior to the occurrence of seizures, for instance post stroke epilepsy and 
epilepsy after traumatic brain injury145,146 (Figure 2.1). Both conditions are associated 
with increased CNS IL-1β levels8,9. This IL-1β is predominantly found in microglial cells 
in the lesioned area. It is conceivable that IL-1β released by microglia, activates 
neuronal IL-1RI, resulting in a decreased seizure threshold due to the mechanisms 
described above21-23,25,26.  
Apart from experimental seizures and epilepsies that are associated with neuronal 
injury, there is evidence that suggests that IL-1 also plays a role in experimental 
epilepsies and epilepsies in humans that are not associated with neuronal 
injury62,64,119,120. 
It is still unclear what the source of this IL-1 expression is. The seizure-induced BBB 
opening leads to the entrance of marcomolecules such as albumin5. IL-1β may be 
produced locally (by perivascular microglia) in a reaction to these macromolecules. 
During BBB opening, reactive astrocytes produce prostaglandins that activate 
microglia which in turn  express IL-1β (Figure 2.1). In addition, circulating IL-1β may 
diffuse into the brain if the BBB is opened.  Alternatively, CNS cells may express IL-1β 
prior to seizure onset.  
Irrespective of the source, none of the data that are currently available, prove that 
postictally increased CNS IL-1 levels, have contributed to the development of this 
seizure.  
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Figure 2.1 Many CNS conditions such as a seizure, cerebral ischemia and neurotrauma are associated 
with BBB leakage and extravasation of CNS-foreign proteins such as albumin. Increased 
cerebral blood flow can contribute to this extravasation. During BBB opening, perivascular 
astrocytes activate microglia, which in turn produce IL-1β. Simultaneously, excitotoxic 
damage, caused by the seizure, ischemia or neurotrauma itself, and leading to 
neurodegenerative changes, causes microglial IL-1β expression as well. 
 Whether this increased IL-1β expression leads to decreased seizure thresholds and ultimately 
to epilepsy, may depend on the amount of neuronal IL-1RI and IL-1RII that is present. In case 
IL-1RI outnumbers IL-1RII (left side of the figure), IL-1β activates IL-1RI which leads to 
increased phosphorylation (P) of the NR2A/B subunits of the NMDA-R through Src-kinases, 
resulting in increased influx of Ca2+. Moreover, IL-1β augments the Ca2+ influx though 
activation of the voltage-dependent Ca2+ channel (VGCC), while it inhibits K+ efflux though 
the Ca2+ dependent K+ channels (KCa2+C). These IL-1β-induced changes result in increased 
inward currents and decreased outward currents, leading to increased excitability and 
decreased seizure thresholds, contributing to the development of a subsequent seizure and 
to epilepsy.  
 In case IL-1RII outnumbers IL-1RI (right side of the figure), the IL-1β signal is not processed 
and does not lead to changes in inward and outward currents. In this situation, neuronal 
excitability and seizure threshold remain unchanged and thus, IL-1β does not contribute to 
the development of a subsequent seizure. 
 BBB: blood brain barrier, μglia: microglia, I: Il-1RI, II: IL-1RII, P: phosphorylation, NR2A/B: NR2A 
and NR2B subunits of the NMDA-R, VGCC: voltage-gated calcium channel, KCa2+C: calcium-
gated potassium channel. 
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CNS IL-1β expression is not restricted to neurological diseases that are associated 
with epilepsy, but has also been found in MS11, DS and AD12. A plausible explanation 
for IL-1β expression in these different conditions, is the fact that they are all 
associated with neuronal injury. The question is, if you attribute seizure-susceptibility 
to increased IL-1β expression, why some of these neurological conditions are 
associated with an increased frequency of epilepsy, while others are not. Moreover, 
most people that suffer from stroke or traumatic brain injury do not develop 
epilepsy; those that do develop epilepsy are apparently more vulnerable to 
excitotoxic changes, or these changes are more marked in those that do develop 
epilepsy. In line with this, is the finding that some patients suffer from a single 
seizure, while in other patients the first seizure is followed by epileptogenic changes 
that lead to subsequent seizures, and thus to epilepsy.  
The reason for these differences may (in part) lie in the IL-1Rs. In animal experiments, 
different excitotoxic stimuli lead to different responses in IL-1RI or IL-1RII 
expression103,147. It is plausible that these differences occur in human neurological 
diseases as well, and if so, they may explain why some conditions result in seizures, 
while others do not. If IL-1RII is quickly upregulated after release of microglial IL-1β, 
the neuronal IL-1RI is not activated and subsequent signal transduction pathways 
that may contribute to increased seizure-susceptibility, are not activated (Figure 2.1). 
Interindividual variability in IL-1R upregulation may explain why some patients with 
stroke or traumatic brain injury develop epilepsy, while others do not. There is no 
literature available on differences in IL-1RI and IL-1RII expression in epilepsy, but this 
could play an important role in establishing these potential effects.  
Future directions 
The currently available literature on IL-1 and epilepsy does not show conclusive 
evidence on the critical involvement of IL-1 in seizure generation. However, it is clear 
that IL-1 has the ability to modulate neuronal excitability and contribute to 
astrogliosis, which may lead to facilitated seizure generation and epileptogenesis.  
The hypothesis that IL-1 is merely a biochemical epiphenomenon of a seizure is 
therefore unlikely.  
Consequently, inhibition of IL-1β may be a new target for anticonvulsive therapy. In 
this respect, future studies  in IL-1 and epilepsy research should be aimed at 
selectively managing the temporal and local IL-1β-excess that coincides with a 
seizure.   
IL-1 production and activity are regulated by many factors, such as caspase-1, IL-1RI 
and IL-1RII, IL-1ra and by other factors that regulate the action of these regulators 
(e.g. pro-caspase-1 has to be cleaved first)15. This means that there are many ways to 
interfere with IL-1β activity, of which the anti-convulsive effects can be explored.  
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These future studies will provide clinically relevant data if animal models for 
epilepsies are used that are not associated with extensive neuronal injury (such as 
the amygdala kindled rat, or genetic epilepsy models). Finally, the contribution of 
other members of the IL-1 family should not be overlooked, for IL-18 has been 
referred to as ‘key player in neuroinflammation’ as well148.  
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Abstract 
Although interleukin-1 beta (IL-1β) can affect cellular excitability, and is upregulated after seizures, it is still 
unclear to what extent this contributes to epileptogenesis. Studies on IL-1β involvement in epilepsy have 
mainly been conducted in models that are associated with neuronal damage induced by excitotoxicity. 
This can have major impact on network excitability and can directly affect IL-1β expression via activation of 
amongst others nuclear factor kappa B (NFκB). To study to what extent IL-1β is upregulated in the absence 
of neuronal damage we determined chronic IL-1β expression in the amygdala kindled rat. Moreover, to 
get more insight in NFκB activity, we determined the expression of the ceramide transfer protein (CERT) 
since the expression of this protein is associated with NFκB activity.  
Rats were implanted in the left basolateral amygdala with kindling electrodes. Half of them were fully 
kindled while the other half served as sham. Animals were sacrificed 48 hours after the last generalized 
seizure after which IL-1β and CERT were determined in hippocampus and cortex. Two anti-IL-1β antibodies 
and one antibody directed against CERT were used.  
No IL-1β was detected in the brains of kindled animals nor in shams. Some IL-1β immunopositive cells 
were observed in the cortex area where the kindling electrode pierced the dura. No differences in intensity 
of CERT staining were observed between kindled animals and shams. 
IL-1β is not chronically upregulated in fully kindled rats. This may be related to the fact that kindling is not 
associated with excitotoxic damage, and may not be associated with NFκB upregulation either. This last 
assumption is supported by the fact that we did not observe differences in CERT staining either. Further 
studies aimed at NFκB are needed to elucidate this. 
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Introduction 
The brain shows increased expression of the pro-inflammatory cytokine interleukin-1 
beta (IL-1β) after experimental seizures and epilepsy1. It is thought that this IL-1β 
plays a key role in the development of seizures and epilepsy2.  
Neuronal injury in general leads to rapid production of IL-1β3. In line with this, 
seizure-induced IL-1β is predominantly found brain structures that show most severe 
seizure-induced neuronal damage4-14. On the cellular level, this IL-1β 
expression5,7,9,11,15 can be induced by the release of heat shock proteins (HSP) during 
the seizure that activate Toll-like receptors (TLR) which in turn induce IL-1β 
production via activation of nuclear factor kappa B (NFκB)16-18, see Figure 3.1. 
Activation of NFκB also induces expression of the ceramide transfer protein (CERT, 
also known as the Goodpasture antigen binding protein) a transporter involved in 
transporting ceramide from its production-site the endoplasmatic reticulum to the 
Golgi19.  
Many patients with epilepsy have never suffered from severe neuronal damage. Brain 
MRI is normal in 23% of epilepsy patients20. The majority of these MRI-negative 
epilepsy patients have focal cortical dysplasia21, a developmental abnormality 
unrelated to excitotoxic damage or neuronal death22. Still, brain tissue of these focal 
cortical dysplasia patients and from experimental epilepsies that are not associated 
with neuronal injury show IL-1β expression as well23-26. It has been hypothesized that 
central nervous system (CNS) IL-1β expression can result from seizure-induced 
opening of the blood-brain barrier (BBB) and subsequent entrance of 
macromolecules27 as well, while IL-1β expressing leucocytes can enter the CNS too 
after seizure-induced changes in the expression of vascular cell adhesion molecules28 
(Figure 3.1).  
On the cellular level IL-1β has properties that support its presumed key role in 
epileptogenesis. When IL-1β binds to its type I receptor (IL-1RI), several cascades are 
initiated. Immediately Src kinases are activated which in turn increase the degree of 
phosphorylation of the NMDA-R. This results in increased Ca2+ influx29,30, immediately 
leading to cellular hyperexcitability (Figure 3.1). Slower transcriptional pathways 
result in the transcription of proinflammatory genes (including IL-1β) and may affect 
excitability on the long run as well31.  
The role of IL-1β in seizures and epilepsy has mainly been studied in animal models 
that are associated with glutamate excitotoxicity and related neuronal damage1. 
Studies on BBB integrity after seizures have been performed on these types of animal 
models as well27,28.  
Glutamate excitotoxicity occurs when glutamate (being released during the 
(prolonged) seizure) activates the NMDA-R, leading to massive calcium influx. 
Chronically elevated intracellular calcium levels can be toxic to the cell and cause 
neuronal death. If the high calcium levels are reversible, neuronal death is prevented 
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and sprouting can occur32. Both neuronal death and sprouting contribute to network 
hyperexcitability (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.1 Scheme depicting seizure-induced actions of IL-1β in the brain. If a seizure evolves in a status 
epilepticus this can cause glutamate excitotoxicity, that is associated with the release of 
heath shock proteins (HSPs). HSPs are endogenous ligands for the Toll like receptors which in 
turn induce NFκB production. NFκB stimulates the neurons to produce IL-1β. 
Simultaneously, the blood brain barrier becomes disrupted during a seizure and during 
status epilepticus. This leads to entrance of macromolecules and leucocytes from the general 
circulation which either activate microglial IL-1β expression, or express IL-1β themselves.  
 When this seizure-induced IL-1β  signal is picked up by IL-1 receptors on neurons, a cascade 
of events is initiated: firstly upregulation of the Src family of kinases occurs, which increases 
the degree of phosphorylation of the NDMA-R, in turn leading to augmented calcium influx. 
This ultimately causes cellular hyperexcitability for as long as the NMDA-R are letting more 
calcium in.  
BBB opening
glumatmate excitotoxicity entrance of macromolecules 
or leucocytes 
microglial IL-1β
activation of neuronal IL-1RI
activation of src kinases
↑ NMDA-R phosphorylation
↓ seizure threshold
heath shock proteins
Toll-like receptors
status epilepticus
nuclear factor kappa B
neuronal IL-1β
↑ calcium influx, transient
cellular hyperexcitability
↑ calcium influx, long-lasting and 
reversible 
↑ calcium influx, chronic and 
irreversible
sprouting
hyperexcitable neuronal network 
neuronal death
CERT
……?
……?
NMDA-R activation
seizure
 Neuroimmunological changes in epilepsy?⏐65 
 In many epilepsy models, especially those that are based on status epilepticus, other 
cascades contribute to hyperexcitability as well. Glutamate excitotoxicity that occurs during 
status epilepticus leads to activation of NMDA-R, resulting in massive calcium influx into the 
neurons. Neuronal death occurs if the intracellular calcium concentrations remain chronically 
elevated, while reversibly high calcium levels  cause sprouting. Neuronal death and 
sprouting lead to network changes, ultimately resulting in network hyperexcitability. If both 
network hyperexcitability and cellular hyperexcitability are present, it is likely that network 
hyperexcitability contributes more to epileptogenesis than cellular hyperexcitability caused 
by IL-1β. In the absence of glutamate excitotoxicity, the contribution of seizure-induced IL-1β 
may be relatively bigger. 
 
 
Even though both excessive glutamate release and IL-1β expression lead to 
increased calcium influx via the NMDA-R, the contribution of glutamate is likely to be 
much bigger than the contribution of IL-1β, especially in cases associated with 
neuronal damage (Figure 3.1). We therefore hypothesize that in these cases, network 
hyperexcitability is established by cascades that are initiated after glutamate-
induced enhancement of NMDA-R functioning. IL-1β-induced enhancement of 
NMDA-R functioning may on the other hand play an important role in cases where 
seizures occur but excessive glutamate release remains limited.  
Since the majority of studies on the role of IL-1β in epilepsy has been performed 
using animal models that are associated with excitotoxic neuronal damage, the 
question still remains to what extent IL-1β contributes to epileptogenesis in cases 
that are not associated with neuronal damage but comprise an important part of the 
patient population20.  
We hypothesized that, if IL-1β is  required for epileptogenesis, it must be expressed 
chronically during epileptogenesis, also in the absence of neuronal damage. We 
further hypothesized that, if IL-1β is indeed chronically expressed in the absence of 
neuronal damage, this expression may depend on both BBB disruption (which 
remains present up to one week after experimental seizures27) and NFκB activation 
(Figure 3.1).   
 We have therefore investigated, using immunohistochemistry, whether IL-1β is 
chronically expressed in an animal model for chronic epilepsy that is not associated 
with glutamate excitotoxicity-associated neuronal cell death33-36, the amygdala 
kindled rat37. As a second readout parameter for NFκB activation we have 
determined the ceramide transfer protein38 (CERT, also known as the Goodpasture 
antigen binding protein19). 
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Materials and Methods 
Animals 
Male 12-weeks old Sprague-Dawley (SD) rats purchased from Harlan (Horst, The 
Netherlands) were housed under controlled conditions (21 ± 2°C ambient 
temperature, a 12 hour light/dark schedule, background noise provided by radio, 
and ad libitum food and water. The animals were allowed to adapt to the laboratory 
for one week before surgery. Adequate measures were taken to minimize pain and 
discomfort. All experimental procedures were conducted in accordance with 
international standards as defined by the European Communities Council Directive 
of November 24th 1986 and approved by the Animal Ethics Committee of Maastricht 
University. 
Surgery 
Twenty-five rats were implanted with a set of kindling/EEG electrodes. Thirty minutes 
prior to surgery all rats received 0.1 ml buprenorfine hydrochloride (Temgesic®, 
Schering-Plough Inc., Amstelveen, The Netherlands) for perioperative pain relief. All 
surgical procedures were performed under general isoflurane anesthesia (5% for 
induction and 2.5% for maintenance).  
The set of electrodes for kindling/EEG was implanted stereotaxically (Dual 
Manipulator Lab Standard Stereotaxic, Stoelting Inc., Wood Dale, IL, USA). The 
amygdala stimulating/recording electrode39 (Department of Instrument 
Development, Engineering & Evaluation of Maastricht University) was implanted in 
the left basolateral amygdala (coordinates derived from a rat stereotaxic atlas40 
relative to bregma: -2.5 mm posteriorly, 4.8 mm laterally, and 9.6 mm ventrally). 
Three monopolar stainless steel electrodes were implanted in the cerebral cortex at 
1 mm depth. One of three 3.8 mm laterally on the right and 2.5 mm posteriorly to 
bregma, was used for EEG, one 4.8 mm laterally to the left and 5 mm posterior to 
bregma for reference, and one 3.8 mm laterally on the right and 5 mm posterior to 
bregma for ground. Connectors for the kindling/EEG electrodes were fixed on the 
skull using dental acrylic. 
Amygdala kindling 
As described previously41, ten days after surgery the pre-kindling afterdischarge 
threshold (pre-KADT) was assessed in all rats. It was defined as the stimulus 
amplitude necessary to elicit a two-second discharge with a high frequency and high 
voltage in the amygdala, evoked by stimulating the amygdala with a series of pulses 
delivered at an interstimulus interval of two minutes using steps of 10 μA starting at 
10 μA (50 Hz, 0.2 ms square wave delivered by a WPI Accupulser A310 connected to a 
WPI Stimulus Isolation Unit A360 (World Precision Instruments, Sarasota, FL, USA).  
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Kindling was started the next day. The amygdala was stimulated twice per day (first 
stimulus between 8 and 10 am, second stimulus between 2 and 4 pm; interstimulus 
interval at least 6 hours) with a two-second 50 Hz stimulus (400 μA, 0.2 ms square 
wave pulses). 400 μA  was chosen as stimulus intensity since it was at least 200% 
above pre-KADT for all rats. Seizure stage was determined based on Racine’s five-
point scale37 in which stage one seizures are characterized by unilateral eye closure 
(mild facial clonus), stage two by bilateral eye closure and chewing (severe facial 
clonus), stage three by unilateral forelimb clonus, stage four by rearing and stage five 
by loss of balance and falling. After five consecutive stage five seizures, the animals 
were considered fully kindled. Subsequently, the amygdala was stimulated once per 
day for two more weeks.  
All rats were videotaped (Minolta DiMage G400, Konica Minolta Inc., Tokyo, Japan) 
during delivery of the kindling stimulus and for as long as the behavioral seizure 
lasted. Videos were analyzed offline by two blinded observers who assessed seizure 
severity based on Racine’s scale.  
EEG analysis 
The EEG recordings from the amygdala and cortex were performed using a Vangard 
system (Vangard Systems, Cleveland Clinic Foundation, Cleveland, USA). Recordings 
were made with a sample frequency of 200 Hz, frequency band of 0.5 - 70 Hz and 
with a 50 Hz notch filter. The total seizure duration was determined by a blinded 
observer and defined as the duration of rhythmic activity (spikes, sharp waves or 
slow waves) on the EEG. A seizure was considered to have ended when these wave 
forms occurred less than once per ten seconds.  
Histochemistry and immunohistochemistry 
Forty-eight hours after the last seizure the rats received an overdose of pentobarbital 
(Nembutal) followed by transcardial perfusion with tyrode buffer (in mM:  136.9 NaCl, 
2.7 KCl, 0.2 MgCl2, 11.9 NaHCO3, 0.3 NaH2PO4, 5.0 glucose, equilibrated with 5% CO2 / 
95% O2), and then with fixative (4% paraformaldehyde dissolved in 0.1 M phosphate 
buffer, pH 7.6).  
The brains were removed and postfixed in the same fixative (4°C, 48h), cryoprotected 
in 20% sucrose/0.1M phosphate buffer at (4°C, 24h) and rapidly frozen and stored at -
80°C until further processing. 
Coronal 10 μm serial sections through the hippocampus were cut on a cryostat, 
mounted on gelatin-coated glass slides, and stored at -20°C until processing for 
(immuno)histochemistry. Standard haematoxylin-eosin (Merck, Germany) staining 
was used to identify the location of the tip of the kindling electrode. 
For IL-1β-immunohistochemistry, two antibodies against IL-1β  were used: one 
polyclonal antibody generated in goat to rat IL-1β (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) and one monoclonal antibody generated in mice to 
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recombinant rat IL-1β, referred to as SILK 2242 and kindly provided by Dr. A.-M. van 
Dam (Vrije Universiteit, Amsterdam, The Netherlands).  
For the polyclonal antibody, sections were rinsed in 0.1 M phosphate buffer (PB), Tris-
buffered saline (TBS), and TBS containing 0.3% Triton (TBS-T) and 0.3% H2O2. 
Subsequently sections were rinsed in TBS-T and incubated in 0.3% normal donkey 
serum (NDS) dissolved in TBS-T for one hour. Then they were incubated for 24 hours 
at room temperature with the goat polyclonal anti rat IL-1β antibody (sc-1252, Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA), diluted 1:100 in TBS-T containing 
0.03% NDS. The next day, sections were rinsed in TBS and incubated for one hour 
with the rabbit anti goat peroxidase conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA), diluted 1:100 in TBS. The 
staining was visualized using diaminobenzidine. One glass containing four sections 
in which the primary antibody was omitted, was included to confirm specificity of 
immunoreactivity.  
For the SILK 22 antibody, sections were rinsed in TBS followed by TBS containing 
0.3% H2O2. Subsequently sections were rinsed in TBS-T and incubated for 20 minutes 
in TBS-T containing 2% NDS. Then they were incubated for 24 hours at 4°C with the 
mouse monoclonal against recombinant rat IL-1β antibody diluted 1:50 in TBS-T 
containing 0.2% NDS. The next day, sections were rinsed in TBS and incubated for 
two hours with the donkey anti mouse biotin conjugated secondary antibody 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA), diluted 1:400 in 
TBS-T. Subsequently, sections were rinsed in TBS-T and incubated for two hours with 
avidin-biotin (Vectastain ABC-kit, Vector Laboratories Inc., Burlingame, CA, USA), 
diluted 1:400 in TBS-T. The staining was visualized using diaminobenzidine. One glass 
containing four sections in which the primary antibody was omitted, was included to 
confirm specificity of immunoreactivity. 
For CERT immunohistochemistry, sections were incubated for 12 minutes in 4% 
paraformaldehyde containing 0.2% gluteraldehyde 25% and 15% picric acid at 4°C. 
Then, sections were rinsed in TBS-T and incubated for five minutes in sodium citrate 
buffer (pH 6.0) at 60°C in the water bath. Sections were thereafter cooled at room 
temperature for five minutes after which they were rinsed in TBS-T. Then the rabbit 
polyclonal against human CERT primary antibody (anti Goodpasture binding protein 
antibody A300-668A, BioConnect B.V. Huissen, The Netherlands) diluted 1:100 in TBS 
containing 5% bovine serum antigen was added. After 48 hours of incubation at 4°C, 
sections were rinsed in TBS-T and incubated for one hour at room temperature with 
the donkey anti rabbit biotin conjugated (D23, Jackson ImmunoResearch 
Laboratories Inc., West Grove, PA, USA) diluted 1:800 in TBS-T. Sections were rinsed in 
TBS-T and incubated for 90 minutes with avidin-biotin (Vectastain ABC-kit, 
VectorLaboratories Inc., Burlingame, CA, USA) diluted 1:400. The staining was 
visualized using diaminobenzidine containing 8% NiCl. One glass containing four 
sections in which the primary antibody was omitted, was included to confirm 
specificity of immunoreactivity. 
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Microscopy: IL-1β  
IL-1β immunoreactivity (ir) in the left hippocampus and cortex was assessed 
qualitatively by microscopic inspection of four sections per rat (12 kindled and 8 
shams) between bregma levels -2.8 and -3.1 using the Olympus AX-70 microscope 
(Olympus, Tokyo, Japan).  
Microscopy: CERT 
CERT ir in the dendate gyrus (DG), cornu ammonis 1 (CA1) and cornu ammonis 3 
(CA3) was measured by a semi-quantitative method. Briefly, within each section 
between 3.1 and 6.0 millimeters posterior to bregma two to eight photographs per 
animal (five kindled animals and three controls) were taken including the left DG (2 
areas), CA1, CA3, cortex and corpus callosum with the Olympus AX-70 microscope 
connected to a digital camera (F-view; Olympus, Tokyo, Japan). To correct for 
potential variability in lighting conditions, all images were collected under identical 
conditions. Photographs were analyzed using NIH ImageJ software 
(http://rsb.info.nih.gov/ij/). Using a trial and error method, a threshold value to 
optimally discern the stained cells was selected and kept the same for all 
measurements (adapted threshold). Subsequently the gray value of the respective 
areas was calculated for each area separately. The gray value of the corpus callosum 
of each section was used to correct for small variations in background staining.  
Statistical analysis 
Differences in pre-KADT between kindled animals and shams (to assess homogeneity 
of the two groups) and in CERT ir signal between kindled animals and shams were 
calculated using Mann Whitney U testing. 
Results 
In total, 25 rats were operated on. Five rats did not complete the experiments 
because of anesthesia-related death (n=1), loss of kindling/EEG electrode (n=1), 
defected kindling/EEG electrode (n=2), not reaching the fully kindled state (n=1). 
Twelve rats were kindled according to the above-mentioned protocol, while eight 
rats served as sham.  
Amygdala kindling 
Kindled rats needed 16 ± 5 stimuli to reach the fully kindled state. Pre-KADT levels did 
not significantly differ between kindled rats (mdn 119 μA, range 30 - 275) and shams 
(mdn 44 μA, range 38 – 80).  
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Immunohistochemistry 
HE staining was compared to the rat stereotactic atlas40 and revealed that in all 
animals the kindling electrode tip was located in the left basolateral amygdala. 
IL-1β  
Both antibodies showed IL-1β ir cells in the cortex areas where the electrodes pierced 
the dura mater. The majority of these cells was found superficially at the level of the 
cortex damage (Figures 3.2A and 3.2B), while some IL-1β ir cells were found in deeper 
cortex layers, predominantly perivascularly (Figures 3.2C and 3.2D). These large ir 
cells had the appearance of macrophages. No IL-1β ir cells were present in the 
hippocampus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Microscopic images of IL-1β stained sections at 10x magnification and depicting IL-1β 
immunopositive cells in the cortex at the level of the electrode damage (A and B) and in 
deeper cortical layers (C and D), visualized using the polyclonal antibody (A and C) and the 
monoclonal antibody (B and D).  
 Arrowheads point at some of the IL-1β ir cells. Asteriks are located inside vessels. A and B are 
adjacent sections (10 μm) of one kindled animal, C and D are adjacent sections of one sham 
animal.  
CERT 
Cells in the cortex, DG, CA1 and CA3 showed CERT immunoreactivity (Figure 3.3). The 
intensity of this signal did not significantly differ in any of the regions between 
kindled animals and shams.  
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Figure 3.3 Microscopic images of CERT-stained sections photographed at 4x magnification and 
depicting CA1 (A, B), CA3 (C, D), ventral DG (E, F) and cortex (G and H) of kindled (B, D, F and 
H) and sham animals (A, C, E and G), at 3.8 mm posterior to bregma. 
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Discussion 
It has recently been hypothesized that IL-1β is crucially involved in seizure 
generation and epileptogenesis43. This hypothesis is supported by studies in which 
IL-1β was blocked during seizure generation, resulting in seizure suppression44-50. 
Several studies have shown that IL-1β is expressed in limbic structures immediately 
after a seizure1. This IL-1β either comes from outside the brain as a result of seizure-
induced BBB leakage27 associated with altered expression of cell-adhesion 
molecules28, or is expressed by the brain upon NFκB activation as response to release 
of HSPs during the seizure.  
The question is whether IL-1β that is found after a seizure has critically contributed to 
the development of the seizure. Scientific evidence for that hypothesis is not yet 
conclusive1, but on a molecular basis there are reasons supporting this hypothesis 
because IL-1β has the ability to augment NMDA-R function, leading to increased Ca2+ 
influx,  and to inhibited K+ efflux; changes that have been shown to directly affect 
neuronal excitability and seizure susceptibility30,51-53. 
The hypothesis that IL-1β is critically involved in seizure generation is based on the 
assumption that seizure-induced IL-1β is present for as long as necessary to create 
effects that ultimately result in a chronic epileptogenic state. The seizure-induced 
peak in IL-1β expression is found between 5 and 10 hours after a seizure after which 
it quickly decreases to disappear between 24 and 48 hours6,54. In a number of studies, 
chronic IL-1β expression has been described as well, up to 8 days after trimetyltin-
induced seizures55, 30 days after sarin-induced seizures56 and in the latent phase 
three to seven days after status epilepticus induced by electrical stimulation of the 
ventral hippocampus57 as well as in the chronic phase (60 days)50.  
In contrast to these four chronic studies, we did not find IL-1β expression 48 hours 
after a seizure in fully kindled animals. This time point was chosen specifically to 
avoid IL-1β expression that has been the result of excitotoxicity alone, and detect 
changes that are related to chronic seizure-induced NFκB activation or disruption of 
BBB integrity. The staining was not false negative because locally around the 
kindling/EEG electrodes some IL-1β immunopositive cells were found. 
Morphologically these cells resembled macrophages. In the negative controls these 
cells were not stained, and therefore we concluded that this signal was IL-1β specific.  
No other studies have been published in which IL-1β expression was determined 48 
hours after a seizure in amygdala kindled animals. In only two other studies acute 
IL-1β expression in kindled rats was investigated, and the results of these studies are 
contradictory23,24 since both describe seizure-induced increases in IL-1β expression 
while Yi et al. also describe that if rats are kindled during the night, Il-1β is not 
expressed at all24.  
The lack of IL-1β 48 hours after a seizure suggests that both mechanisms for the 
induction and maintenance of IL-1β (NFκB and BBB leakage) are not actively present 
anymore. To further investigate this with regard to NFκB, we determined a second 
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readout parameter for NFκB activation, namely CERT expression38. CERT transports 
ceramide from its production site the ER, to the Golgi19. It is a fundamental protein 
and is present in all CNS cells. The antibody used in the current study only detects 
neuronal CERT expression, as has been shown previously using double stainings with 
Neu-N, GFAP and Ox-4258. In line with its fundamental role we observed basal CERT 
expression throughout the brains of both kindled and sham animals. Similar to our 
IL-1β findings, we did not observe any differences between kindled animals and 
shams regarding neuronal CERT expression either. Since the same brain tissue that 
was used in the current study has been used successfully for other 
immunohistochemistry studies before41 and because our lab is experienced in 
performing CERT immunohistochemistry58, we are convinced of the validity of our 
results in the current study. To our knowledge, no other studies have been published 
on CERT expression after seizures or epilepsy. 
Future studies are aimed at studying BBB integrity and NFκB activation in the 
kindling model at different time-points after seizures. No data are currently available 
on BBB integrity after kindling, nor on NFκB expression. If NFκB appears to be 
upregulated, other NFκB-induced proteins and cascades than those related to IL-1β 
may have contributed to epileptogenesis. Perhaps these unidentified mechanisms 
also play a role in other experimental epilepsies, since seizures can occur in the 
absence of IL-1β, as has been shown in two genetic epilepsy models59,60, and in one 
study using the kainate model61.  
Conclusion 
IL-1β nor CERT are chronically upregulated after a generalized seizure in fully kindled 
rats. Previous studies using seizure models that are associated with excitotoxic 
neuronal damage, suggest that seizure-induced IL-1β upregulation occurs as a result 
of HSP-induced activation of NFκB, and as a result of BBB disruption. Since kindling is 
not associated with excitotoxic neuronal damage, subsequent NFκB activation may 
not be present either. This hypothesis implies that other, currently unidentified 
mechanisms, may be responsible for epileptogenesis in this model. Further studies 
are necessary to elucidate these questions. 
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Abstract 
Seizures are associated with high intracellular calcium levels. However, conditions characterized by high 
intracellular calcium levels, such as stroke or traumatic brain injury, do not always evoke epilepsy. We 
hypothesized that polymorphisms in calcium-related genes CACNA1E and Camk2d contribute to the 
individual variability in seizure susceptibility. 
The distribution of one single nucleotide polymorphism (SNP) in the CACNA1E gene and one in the 
Camk2d gene were determined in Sprague-Dawley rats that were subjected to amygdala kindling or 
hyperthermia-induced seizures.  
The pre-kindling afterdischarge threshold was significantly lower in rats with the CACNA1E GG genotype 
(45.2 ± 6.7 μA) than in the GT genotyped animals (79.3 ± 53.7 μA). Among hyperthermia treated rats, the 
Camk2d G allele was more frequent among rats that did not display behavioral seizures during 
hyperthermia (67%) than in animals that did show behavioral seizures during hyperthermia (52%, 
χ2(1)=3.847, p=0.05).  
SNPs in CACNA1E and Camk2d genes are associated with individual variability in seizure susceptibility in 
two experimental seizure models. 
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Introduction 
Epileptogenesis, the process that transforms a normal brain into a hyperexcitable 
brain, is characterized by high intracellular calcium levels. While irreversible 
elevations in intracellular free calcium levels result in neuronal death, a prolongued 
but reversibly high intracellular calcium concentration in the first place lowers the 
threshold for neurons to depolarize, which results in lower seizure thresholds. This in 
turn can trigger pathological neuronal plasticity, leading to the development of 
epilepsy1. This hypothesis explains the induction and maintenance of acquired 
epilepsy, for instance after traumatic brain injury or stroke. Both conditions are 
associated with an increased risk of epilepsy, but it is not always clear why some 
patients develop epilepsy after stroke or traumatic brain injury, while the majority 
does not (http://www.who.int). Animal models also show individual differences in 
seizure-susceptibility. For instance, 65 – 96% of rat pups that are exposed to 
hyperthermia develop seizures and only 35% of these rats develop spontaneous 
epileptic seizures within 3 - 6 months2-5. In an other model, the amygdala kindled 
(AK) rat, strain-specific and rat-specific variabilities in seizure susceptibility have been 
described as well6,7.  
The aim of the current study was to investigate whether genetic differences in genes 
that are involved in calcium homeostasis are related to individual variability in 
seizure susceptibility. To investigate this, we have explored the occurrence of SNPs in 
calcium related genes among two rat models of provoked seizures that are not 
associated with hippocampal neurodegeneration8 or gliosis4: the AK model9 and the 
hyperthermia (HT) model5. The AK model was used to study both seizure 
susceptibility (using pre-kindling afterdischarge thresholds, pre-KADT) and 
vulnerability to epileptogenesis (using kindling rate), while the HT model was used to 
study seizure susceptibility only.  
The Spague Dawley®™ (SD) rat genome probably contains thousands of SNPs, 53 of 
them have been characterized10. At least two of these SNPs are located in calcium-
related genes: the CACNA1E gene encoding the α1e subunit of the voltage-gated 
calcium channel (VGCC) and the Camk2d gene that encodes the delta chain of 
calcium/calmodulin dependent kinase II (CamkII). Previous research in other epilepsy 
models has demonstrated altered expression levels of these proteins. For example, 
genetic absence epilepsy rats from Strassbourg (GEARS) and genetically epilepsy 
prone rats show an altered expression of the VGCC α1e subunit11,12. In several other 
epilepsy models reduced CamKII expression was found during and immediately after 
seizures13-17 while CamKII is increasingly phosphorylated for several hours after status 
epilepticus18. So far, no studies have been published in which SNPs in the CACNA1E 
or Camk2d gene in relation to seizures or epilepsy have been analyzed. 
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Materials & Methods 
Animals 
Male SD rats, purchased from Harlan (Horst, the Netherlands), were kept under 
controlled conditions (21 ± 2°C ambient temperature, a 12 hour light/dark schedule, 
background noise provided by radio and food and water available ad libitum). The 
animals were allowed to adapt to the laboratory for one week before surgery or 
hyperthermia. All experimental procedures were approved by the animal ethics 
committee of Maastricht University and complied with governmental legislation.  
Amygdala kindling 
Surgery 
The set of electrodes for kindling/EEG was implanted stereotactically (Dual 
Manipulator Lab Standard Stereotact, Stoelting Inc., Wood Dale, USA) as described 
previously7. Briefly, a bipolar platinum/iridium stimulating/recording electrode19 
(designed by the department of Instrument Development, Engineering & Evaluation 
of Maastricht University, Maastricht, The Netherlands) was implanted in the left 
basolateral amygdala (coordinates relative to bregma: -2.5 mm posteriorly, 4.8 mm 
laterally, and 9.6 mm ventrally20) together with three monopolar stainless steel 
electrodes that were implanted in the cortex at 1 mm depth. One of these cortical 
electrodes was used for EEG, one for reference, and one for ground. The electrode 
connectors were fixed on the skull using dental acrylic.  
Amygdala kindling procedure 
Kindling was performed as described previously7. Briefly, ten days after surgery the 
pre-KADT was assessed. Pre-KADT, defined as the stimulus amplitude necessary to 
elicit a two-second discharge with a high frequency and high voltage on the 
amygdala electrode, was assessed by stimulating the amygdala with increasing 
intensitiy starting at 10 μA (10 μA increment and two-minute interstimulus interval). 
Stimuli were delivered at 50 Hz, 0.2 ms square wave using a WPI Accupulser A310 
connected to a WPI Stimulus Isolation Unit A360 (World Precision Instruments, 
Sarasota, FL, USA). The EEG recordings from the amygdala and cortical electrodes 
were performed using a Vangard system (Vangard Systems, Cleveland Clinics 
Foundation, Cleveland, USA). Recordings were made with a sample frequency of 200 
Hz, frequency band of 0.5 – 70 Hz and with a 50 Hz notch filter.  
Kindling started the following day by administering two stimuli per day (each 
stimulus two s, 50 Hz, 400 μA, 0.2 ms square wave) to the amygdala, once between 8 
and 10 am, and again between 2 and 4 pm (interstimulus interval ≥6 hours). All rats 
were video monitored and recorded (Minolta DiMage G400, Konica Minolta Inc., 
Tokyo, Japan) during delivery of the kindling stimulus and for as long as the 
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behavioral seizure lasted. Videos were analyzed offline by two blinded observers who 
graded seizure severity according to Racine’s scale9. Once the animals had reached 
the fully kindled state, i.e. five consecutive stage five seizures, they continued to 
receive one kindling stimulus a day for two more weeks. Finally post-KADT was 
assessed in a similar manner as the pre-KADT. The kindling rate was defined as the 
number of stimuli needed to reach the fully kindled state.  
Hyperthermia  
HT was induced as described previously3,5. Briefly, 9-day old male rat pups were 
placed in a cylinder into which a stream of heated air was blown causing an increase 
in core temperature to 41–42.5°C. Core temperatures were measured before and 
every 2.5 min during the 30 min HT. As reported previously4,21,22 during HT exposure a 
subset of rats displayed behavioral seizures that were characterized by arrest of 
hyperkinesia, followed by falling to the side or back with body flexion and clonic 
contractions of the limbs (referred to as HT+). This behavior has previously been 
shown to correlate with hippocampal EEG discharges5,23. Other rats did not display 
this stereotyped behavior and were referred to as HT-.  
Genotyping 
Rat tail specimens of about 0.5-1 cm (40-50 mg) were collected from sacrificed 
animals and stored at -800C until molecular analysis. Of the 53 SNPs that were found 
when two SD rats from Harlan were compared10,24, we selected one in the CACNA1E 
gene (SNP in intron 7 at position 13:069472098; RGSC v3.4, NCBI assay id: 
ss48531400) and one in the Camk2d gene (SNP in intron 6 at position 2:224024428; 
RGSC v3.4, NCBI assay id: ss48531499).   
For SNP analysis, genomic DNA was extracted from the tail specimen using a Qiagen 
DNeasy® Tissue Kit (Qiagen, Hilden, Germany), which was then submitted to a PCR-
restriction fragment length polymorphism (RFLP) protocol as follows: first, a PCR 
reaction was carried out in a volume of 50 μl containing 200 ng genomic DNA, 0.5 μM 
of each primer, 0.2 mM dNTPs, 1 U Taq DNA polymerase (Roche Applied Sciences, 
The Netherlands), and 1x PCR buffer with 1.5 mM MgCl2 (for PCR conditions see Table 
4.1). Next, SNP dependent fragments were generated by digestion of the PCR 
products with restriction endonucleases according to the manufacturer's 
recommendations (Table 4.2). Finally, the fragments were resolved by gel 
electrophoresis on a 3% agarose gel containing gel star, and visualized by UV light 
using a Biorad Geldoc 2000 system with Quantity One software (Figure 4.1). 
Statistical analysis 
Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS) 16.0 for Mac software. The pre-KADT, ∆ADT (post-KADT minus pre-KADT 
expressed as percentage of pre-KADT) and kindling rate were calculated for each 
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CACNA1E and CamK2 genotype carrier and for all 9 CACNA1E/Camk2d genotype 
combinations. Differences between genotype groups were analyzed using one-way 
ANOVA with a Games-Howell post-hoc test. Carrier differences were analyzed using a 
Mann Whitney U test. 
To calculate if the genotype distribution differed between HT+ and HT- rats, the 
Likelihood Ratio was determined, and to assess if the allele frequency differed 
between HT+ and HT- rats we performed a Pearson’s chi-square test and calculated 
odd’s ratios.  
Values are expressed as mean ± standard deviations. A p value ≤0.05 was considered 
significant. 
 
 
Table 4.1 Primer sequences and conditions for amplification of CACNA1E and Camk2d SNP flanking 
fragments. 
SNP Forward Reverse Denaturation PCR cycle No of 
cycles 
Extension Amplicon 
size (bp) 
CACNA1E 5’ATA TTA 
AGC CAG GCA 
TTT GG-3’ 
5’-CTG GGC AGG 
AAT GTA TGA G-3’
10 min 
95 °C 
45 s 
94 °C 
 
50 s 
55 °C 
 
60 s 
72 °C 
35 5 min 
72 °C 
322 
Camk2d 5’-CCA CTT 
CAT CTG TGT 
TTA CCC-3’ 
5’-AAA GGC ACA 
TAA TCA CAT CG-3’
10 min 
95 °C 
45 s 
94 °C 
 
50 s 
59 °C 
 
60 s 
72 °C 
35 5 min 
72 °C 
421 
 
 
Table 4.2 CACNA1E and Camk2d SNP detection by restriction fragment length polymorphism. 
SNP Restriction  Fragmentsa (bp) 
 endonuclease GG GT TT 
CACNA1Eb MaeI 138, 113, 71 209, 138, 113, 71 209, 113 
Camk2dc MseI 163, 115, 86,  
29, 28 
163, 131, 115, 86,  
32, 29, 28 
131, 115, 86,  
32, 29, 28 
a fragments calculated from NCBI database sequences  
b G/T at position 142 of the amplicon (genomic location 13:069472098; NCBI assay id: ss48531400) 
c G/T at position 189 of the amplicon (genomic location 2:224024428; NCBI assay id: ss48531499) 
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Figure 4.1 Representative agarose gels showing RFLP products visualized by UV and a digital camera 
connected to a computer with Quantity One software (Geldoc 2000, Biorad). M = marker, 
numbers indicate basepairs. 
Results 
Amygdala kindling 
Forty-five rats were implanted with electrodes. Thirty-four were kindled and six 
served as sham. Histological analysis (haematoxylin-eosin) revealed that in all rats 
except five the kindling electrode was located inside the basolateral amygdala. The 
five rats in which the electrode was not inside the basolateral amygdala were 
excluded from analysis. In four kindled rats we were unable to determine the 
CACNA1E and Camk2d genotype.  
CACNA1E  
The CACNA1E GT genotype was more common (67%) than the TT (22%) and GG 
(11%) genotype. The pre-KADT was significantly lower in GG rats (45.2 ± 6.7 μA) than 
in GT rats (79.3 ± 53.7 μA, Figure 4.2A). There were no statistically significant 
differences between the three genotypes regarding ∆ADT or kindling rate. There 
were also no statistically significant differences between the occurrence of the G or T 
allele regarding pre-KADT, ∆ADT or kindling rate.  
Camk2d  
The GG and GT genotypes were most common (44 and 45%, respectively) while TT 
occurred in 11% of the animals. There were no statistically significant differences 
between the three genotypes regarding pre-KADT (Figure 4.2B), ∆ADT or kindling 
rate. There were also no statistically significant differences between the occurrence 
of the G or T allele regarding pre-KADT, ∆ADT or kindling rate. 
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Combination of CACNA1E and Camk2d  
The GT (for CACNA1E) in combination with GT (for Camk2d) was most frequent 
(30%), followed by 28% GT GG, 11% TT GT, 8% GG GG, 8% TT GG, 6% GT TT, 3% TT TT, 
3% GG TT and 3% GG GT. There were no statistically significant differences between 
the nine genotype combinations regarding pre-KADT, ∆ADT or kindling rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Average pre-KADT ± standard deviation of CACNA1E (A) and Camk2d (B) GG, TT and GT-
genotyped animals  *p<0.05 compared to GT. 
Hyperthermia-induced seizures 
In total 112 rats were included this experiment. In 20 cases we were unable to 
determine the CACNA1E or Camk2d genotype leaving 92 rats (26 HT+ and 66 HT-, 
Table 4.3).  
CACNA1E  
The most common CACNA1E genotype was TT (64%), followed by GT (29%) and GG 
(7%). The genotype and carrier distribution were not different between HT+ and HT- 
animals (Table 4.3). Even though the G allele was more often associated with seizures 
after hyperthermia (41%) than the T allele (25%, odds ratio 2.01), this difference did 
not reach the level of statistical significance.  
Camk2d  
The most common Camk2d genotype was GT (53%), followed by GG (37%) and TT 
(10%). The Camk2d genotype distribution did not significantly differ between HT+ 
and HT- animals (Table 4.3). Regarding carrying frequency in HT+ animals the T allele 
was present in 48%, while in HT- rats the T allele was present in 32%, a difference that 
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approaches the level of statistical significance (χ2(1)=3.847, p=0.05). The odds ratios 
illustrate as well that in HT+ rats the T allele is 2.0 times more likely to occur than the 
G allele. Vice versa, 37% of T allele carriers are HT+ versus 23% of G allele carriers 
(odds ratio 1.9). Even though more T carriers (34%) than G carriers (25%, odds ratio 
1.56) are HT+, this difference is not statistically significant.  
 
 
Table 4.3 Distribution of CACNA1E and Camk2d SNPs in hyperthermia rats without (HT-) and with 
(HT+) seizures.  
SNP Genotype Allele 
 GG TT GT G T 
CACNA1E      
HT- (n = 66) 3 (5) 45 (68) 18 (27) 24 (18) 108 (82) 
HT+ (n = 26) 3 (12) 14 (54) 9 (34) 15 (29) 37 (71) 
Camk2d      
HT- (n = 66) 28 (42) 4 (6) 34 (52) 90 (68)  42 (32)a 
HT+ (n = 26) 6 (23) 5 (19) 15 (58) 27 (52) 25 (48) 
Numbers indicate the frequencies of the genotypes, alleles and carriers of CACNA1E and Camk2d among 
HT+ and HT- rats, in absolute numbers and percentages between brackets.  
a χ2(1)=3.847, p=0.05 
 
Combination of CACNA1E and Camk2d  
Amongst all HT rats the TT GT (30%) was most frequent, followed by 29% TT GG, 20% 
GT GT, 7% GT GG, 5% GT TT, 3% TT TT, 3% GG GG, 2% GG TT and 1% GG GT. No 
difference in genotype distribution were noted between HT+ and HT- rats (Figure 
4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Distribution (%) of the 9 possible combinations of CACNA1E and Camk2d genotype in 
animals that did (HT+) and animals that did not (HT-) display behavioural seizures during 
hyperthermia treatment. 
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Discussion 
In this study we analyzed the distribution of CACNA1E and Camk2d SNPs in two SD 
rat models for seizures. First of all we observed a large variability in CACNA1E 
genotype frequency between the two experimental groups. The AK population 
consisted of 67% GT genotyped animals, while 65% of the HT population was 
genotyped as TT. This is a remarkable finding considering the fact that all rats were 
obtained in a relatively short time period (between 2005 and 2008) and from the 
same company (Harlan, Horst, The Netherlands). An explanation may relate to the 
fact that animals used in the kindling experiments came from different litters than 
animals used in the HT experiments. Camk2d genotypes were equally distributed 
since in both studies GT was the most common genotype (45% in AK and 53% in HT), 
followed by GG (44% in AK and 37% in HT) and TT (both 11%).  
CACNA1E 
In the current study we found that CACNA1E GG genotyped SD rats are characterized 
by a significantly lower pre-KADT than GT genotyped animals. The pre-KADT can be 
regarded as an indirect measure of seizure susceptibility. In order to develop seizures, 
the kindling-stimulus intensity has to be higher than the pre-KADT9. This implies that 
rats with a low pre-KADT require a lower stimulus intensity to become epileptic than 
rats with a high pre-KADT. Vulnerability to epileptogenesis was not associated with 
CACNA1E genotype since kindling rate was not significantly different among the 
three genotypes. 
Previous studies have shown that pre-KADT is influenced by a number of factors 
including  rat strain, sex, postoperative recovery time25 and the location of the 
stimulating electrode26. Since these factors were constant in the current study, it is 
tempting to suggest that the CACNA1E genotype can affect pre-KADT. The 
observations in the HT group are consistent with those in the AK group: even though 
not statistically significant, HT+ animals were more often GG genotyped, the G allele 
frequency was higher among HT+ rats (29%) than among HT- rats (17%), and the 
G allele was more often associated with HT+ (41%) than the T allele (25%, odds ratio 
2.01).  
Phenotypes associated with the different CACNA1E genotypes are still to be 
identified. The intronic CACNA1E SNP can affect protein function in two ways. First of 
all it can induce alternative splicing of the mRNA. It fell beyond the scope of the 
current study, but future studies using quantified real-time PCR can further elucidate 
this. Secondly it is possible that the CACNA1E SNP itself is not responsible for the 
phenotype, because this SNP coincides with an other SNP (T/C) at the end of the 
CACNA1E amplicon, at 290 nucleotides from the currently analysed SNP. Of this 
second SNP the C coincides with the T of the first SNP. Based on our results it is 
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unclear which one of these two SNPs functionally contributes to seizure 
susceptibility.  
It has been shown that TT genotyped humans are at higher risk of developing type II 
diabetes due to impaired insulin synthesis27. With regard to epilepsy the function of 
the VGCC α1e subunit has not been elucidated and so far findings are contradictory. 
On the one hand the α1e subunit of the VGCC is less expressed in GEARS11. On the 
other hand, VGCC α1e upregulation is suggested to play a role in the mechanism 
underlying the increased seizure susceptibility of genetically epilepsy-prone rats12.  
Camk2d 
These data also show that SNPs in the Camk2d gene are associated with an increased 
seizure susceptibility since the T allele was found more often in HT+ than in HT-.  
The phenotype of the intronic Camk2d SNP can affect protein function in the same 
two ways as were explained for CACNA1E: via alternative splicing or by coinciding 
with an other SNP. In contrast to the CACNA1E SNP, such a coinciding SNP has not 
been identified for the Camk2d SNP but may be present as well.  
The CamkII protein has been investigated in relation to epilepsy in many different 
epilepsy models. These studies consistently show a reduced CamkII expression 
during and immediately after a seizure13-17. More recently it has been shown that 
CamkII is increasingly phosphorylated up to several hours after a status epilepticus18.  
No other traits associated with SNPs in the rat Camk2d gene have been reported so 
far, while a recent study has demonstrated CamkII involvement in neonatal seizures 
in rats, where a transient increase in CamkII is found after hypoxia-induced seizures28. 
In humans two polymorphisms of the Camk2d gene have been described. These 
polymorphisms have solely been investigated in relation to type II diabetes, where 
no relation was found29. It therefore remains to be determined what the phenotype 
of the SNP is and if this polymorphism contributes to seizure susceptibility.  
CACNA1E & Camk2d 
Analyzing the combined CACNA1E and Camk2d genotypes revealed that none of the 
rats with the GG-GG combination and the GT-GG combination developed seizures 
after hyperthermia (Figure 4.3). This may indicate a protective effect of these 
genotype combinations, allthough the small number of rats with these genotypes 
(n=3 for GG GG and n=4 for GT-GG) may have contributed to this finding as well. In 
the kindling model this analysis did not reveal any correlation between combined 
genotypes and seizure susceptibility.  
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Conclusion 
In this study we have shown that polymorphisms in the CACNA1E and Camk2d genes 
are associated with individual variability in seizure susceptibility in two experimental 
seizure models. Both SNPs are located in introns, and not in de coding DNA. Even 
though they could functionally contribute to the association that we found in the 
current study through alternative splicing, it is possible that these SNPs only 
represent markers for other linked and functional polymorphisms that remain to be 
demonstrated. Therefore, future studies must be aimed at replication of our findings 
and at elucidating the physiological phenotype associated with these SNPs, in order 
to get more insight in epileptogenesis. 
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Abstract 
Vagus nerve stimulation (VNS) is a moderately effective antiepileptic treatment. Clinically relevant animal 
models that are suitable to study the mechanism of action of VNS are not available. The aim of the current 
study was to develop a clinically relevant animal model for VNS-treated epilepsy that can be used to study 
the mechanism of action of VNS.  
The anticonvulsive effect of VNS was studied in fully kindled rats by measuring behavioral and 
electrophysiological parameters. Afferent vagus nerve activation was confirmed by quantifying nNOS 
immunopositive cells in the nucleus of the solitary tract (NTS).  
VNS rats had more nNOS immunopositive cells/mm2 in the NTS than shams. VNS induced a >25% decrease 
in stage 5 duration (S5D) in 32% of rats. Prior to VNS this type of responders suffered from seizures with a 
longer total seizure duration (TSD) than non-responders. In 21% of rats VNS resulted in a >25% decrease in 
TSD. This type of responders had a shorter TSD prior to VNS than non-responders. In 29% of rats VNS 
resulted in >200% increase in stage 5 latency (S5L). This type of responders had higher kindling rates than 
non-responders.  
We conclude that the VNS-treated kindled rat is a clinically relevant animal model because it is a chronic 
epilepsy model that responds to VNS with effects that are comparable to the effects of VNS in epilepsy 
patients. In addition, this study demonstrates that VNS-treated kindled rats can be used to study the mode 
of action of VNS using immunohistochemical techniques. 
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Introduction 
Vagus nerve stimulation (VNS) is a type of neuromodulation therapy that has been 
used to treat refractory epilepsy patients since 1988 1. Average seizure frequency 
reduction is 12.8%, while 11.7% of patients have >50% seizure frequency 
reduction2-4. Besides this chronic effect on seizure frequency reduction observed 
after 3-6 months of VNS treatment, VNS has an acute seizure-suppressing effect as 
well. Acute activation of the pulse generator can abort 20% of seizures in patients 
who experience auras or simple partial seizures, while placebo-activation aborts 
approximately 10%5-7. 
Even though VNS has been applied in a number of animal models8-25, including three 
studies in freely moving, awake animals suffering from experimental epilepsy17,18,22, a 
study using a clinically relevant animal model and experimental design has not been 
conducted so far.  
The aims of the current study were to develop a clinically relevant animal model for 
VNS-treated epilepsy that can be used to study the mechanism of action of VNS, and 
to characterize rats that responded to VNS.  
Therefore we applied VNS in fully amygdala kindled (AK) rats, and evaluated its acute 
seizure suppressing effect by measuring behavioral and electrophysiological 
parameters. The AK rat has been developed as an epilepsy model several years ago 
and has been used to study the effectiveness of several anti-epileptic drugs6. After 
establishing the effectiveness of VNS, responders were further analyzed regarding 
epilepsy-related parameters before VNS. To confirm afferent vagus nerve activation, 
we quantified neuronal NO synthetase (nNOS) immunoreactivity (ir) in the nucleus of 
the solitary tract (NTS), the primairy projection site of the vagal afferents. 
Experimental procedure 
Animals 
Male, 12-weeks old adult Sprague-Dawley rats, purchased from Harlan (Horst, The 
Netherlands) were kept under controlled conditions (21 ± 2°C ambient temperature, 
a 12 hour light/dark schedule, background noise provided by radio, and food and 
water available ad libitum). The animals were allowed to adapt to the laboratory for 
one week before surgery. All experimental procedures were approved by the animal 
ethics committee of Maastricht University and complied with governmental 
legislation. Adequate measures were taken to minimize pain and discomfort.  
Surgery 
Fifteen rats were implanted with a set of electrodes for kindling and EEG registration 
(AK; untreated controls). An additional group of thirty-three rats underwent surgery 
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to implant two types of electrodes: one electrode for VNS and one set of 
kindling/EEG electrodes. Sixteen of these rats were kindled and treated with VNS 
(VNS), while 17 were kindled but not treated (sVNS). Thirty minutes prior to surgery 
all rats received 0.1 ml buprenorfinehydrochloride (Temgesic®, Schering-Plough Inc., 
Amstelveen, The Netherlands) subcutaneously for peri-operative pain relief. All 
surgical procedures were performed under general isoflurane anesthesia (5% for 
induction and 2.5% for maintenance).  
Vagus nerve electrode  
A detailed description of the surgical procedure was published previously26. Briefly, 
the left carotid artery and vagus nerve were exposed. The vagus nerve was found on 
the surface of the carotid artery. A custom made circular bipolar electrode (P. van 
Venrooij & V. Duysens, Medtronic Bakken Research Center, Maastricht, The 
Netherlands) was wrapped around both carotid artery and vagus nerve. 
Electrodes for kindling/EEG  
A set of electrodes for kindling/EEG was implanted stereotactically (Dual Manipulator 
Lab Standard Stereotact, Stoelting Inc., Wood Dale, USA). This set consisted of a 
bipolar stimulating/recording electrode (Department of Instrument Development, 
Engineering & Evaluation of Maastricht University & Dr. Y. Temel, Maastricht, The 
Netherlands) that was implanted in the basolateral amygdala (coordinates relative to 
bregma: -2.5 mm posteriorly, 4.8 mm laterally, and 9.6 mm ventrally27) and three 
monopolar stainless steel electrodes that were implanted in the cortex at 11 mm 
depth. One of these cortical electrodes was used for EEG, one for reference, and one 
for ground. Connectors for the kindling/EEG and VNS electrodes were fixed on the 
skull using dental acrylic. 
Amygdala kindling 
Ten days after surgery the pre-kindling afterdischarge threshold ADT (pre-KADT) was 
assessed in all rats by stimulating the amygdala with a series of pulses of increasing 
intensity starting at 10 μA (50 Hz, 0.2 ms block pulse). Stimuli were delivered through 
a WPI Accupulser A310 connected to a WPI Stimulus Isolation Unit A360 (World 
Precision Instruments, Sarasota, FL, USA).  
Kindling was started the next day. The amygdala was stimulated twice-a-day (first 
stimulus between 8 and 10 am, second stimulus between 2 and 4 pm; interstimulus-
interval >6 hours) with a two-second 50 Hz stimulus (400 μA, 0.2 ms block pulses). 
Seizure stage was determined based on Racine’s five-point scale28. After five 
consecutive stage five seizures, the animals were considered to be fully kindled. 
Subsequently, the amygdala was stimulated once a day for two more weeks. 
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All rats were videotaped (Minolta DiMage G400, Konica Minolta Inc., Tokyo, Japan) 
during delivery of the kindling stimulus and for as long as the behavioral seizure 
lasted. Videos were analyzed offline by two blinded observers who assessed kindling 
rate (number of stimuli needed to reach the fully kindled state), seizure severity 
based on Racine’s scale, stage 5 duration (S5D) and stage 5 latency (S5L; the interval 
between kindling stimulus and start of the behavioral stage 5 seizure).  
Twenty-four hours after the last kindling stimulus post-kindling ADT (post-KADT) was 
determined using the same method as described above for pre-KADT. The difference 
between pre-KADT and post-KADT was defined as ΔADT.  
EEG analysis 
The EEG registrations from the amygdala and cortical electrodes were performed 
using a Vangard system (Vangard Systems, Cleveland Clinics Foundation, Cleveland, 
USA). Recordings were made with a sample frequency of 200 Hz, frequency band of 
0.5–70 Hz and with a 50 Hz notch filter.  
Total seizure duration (TSD) was determined by a blinded observer and defined as 
the duration of rhythmic activity (spikes, sharp waves or slow waves) on the EEG. A 
seizure was considered to have ended when the frequency of the spikes, sharp waves 
or slow waves was <0.1 Hz.  
Afterdischarge activity was determined as high frequency, high voltage activity in the 
amygdala following electrical stimulation. It was not per se accompanied by 
epileptiform activity in the cortex or amygdala, nor by epileptic behavior. ADT was 
defined as the stimulus amplitude necessary to elicit a 2-second discharge with a 
high frequency and high voltage. 
Vagus nerve stimulation 
For VNS, rats were connected to an external pulse-generator (Pulse™ Model 102 
Generator, Cyberonics Inc., Houston, Texas) and stimulated with 30 Hz, 1.0 mA 
amplitude, 0.5 ms block pulses, using a 30s/12s ON/OFF cycle. VNS was administered 
for three minutes starting one minute prior to the last kindling stimulus. The sVNS 
rats were handled in exactly the same way as the VNS rats, apart from the fact that 
the current was not turned on in the sVNS group.  
Histology and immunohistochemistry 
Twenty-four hours after post-KADT determination (i.e. 48 hours after the last seizure), 
the rats received an overdose of pentobarbital (Nembutal), followed by perfusion 
with tyrode buffer (in mM: 136.9 NaCl, 2.7 KCl, 0.2 MgCl2, 11.9 NaHCO3, 0.3 NaH2PO4, 
5.0 glucose, equilibrated with 30% CO2/70% O2), and then with 4% 
paraformaldehyde dissolved in 0.1M phosphate buffer, pH 7.6.  
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The brains were removed and postfixed in the same fixative (4°C, 48h), cryoprotected 
in 20% sucrose/0.1M phosphate buffer (4°C, 24h) and rapidly frozen and stored at 
-80°C until further processing. The vagus nerve was exposed in order to visually 
check electrode position.  
Coronal 10 μm serial sections through the brainstem and hippocampus were cut on a 
cryostat, mounted on gelatin-coated glass slides, and stored at -20°C until processing 
for (immuno)histochemistry. 
Histology  
Standard haematoxilyn-eosin (HE, Merck, Germany) staining of coronal sections 
containing the amygdala electrode was used to visualize the location of the 
electrode tip. The evaluation of the location of the electrode tip was based on a 
stereotaxic atlas27. 
Immunohistochemistry  
For nNOS immunohistochemistry, sections were rinsed in tris-buffered saline (TBS: 
0.1M Tris-base, 0.15M NaCl, pH 7.4) and incubated overnight with anti-nNOS 
antibody (rabbit anti-nNOS, ImmunoStar, Inc., Hudson, WI, USA) diluted 1:400, 
followed the next day by incubation for 90 minutes with the secondary antibody 
(donkey anti-rabbit alexa 488, Invitrogen Inc., Eugene, Oregon, USA) diluted 1:100. 
Sections were rinsed in TBS and cover-slipped with 80% glycerol in TBS.  
Microscopic analysis 
Microscopic analysis of nNOS stained sections was performed with a MicroBrightField 
(MBF) Bioscience Stereo Investigator stereology system (MBF Bioscience Inc., 
Williston, VT, USA), consisting of a modified Olympus BX50 fluorescence microscope 
(Olympus, Tokyo, Japan) with Olympus UPlanApo objectives 10x (N.A.=0.40) and 20x 
(oil; N.A.=0.80), three-axis high-accuracy computer-controlled stepping motor 
specimen stage (4x4 Grid Encoded Stage; Ludl Electronic Products, Hawthorne, NY, 
USA), linear z-axis position encoder (Ludl), MBF-CX9000 CCD color camera 
(1.200x1.800 pixels) and controlling software (MBF Bioscience). 
In 5 VNS rats and 5 sVNS rats the NTS was studied at levels between bregma -12.7 
and - 13.1 mm. In 9 remaining rats (3 VNS and 6 sVNS), the caudalmost portion of the 
brain stem (including the NTS) was not included in the brain stem slices and could 
not be analyzed. Every 10th section was analyzed with the Fractionator probe of the 
StereoInvestigator software (MBF Bioscience Inc., Williston, VT, USA). The NTS was 
delineated and all nNOS ir cells in this area were counted and expressed as the 
number of cells per mm2. 
 Acute seizure-suppressing effect of vagus nerve stimulation in the amygdala kindled rat⏐97 
Statistical analysis 
Statistical analysis was performed using SPSS v16.0 for MacOSX. In general, outliers 
were defined as values diverging more than two standard deviations from the mean 
and were excluded from further analysis. A p-value of <0.05 was considered 
statistically significant. Data are expressed as mean ± sd or as median + range.  
To assess rater reliability, the amount of measurement error for the two observers 
concerning S5D and seizure severity was determined by calculating the intraclass 
correlation coefficient (ICC)29 and the weighted kappa (κω)30,31, respectively.  
In order to estimate the treatment effect, S5D, TSD and S5L during VNS were 
expressed as percentage of their respective means over five preceding seizures. 
Additionally, the difference in average S5D, TSD, S5L, kindling rate, pre-KADT, post-
KADT and ΔADT between the three experimental groups was statistically tested by a 
one-way ANOVA followed by the Games-Howell procedure as post-hoc test. 
Wilcoxon signed ranks test was used to compare pre-KADT and post-KADT. 
Responders were identified as those rats that responded to VNS treatment by either 
a decrease in seizure severity based on Racine’s scale, or >25% decrease in TSD or 
S5D, or >200% increase in S5L. 
The difference in number of nNOS ir cells/mm2 between VNS and sVNS rats was 
calculated using a Mann-Whitney U test, and between the left and right NTS by 
Wilcoxon signed ranks test.  
Responder characteristics were determined by comparing the average kindling rate, 
pre-KADT, post-KADT, ΔADT, S5D, TSD and S5L between responders and non-
responders using the independent samples t-test for normally distributed values and 
the Mann-Whitney U test for non-normally distributed values. 
Results 
Forty-eight rats were operated on. Seventeen rats did not complete the experiments 
because of anesthesia-related death (n=2), severe post-operative dyspnea due to 
glottisedema (n=2), loss of AK electrode (n=9), defective AK electrode (n=2), or not 
reaching the fully kindled state (n=2). We observed left sided Horner’s syndrome 
immediately after surgical placement of the vagus nerve electrode in 20 of 33 rats5. 
Thirty-one rats (12 AK, 8 VNS and 11 sVNS) completed the experiments and were 
used for further analysis.  
In all VNS-rats, the VNS electrode was located around the vagus nerve and carotid 
artery during post-mortem examination, while in 3 sVNS rats, the electrode was 
found detached from artery and nerve but still in close proximity to these structures.  
Kindling rates did not significantly differ between VNS rats (19 ± 4 stimuli), sVNS rats 
(16 ± 4) and AK rats (16 ± 5 stimuli). 
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VNS effects 
Seizure severity  
The amount of measurement error for the two observers concerning seizure severity 
was low (κω 0.96). Seizure severity during VNS treatment (stage 5) did not differ from 
the average seizure severity of the 5 seizure preceding VNS (stage 5).  
Stage 5 duration  
Determination of S5D by two observers resulted in a low amount of measurement 
error (ICC 0.918). We therefore averaged the S5Ds of the two observations and used 
this number for analysis. The S5D of the five seizures preceding VNS or sham 
treatment did not significantly differ between VNS (25 ± 6), sVNS (25 ± 6) and AK rats 
(23 ± 9 s). Animals with >25% reduced S5D upon VNS treatment were considered 
responders (S5D-responder), and represented 50% of VNS, 18% of sVNS and 9% of AK 
rats (Figure 5.1A). We attributed the S5D reductions in sVNS and AK rats as normal 
fluctuations, and the corrected responder rate in the VNS group was therefore 32%. 
Further analysis of the S5D-responders in the VNS group showed that their average 
TSD prior to VNS was significantly longer than the TSD of non-responders (Table 5.1). 
 
Table 5.1 Characteristics of S5D responders and S5D non-responders. 
factor responder non-responder p-value 
kindling rate 18 stimuli (14 – 21) 19.5 stimuli (15 – 26)  0.77 
pre-KADT 72.5 μA (37.5 – 82.5) 56.25 μA (37.5 – 112.5)  0.559 
post-KADT 66.25 ± 42.5 μA 37.5 ± 13.22 μA  0.244 
ADT change 7.5 μA (-32.5 – 57.5) 23.75 μA (7.5 – 57.5)  0.468 
mean S5D 24.45s (16.4 – 32.3) 28.05s (19.6 – 29)  1 
mean TSD 254.45 ± 30.41s 113.85 ± 30.16s  0.001 
Differences between S5D responders and S5D non-responders regarding kindling rate, pre-kindling 
afterdischarge threshold (pre-KADT), post-kindling afterdischarge threshold (post-KADT), difference 
between pre- and post-KADT (ADT change), mean stage 5 duration prior to VNS treatment (mean S5D) and 
mean total seizure duration prior to VNS treatment (mean TSD). μA = micro Ampère, s =  seconds. Values 
for responders and non-responders are either means ± standard deviations (analysed with an 
independent-samples t-test), or medians with range (analysed with Mann-Whitney U test). 2-tailed p-
value. 
 
Seizure duration  
The mean TSD prior to VNS or sham treatment did not significantly differ between 
VNS rats (184 ± 80 s), sVNS rats (246 ± 66 s) and AK rats (181 ± 76 s). Animals with a 
>25% reduced TSD upon VNS treatment were considered responders (TSD-
responder), and represented 57% of VNS, 36% of sVNS, and 9% of AK rats Figure 
5.1B). The TSD reductions in sVNS rats and AK rats were considered normal 
fluctuations in TSD. Therefore the corrected responder rate based on TSD reduction 
is 21%. Further analysis of the TSD-responders in the VNS group showed that their 
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average TSD prior to VNS was significantly shorter than that of non-responders (Table 
5.2). 
 
 
Table 5.2 Characteristics of TSD responders and TSD non-responders. 
factor responder non-responder p-value 
kindling rate 20.5 ± 4.51 stimuli 17 ± 3 stimuli 0.301 
pre-KADT 56.25 μA (37.5 – 82.5) 62.5 μA (37.5 – 125) 0.719 
post-KADT 27.5 μA (25 – 40) 95 μA (35 – 110) 0.074 
ADT change 23.75  μA (7.5 – 57.5) 2.5 μA (-32.5 – 12.5) 0.157 
mean S5D 28.05s (16.4 – 29) 29.6s (19.3 – 32.3) 0.289 
mean TSD 134.5s (86.8 – 218) 266.6s (244.2 – 289) 0.034 
Differences between TSD responders and TSD non-responders regarding kindling rate, pre-kindling 
afterdischarge threshold (pre-KADT), post-kindling afterdischarge threshold (post-KADT), difference 
between pre- and post-KADT (ADT change), mean stage 5 duration prior to VNS treatment (mean S5D) and 
mean total seizure duration prior to VNS treatment (mean TSD). μA = micro Ampère, s =  seconds. Values 
for responders and non-responders are either means ± standard deviations (analysed with an 
independent-samples t-test), or medians with range (analysed with Mann-Whitney U test). 2-tailed p-
value. 
Stage 5 latency  
The mean S5L of the five seizures preceding VNS or sham treatment did not 
significantly differ between VNS (6 ± 6 s), sVNS (2 ± 2 s) and AK rats (4 ± 3 s). After the 
last kindling stimulus, those rats that were treated with VNS had a longer S5L (9 ± 8s) 
than sVNS (1 ± 1 s) and AK rats (3 ± 3 s). There was a trend towards statistical 
significance between VNS treated rats and sVNS treated rats (p=0.056). 
Animals in which S5L increased with >200% upon VNS treatment, were considered 
responders (S5L-responder), and represented 38% of VNS, none of sVNS and 8% of 
AK rats (Figure 5.1C). The corrected responder rate based on S5L increase was 
therefore 30%. Further analysis of S5L-responders in the VNS group showed that 
their kindling rate was significantly slower than that of non-responders (Table 5.3).  
 
Table 5.3 Characteristics of S5L responders and S5L non-responders. 
factor responder non-responder p-value 
kindling rate 22.3 stimuli (range 20 – 26) 17 stimuli (14 – 20) 0.035 
pre-KADT 62.5 μA (37.5 – 82.5) 62.5 μA (37.5 – 125) 0.651 
post-KADT 25 μA (25 - 35) 55 μA (30 – 110) 0.051 
ADT change 37.5  μA (2.5 – 57.5) 11 μA (-32.5 – 57.5) 0.549 
mean S5D 27.4s (16.4 – 29.6) 28.7s (19.3 – 32.3) 0.655 
mean TSD 218s (112.8 – 244.2) 156.2s (86.8 – 289) 0.881 
Differences between S5L responders and S5L non-responders regarding kindling rate, pre-kindling 
afterdischarge threshold (pre-KADT), post-kindling afterdischarge threshold (post-KADT), difference 
between pre- and post-KADT (ADT change), mean stage 5 duration prior to VNS treatment (mean S5D) and 
mean total seizure duration prior to VNS treatment (mean TSD). μA = micro Ampère, s = seconds. Values 
for responders and non-responders are medians with range, and analysed with Mann-Whitney U test). 
2-tailed p-value. 
100⏐Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Distribution of responders.  
 Stage 5 duration responders (S5DR) were defined as rats that showed >25% reduction in 
S5D after the last AK stimulus compared to the mean of the previous 5 S5D.  
 Total seizure duration responders (TSDR) were defined as rats that showed >25% 
reduction in TSD after the last AK stimulus compared to the mean of the previous 5 TSD. 
 Stage five latency responders (S5LR) were defined as rats that showed >200% increase in 
the latency period between kindling stimulus and start of the convulsive seizure 
compared to the mean of the previous 5 S5L. 
 Y-axis: percentage of animals, X-axis: S5DR, TSDR and S5LR (>25% decrease for S5D and 
TSD and >200% increase for S5L) and S5D non-responders, TSD non-responders and S5L 
non-responders (<25% decrease and increase for TSD and S5D and <200% decrease or 
increase for S5L). 
 
Afterdischarge thresholds 
The pre-KADT did not differ between the three groups. Within each treatment group, 
the post-KADT was lower than pre-KADT (VNS: p=0.03, sVNS: p=0.004 and AK: 
p=0.001). The post-KADT did not statistically differ between the experimental 
groups.  
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(Immuno)histochemistry  
HE staining revealed that in all animals, the kindling electrode tip was located in the 
amygdala.  
VNS treated rats had more nNOS ir cells/mm2 in the right NTS (153, 75-233) than sVNS 
treated rats (100, 43-142; p<0.001). Similarly, higher nNOS ir cell density was found in 
the left NTS of VNS rats (140, 61–261) than in the left NTS of sVNS rats (105, 38-148; 
p<0.001, Figures 5.2 & 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Photographs A and B show a relatively high background staining as well as nNOS stained 
neurons throughout the NTS, while C and D show less background staining and less nNOS 
stained neurons. 
 nNOS immunohistochemistry of the left NTS at bregma -12.9 
 A: left NTS of a VNS treated rat at 10x magnification.  
 B: left NTS of a VNS treated rat at 40x magnification. 
 C: left NTS of a sVNS treated rat at 10x magnification.  
 D: left NTS of a sVNS treated rat at 40x magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Median number of nNOS expressing cells in the nucleus of the solitary tract (NTS).  
 y-axis: nNOS expressing cells in the NTS per mm2 of NTS, median values; x-axis: left and 
right NTS of VNS and sVNS treated rats. * : p<0.001, Mann Whitney U 
102⏐Chapter 5 
Discussion 
Technical notes  
In humans VNS is performed with an electrode that is placed around the vagus nerve 
alone. In several studies using epileptic rats VNS has been applied in a similar 
way10,11,13.16,17,19,20,21,24. However, manipulation of the vagus nerve can lead to nerve 
damage, chronically followed by Wallerian degeneration of the axons and 
subsequent structural changes at the level of the NTS and dorsal motor nucleus of 
the vagus nerve32. To prevent this type of damage we chose to minimize the amount 
of nerve manipulation by wrapping the electrode around both the carotid artery and 
vagus nerve, a technique previously used by Folessa et al.33. Similar to Follesa et al., 
brain circulation was not measured in the current study. Therefore it is not know 
what the effect of placement of an electrode around the carotid artery alone is on 
brain circulation. Since we did not observe statistically significant differences on any 
of the epilepsy-related parameters between untreated controls and sham controls, 
we believe that placement of this electrode alone does not affect brain circulation in 
such a way that it influences seizure severity.  
By minimizing the amount of vagus nerve manipulation, it was necessary to 
manipulate the surrounding structures. This led to the occurrence of Horner’s 
syndrome in 20 of 33 rats, which did not affect the seizures26.  
Similar to other studies that have described the anticonvulsive effect of VNS in 
epileptic rats10,11,13,16,19,20,21, we did not measure the electrode impedance prior to 
applying the VNS stimulus. The contact surface between electrode and vagus nerve 
in the current study is approximately 0.06 mm2, while in humans this is 7.2 mm2 
(Cyberonics, Inc., Houston, Texas). The expected impedance in a correctly placed 
Pulse™ Model 102 Generator (Cyberonics, Inc., Houston, Texas) system in humans is 
<4 kOhm. Using the same pulse generator connected to a 0.06 mm2 electrode, an 
impedance value >4 kOhm can be expected. This measurement will therefore not 
inform us about the integrity of the system. Furthermore, measuring the impedance 
implicates that an electrical stimulus is applied. For methodological issues, the 
impedance should have been measured in both VNS and sVNS rats. This could have 
interfered with the immunohistochemical changes in the NTS that may have 
occurred as a result of the impedance stimulus.  
The fact that we did not measure the impedance implies that it is unclear whether all 
rats received the exact same stimulation. In all rats, 1 mA was the maximally tolerated 
stimulus since at higher intensities they started to cough or vocalize.  
The effectiveness of acute VNS  
In humans, the effectiveness of an anticonvulsive treatment is quantified by 
measuring the seizure frequency using seizure diaries. In the kindling model as it was 
used in the current study, seizure frequency cannot be measured since the rats do 
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not suffer from spontaneous seizures. When the kindling model is used to evaluate 
antiepileptic drugs, parameters such as seizure severity (according to Racine’s scale), 
TSD, S5L and post-KADT are used to study an anticonvulsive effect. Here, we added 2 
other new parameters: S5D and ΔADT.  
Pharmacological treatment with anti-epileptic drugs such as gabapentin and 
levetiracetam  can reduce seizure stage in fully kindled rats34. We did not observe a 
decrease in seizure stage during VNS. Recently, Wyckhuys et al. were also unable to 
affect seizure stage in fully kindled rats using hippocampal deep brain stimulation35, 
a treatment option that can be effective in epilepsy patients36,37.  
Our findings are in contrast with an earlier study on VNS in fully kindled rats, where 2 
out of 6 rats showed suppression of a stage 5 seizure17. This difference may be 
explained by the rat strains that were used, since we used Sprague Dawley rats while 
Dedeurwaerdere et al. used a fast-kindling rat strain that was created through 
selective breeding. Fast and slow-kindling rats show large differences in their 
response to GABA-ergic drugs38. Similar differences in pharmacological response may 
play a role in the VNS effect as well. A second explanation may be related to VNS 
protocol: we used continuous cyclic stimulation of the vagus nerve starting one 
minute prior to the kindling stimulus and lasting until 2 minutes thereafter, while 
Dedeurwaerdere et al. stimulated the vagus nerve for 60 seconds, starting 2 minutes 
after the kindling stimulus17. We chose to start VNS prior to the kindling stimulus in 
an attempt to mimic the clinical situation, where the patient can activate the pulse-
generator when perceiving an upcoming seizure prior to generalization. 
Although seizure stage was not affected, VNS reduced S5D with >25% in 32% of the 
rats. This parameter has never been used to evaluate the effect of VNS, which may be 
related to the subjective interpretation of seizure behavior. By using two blinded, 
independent observers that showed low inter-observer variability we have shown 
that S5D can be used as an objective parameter to evaluate VNS treatment effects.  
A second effect of VNS on seizure duration was found by electrophysiological 
measurement of TSD. In 21% of the VNS-treated rats we found >25% reduction in 
TSD. This effect of VNS is modest compared to that of pharmacological treatments, in 
which often a TSD reduction of >50% is seen in the majority of animals34.  
Using a third, behavioral, parameter, we again found that VNS affected kindling-
induced seizures in a significant number of rats: 29% of the VNS-treated rats showed 
a >200% increase in S5L. Similar effects were found after hippocampal deep brain 
stimulation in kindled rats35, but not after VNS in AK rats in the study of 
Dedeurwaerdere et al.17. Again, the latter may be explained by differences in rat 
strain or in VNS protocol.  
Here we identified treatment responders based on arbitrarily chosen effects, such as 
a 25% reduction in TSD and a 200% increase in S5L. Although this approach resulted 
in responder rates that are comparable to the effects in epilepsy patients, additional 
studies are necessary to validate these parameters. In epilepsy patients, a seizure 
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frequency reduction of >50% is used identify a responder. This parameter has been 
arbitrarily chosen as well, but has proven its effectiveness over the years. 
Despite the differences in experimental setup, our results as well as those of 
Dedeurwaerdere et al.17 illustrate that acute VNS can affect different characteristic of 
a seizure, but it does not have the power to prevent or terminate a seizure in all fully 
kindled animals. This is partly in line with clinical practice where 10% of VNS treated 
patients can completely abort a seizure by acute activation of the VNS device, while 
more patients report on having a shorter seizure or shorter recovery time5-7. 
The finding that different characteristics of a seizure can be affected by acute VNS 
suggests that chronic VNS may have more effects than seizure frequency reduction 
alone. Indeed, many patients that are designated as non-responder based on seizure 
frequency reduction report on beneficial effects of VNS on other seizure 
characteristics, such as seizure severity or recovery time. Possibly hampered by their 
subjective nature, these additional effects of VNS have been reported in a small 
number of prospective studies39,40. 
Afferent vagus nerve activation 
It is generally thought that the anticonvulsive effect of VNS is the result of afferent 
vagus nerve activation. We chose an immunohistochemical approach to confirm 
activation of afferent vagus nerve fibers instead of electrophysiology to avoid the 
risks associated with implanting an extra set of electrodes for recording purposes. 
Immunohistochemical detection of changes in neuronal activity is often done using 
markers such as c-fos, fos-b, or Δfos-b. Indeed, c-fos staining of the NTS immediately 
after VNS has confirmed NTS activation9,41,42, while chronic cyclic VNS induces ΔFosB 
expression in the NTS41. In the current study we sacrificed the rats 48 hours after VNS. 
At this time point, c-fos is not present anymore41, while fos-b and Δfos-b are less 
likely to be detected due to the short half life of fos-b and expected lack of 
accumulation of Δfos-b after a single VNS stimulus in our study, respectively43. We 
therefore used nNOS, an enzyme that is known to be present under normal 
conditions in the NTS44,45. Its activity in the NTS increases between 2 and 10 days after 
manipulating the vagus nerve46, but not immediately after VNS41. In the current study 
we have shown that 48 hours after VNS, more nNOS-ir cells are present in the NTS of 
VNS treated rats than in that of sVNS rats.  
Responder identification 
VNS did not elicit a uniform anticonvulsive effect in the current study. Some animals 
displayed a reduced S5D, while others responded to VNS with a reduction in TSD or 
an increased S5L. According to the current standards of seizure frequency reduction, 
a minority of epilepsy patients responds to VNS2-4. Improved effectiveness may come 
from identifying responders prior to advancing with VNS. For this reason, we 
characterized responders based on behavioral and electrophysiological parameters 
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that were measured prior to treatment. This analysis did not identify a single 
predictive parameter but learned that S5D-responders are characterized by a longer 
TSD, TSD-responders by a shorter TSD and S5L-responders by a slower kindling rate 
than non-responders. Future experiments in which similar VNS responder 
characterization studies are carried out may ultimately lead to clinical identification 
of suitable candidates for VNS. 
Conclusion 
The VNS-treated kindled rat is a clinically relevant animal model because it is a 
chronic epilepsy model that responds to VNS with a reduction in TSD and S5D, and 
an increase in S5L in a subpopulation of rats. These effects are comparable to the 
anticonvulsive effects of VNS in epilepsy patients. Future translational studies may 
identify responders and non-responders when analyzing more than seizure 
frequency reduction alone.  
This study has furthermore shown that VNS-treated kindled rats can be used to study 
the mode of action of VNS using immunohistochemical techniques. Future studies 
must be aimed at identifying afferent vagus nerve projection nuclei that are critically 
involved in the anticonvulsive effect of VNS. Perhaps one of these is the optimal 
target for anticonvulsive or antiepileptic deep brain stimulation. 
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Abstract 
Vagus nerve stimulation (VNS) is a moderately effective treatment for intractable epilepsy. However, the 
mechanism of action is poorly understood. The effect of VNS in amygdala kindled rats was investigated by 
studying changes in nNOS and ∆fos B expression in primary and secondary vagus nerve projection nuclei: 
the nucleus of the solitary tract (NTS), dorsal motor nucleus of the vagus nerve (DMV), parabrachial nucleus 
(PBN) and locus coeruleus (LC).  
Rats were fully kindled by stimulation of the amygdala. Subsequently, when full kindling was reached and 
then maintained for ten days, rats received a single three-minute train of VNS starting one minute prior to 
the kindling stimulus and lasting until two minutes afterwards. In control animals the vagus nerve was not 
stimulated. They were sacrificed 48 hours later. The brain stems were stained for neuronal nictric oxide 
synthetase (nNOS) and ∆fos B. 
VNS decreased seizure duration with more than 25% in 21% of rats. No changes that could be attributed to 
VNS in nNOS immunoreactivity were observed in the NTS and no changes in Δfos B were observed in the 
NTS, PBN or LC. High nNOS immunopositive cell densities of >300 cells/mm2 were significantly more 
frequent in the left DMV than in the right (χ2(1) = 26.2, p<0.0001) independent of whether the vagus nerve 
was stimulated.  
We concluded that the observed nNOS immunoreactivity in the DMV suggests surgery-induced axonal 
damage. A three-minute train of VNS in fully kindled rats does not affect ∆fos B expression in primary and 
secondary projection nuclei of the vagus nerve. 
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Introduction 
Vagus nerve stimulation (VNS) has been used to treat refractory epilepsy patients 
since 19881. The therapy consists of prolonged cyclic electrical stimulation of the 
vagus nerve and has a number of anticonvulsive effects. In the first place, it has a 
chronic effect of reducing seizure frequency. Controlled trials have shown >50% 
seizure frequency reduction in 28-31% of patients in a treatment group versus 
13-15% in a placebo group2,3. In addition, VNS reduces seizure severity and duration 
of the post-ictal phase4,5. Moreover, approximately 10% of patients that experience 
partial onset seizures or auras prior to seizure onset can abort the seizure by on-
demand activation of the stimulator6-8. The moderately ameliorating effects9, in 
combination with the positive side effects on mood and cognition10 result in the fact 
that the vast majority of epilepsy patients, in spite of a moderate effect on seizure 
frequency, asks for replacement when the end of battery life is near.  
In spite of a consensus that VNS is moderately effective9 the mechanisms by which 
this is achieved are unknown. Other neuromodulation therapies that are currently 
used in treating patients with seizures include trigeminal nerve stimulation11 and 
deep brain stimulation of several different targets: the anterior thalamus12,13, 
subthalamic nucleus and substantia nigra pars reticulata14, hypothalamus15, zona 
incerta15, medial temporal lobe16, and centromedian nucleus of the thalamus17. These 
different targets for neuromodulation treatment result in similar anticonvulsive 
effectiveness. This raises the question as to whether these treatments, including VNS, 
are effective because they cause a nonspecific imbalance in an epileptic brain 
resulting in seizure frequency reduction, rather than causing specific deactivation of 
neuronal networks involved in seizure generation.  
The vagus nerve is a complex nerve with visceral afferent, and somatomotor and 
autonomic efferent axons. Afferent axons ending in the nucleus of the solitary tract 
(NTS) represent 80% of vagal axons. The cell bodies of the efferent vagus nerve fibers 
originate in the dorsal motor nucleus of the vagus nerve (DMV) and nucleus 
ambiguus. Ninety percent of the afferents and 70% of efferents are unmyelinated 
C-fibers18. C-fiber activation is not required for obtaining an anticonvulsive effect19. 
This implies that only 14% of vagus nerve fibers, consisting of myelinated A and B 
fibers that are normally involved in mediating reflexes20, are responsible for the 
anticonvulsive effects. The anticonvulsive effects of VNS are attributed to 
orthodromic activation of afferent vagus nerve fibers, but because VNS activates all 
vagal axons, antidromic activation of efferent vagus nerve fibers may play a role as 
well.  
The NTS, primary projection site of vagus nerve afferents, projects to both ipsilateral 
and contralateral NTS21. Inside the brainstem second order NTS neurons project 
monosynaptically to a number of other nuclei. The parabrachial nucleus (PBN) is a 
major target of the NTS22,23 that, in turn, relays information from the NTS to higher 
levels of the CNS. The NTS is also connected monosynaptically to the locus coeruleus 
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(LC)24, a nucleus that appears to be crucial in the establishment of the anticonvulsive 
effects of VNS25.  
Neuroanatomical tracing studies have further demonstrated that the vagus nerve is 
directly and indirectly connected to limbic structures that are involved in 
epileptogenesis, such as the amygdala26,27 and the hippocampus28. Neuroimaging 
studies in humans29 and immunohistochemical30,31 and electrophysiological32 studies 
in animal models have demonstrated that VNS induces changes in direct and indirect 
projection nuclei of the vagus nerve.  
These data suggest that VNS can affect epilepsy via its afferent connections. To 
investigate if this is the case we applied acute VNS in an animal model for chronic 
epilepsy, i.e., the amygdala kindled (AK) rat33, in which we recently confirmed the 
acute seizure suppressing effect of VNS34. In the current study we analyzed the brain 
stems of these animals using neuronal nitric oxide synthetase (nNOS) and Δfos B 
immunohistochemistry.  
The enzyme nNOS synthesizes nitric oxide (NO) from L-arginine. Amongst its many 
functions in the brain NO has a neurotransmitter role in the NTS35. Previous studies 
have shown nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d)36 
and nNOS37,38 staining in the NTS, a signal that is quickly upregulated in vagal 
afferents and motorneurons, after vagus nerve manipulations37-40; nNOS 
immunoreactivity can therefore be used to detect changes in neuronal activation41.  
∆FosB is a highly stable FosB isoform that persists in the brain for several weeks after 
an initial stimulus42. It is one of the immediate early genes that can be used as 
immunohistochemical marker of neuronal activity and has been shown to be present 
bilaterally in the NTS after chronic VNS31. 
The aims of the study were:  
- To investigate the degree of  vagus nerve surgery and vagus nerve stimulation-
induced changes in the NTS and DMV by means of nNOS immunohistochemistry.  
- To determine whether VNS-induced changes in neuronal activation occur in the 
NTS, PBN and the LC, by means of ∆fos B immunohistochemistry.  
Materials and Methods 
Animals 
Male 12-weeks old Sprague-Dawley (SD) rats purchased from Harlan (Horst, The 
Netherlands) were housed under controlled conditions (21 ± 2°C ambient 
temperature, a 12 hour light/dark schedule, background noise provided by radio, 
and ad libitum food and water). Adequate measures were taken to minimize pain 
and discomfort. All experimental procedures were conducted in accordance with 
international standards as defined by the European Communities Council Directive 
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of November 24th 1986 and approved by the Animal Ethics Committee of Maastricht 
University.  
Surgery 
In total, 63 rats were implanted with kindling/EEG electrodes. A subgroup of 33 rats 
was implanted with an electrode for VNS as well. In this subgroup, both procedures 
were performed in the same surgery session in which the VNS electrode was 
implanted first. Thirty minutes prior to surgery all rats received 0.1 ml buprenorphine 
hydrochloride (Temgesic®, Schering-Plough Inc., Amstelveen, The Netherlands) for 
peri-operative pain relief. All surgical procedures were performed under general 
isoflurane anesthesia (5% for induction and 2.5% for maintenance). 
Vagus nerve surgery 
Detailed descriptions of the custom made circular bipolar electrode (Medtronic 
Bakken Research Center, Maastricht, The Netherlands) and surgical procedure were 
published previously43. Briefly, the left carotid artery and vagus nerve were exposed 
in the neck. The vagus nerve was identified on the surface of the carotid artery and 
the electrode was wrapped around the nerve and artery, a technique successfully 
used by others as well31,44,45.  
Kindling/EEG surgery 
The set of electrodes for kindling/EEG was implanted stereotaxically (Dual 
Manipulator Lab Standard Stereotaxic, Stoelting Inc., Wood Dale, IL, USA). The 
amygdala stimulating/recording electrode46 (Department of Instrument 
Development, Engineering & Evaluation of Maastricht University) was implanted in 
the left basolateral amygdala with stereotaxic coordinates relative to bregma: 
-2.5 mm posteriorly, 4.8 mm laterally, and 9.6 mm ventrally derived from Paxinos47). 
Three monopolar stainless steel electrodes were implanted in the cerebral cortex at 
1 mm depth. One of three 3.8 mm laterally on the right and 2.5 mm posteriorly to 
bregma, was used for EEG, one 4.8 mm laterally to the left and 5 mm posterior to 
bregma for reference, and one 3.8 mm laterally on the right and 5 mm posterior to 
bregma for ground. Connectors for the kindling/EEG and VNS electrodes were fixed 
on the skull using jeweler screws and dental acrylic. 
Amygdala kindling 
As described previously34, ten days after surgery the pre-kindling afterdischarge 
threshold (pre-KADT) was assessed in all rats (Figure 6.1). The pre-KADT was defined 
as the stimulus amplitude necessary to elicit a two-second discharge with a high 
frequency and high voltage in the amygdala. For this, the amygdala was stimulated 
with a series of pulses delivered at an interstimulus interval of two minutes using 
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steps of 10 μA starting at 10 μA (50 Hz, 0.2 ms square wave delivered by a WPI 
Accupulser A310 connected to a WPI Stimulus Isolation Unit A360 (World Precision 
Instruments, Sarasota, FL, USA).  
Kindling was started the next day (Figure 6.1) with a two-second 50 Hz stimulus 
(400 μA, 0.2 ms square wave pulses). 400 μA was chosen as stimulus intensity since it 
was at least 200% above pre-KADT for all rats. The amygdala was stimulated twice 
per day (first stimulus between 8 and 10 am, second stimulus between 2 and 4 pm; 
interstimulus interval at least 6 hours). Seizure stage was determined based on 
Racine’s five-point scale48 in which stage one seizures are characterized by unilateral 
eye closure (mild facial clonus), stage two by bilateral eye closure and chewing 
(severe facial clonus), stage three by unilateral forelimb clonus, stage four by rearing 
and stage five by loss of balance and falling. After five consecutive stage five seizures, 
the animals were considered fully kindled. Subsequently, the amygdala was 
stimulated once per day for two more weeks. Sham-kindled rats were handled in 
exactly the same way as the kindled animals, but did not receive the kindling 
stimulus.  
All rats were videotaped (Minolta DiMage G400, Konica Minolta Inc., Tokyo, Japan) 
during delivery of the kindling stimulus and for as long as the behavioral seizure 
lasted. Videos were analyzed offline by two blinded observers who assessed seizure 
stage based on Racine’s scale.  
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Time line in days illustrating the series of experiments. 
 
EEG analysis 
The EEG recordings from the amygdala and cortex were made using a Vangard 
system (Vangard Systems, Cleveland Clinic Foundation, Cleveland, USA). Recordings 
were made with a sample frequency of 200 Hz, frequency band of 0.5-70 Hz and with 
a 50 Hz notch filter. The total seizure duration was determined by a blinded observer 
and defined as the duration of rhythmic activity (spikes, sharp waves or slow waves) 
on the EEG. A seizure was considered to have ended when these wave forms 
occurred less than once per ten seconds. The VNS-induced effect on total seizure 
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duration was determined as follows: seizure duration during VNS was expressed as 
the percentage of the average seizure duration of the five preceding seizures.  
Vagus nerve stimulation 
For VNS, rats were connected to an external pulse generator (Pulse™ Model 102 
Generator, Cyberonics Inc., Houston, Texas) and stimulated with 30 Hz, 1.0 mA 
amplitude, 0.5 ms square waves, using a 30s/12s ON/OFF cycle. VNS was 
administered for three minutes starting one minute prior to the last kindling 
stimulus, and continuing for two minutes thereafter (Figure 6.1). This stimulation 
paradigm mimics the clinical situation where a patient with partial onset seizures or 
an aura prior to seizure onset can acutely activate the pulse-generator to stop further 
seizure progression7.  
Experimental groups 
Rats were divided into four experimental groups and were handled in exactly the 
same way: 1) rats that were kindled (AK, n=12), 2) rats that were implanted with an 
amygdala electrode and in which pre-KADT was measured, but that were not kindled 
(sham AK; sAK, n=8), 3) kindled rats that were treated with VNS (VNS, n=8), and 4) 
kindled rats that were implanted with a VNS electrode, but not received actual 
electrical stimulations through this electrode (sham VNS, sVNS, n=11).  
Histology and immunohistochemistry 
Forty-eight hours after the last seizure the rats received an overdose of pentobarbital 
(Nembutal) followed by transcardial perfusion with tyrode buffer (in mM: 136.9 NaCl, 
2.7 KCl, 0.2 MgCl2, 11.9 NaHCO3, 0.3 NaH2PO4, 5.0 glucose, equilibrated with 5% CO2 / 
95% O2), and then with fixative (4% paraformaldehyde in 0.1M phosphate buffer, 
pH 7.6).  
The brains were removed and postfixed in the same fixative (4°C, 48h), cryoprotected 
in 20% sucrose/0.1M phosphate buffer at (4°C, 24h) and rapidly frozen and stored at -
80°C until further processing. The vagus nerve was exposed in order to confirm the 
electrode position.  
Coronal 10 μm serial sections through the brain stem from the level of the central 
canal – fourth ventricle junction (bregma -13.6) caudally to the level of the inferior 
colliculus (bregma -9.6) rostrally were cut on a cryostat, mounted on gelatin-coated 
glass slides, and stored at -20°C.  
Standard haematoxylin-eosin (Merck, Germany) staining was used to identify the 
location of the tip of the kindling electrode.  
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nNOS immunohistochemistry 
For nNOS immunohistochemistry, sections were rinsed in Tris-buffered saline 
containing 0.3% Triton (TBS-T) and incubated 24 hours with rabbit anti-nNOS 
antibody (ImmunoStar, Inc., Hudson, WI, USA) diluted 1:400 in TBS-T. The next day 
sections were rinsed in TBS-T and incubated for 90 minutes with donkey anti-rabbit 
antibody conjugated to Alexa 488 (Invitrogen Inc., Eugene, Oregon, USA) diluted 
1:100 in TBS-T. Sections were rinsed with Tris-buffered saline (TBS), and coverslipped 
with 80% glycerol in TBS.  
∆fos B immunohistochemistry 
For ∆fos B immunohistochemistry, sections were rinsed in TBS-T, and incubated 48 
hours at 4°C with rabbit polyclonal antibody against mouse fos B (sc - 48, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) diluted 1:250 in TBS-T containing 0.5% 
bovine serum albumin. Next, sections were rinsed in TBS-T, and incubated overnight 
with the donkey-anti rabbit biotinylated secondary antibody (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA, USA) diluted 1:400 in TBS-T 
containing 0.5% bovine serum antigen. The next day, sections were rinsed, incubated 
for 2 hours with avidin/biotin (Vectastain ABC-kit, Vector Laboratories Inc., 
Burlingame, CA, USA) diluted 1:800. Immunohistochemical staining was visualized 
using diaminobenzidine and 0.5% NiCl.  
 
The primary antibody was omitted for some sections to confirm specificity of 
immunohistochemical staining for both antibodies.   
Stereology for nNOS stained sections 
nNOS ir cell densities in the NTS and DMV were analyzed in VNS and sVNS animals 
using a MBG Bioscience Stereo Investigator system (MBF Bioscience; Williston, VT, 
USA). The system consisted of an Olympus BX50 fluorescence microscope (Olympus, 
Tokyo, Japan) with an Olympus UPlanApo 20x (oil; N.A. =0.80) objective, a three-axis 
high-accuracy computer-controlled stepping motor specimen stage (4x4 Grid 
Encoded Stage; Ludl Electronic Products, Hawthorne, NY, USA), a linear z-axis 
position encoder (Ludl Electronic Products, Hawthorne, NY, USA), a CX9000 CCD 
color camera (1.200x1.800 pixels; MBF Bioscience) and controlling and 
StereoInvestigator software (MBF Bioscience). Every 10th section was analyzed with 
the Fractionator probe. The NTS (~10 sections, 4 animals per group) and DMV (~8 
sections, 4 animals per group) were delineated in sections between bregma -12.5 
and -13.6 mm. All nNOS immunopositive cells in the delineated areas were counted.  
In the NTS the following subnuclei were analyzed separately as well: central 
subnucleus (cNTS), medial subnucleus (mNTS), oval subnucleus (oNTS), ventrolateral 
subnucleus (vlNTS), parvocellular subnucleus (pcNTS) and the dorsomedial subnuclei 
(dmNTS). These NTS subnuclei were identified according to the parcellations of 
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Altschuler et al.21 and the results of differential staining after lesions of the vagus 
nerve41. Cell densities were calculated by dividing the number of immunopositive 
neurons by the cross-sectional area of the relevant parts of the NTS at 20x 
magnification.  
∆FosB immunopositive cell counts 
∆FosB immunopositive cell densities in the NTS (5-6 animals per group), PBN (3-6 
animals per group) and LC (5-6 animals per group) of AK, sAK, VNS and sVNS rats 
were estimated as follows. The three regions were photographed in every 10th 
section at 4x magnification. The NTS was studied between bregma -11.7 and -14 (~10 
sections), the PBN between bregma -9.6 and -9.9 (~3 sections) and the LC between 
bregma -9.6 and -10.5 (~8 sections) with an Olympus AX-70 microscope connected to 
a digital camera (DP70; Olympus, Tokyo, Japan). In these photographs the areas of 
interest were delineated and immunopositive neurons were counted using NIH 
ImageJ software (http://rsb.info.nih.gov/ij/). A cell was counted as ∆FosB positive if its 
density was 75% higher than background density, a method previously used for 
counting C-Fos positive cells49. The same black/white threshold conditions were used 
for all sections. Cell densities were calculated by dividing the number of 
immunopositive neurons by the area of the selected nuclei.  
Statistical analysis 
Statistical analysis was performed using SPSS v16.0 for MacOSX. Values are expressed 
as means ± standard deviations.  
Differences in nNOS immunopositive cell densities in the NTS and DMV between VNS 
and sVNS rats were analyzed using a Mann-Whitney U test. Differences between left 
and right were calculated using a Wilcoxon signed ranks test. Pearson Chi-Square 
test and odds ratios were used to calculate whether a high DMV nNOS cell density of 
>300 cells/mm2 was more frequent in either left or right DMV.  
Differences in ∆FosB immunopositive neuron densities in the NTS, PBN and LC 
between AK, sAK, VNS and sVNS animals were analyzed using a Kruskal-Wallis test, 
followed by Mann-Whitney U tests on selective comparisons (with adapted critical 
significance levels) as post-hoc tests. Differences between left and right were 
calculated using a Wilcoxon signed-rank test. 
The correlation between ∆FosB immunopositive cell density in the NTS, PBN and LC 
and the response to VNS was analyzed using Spearman’s correlation coefficient. 
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Results 
Of the 63 rats that were operated on, twenty-four rats did not complete the 
experiments due to surgery related, anesthesia related and hardware complications, 
while 39 rats completed the experiments. After implanting the VNS electrode, 20 of 
33 rats had Horner’s syndrome43, which has also been reported as a complication of 
VNS in humans50. Postmortem visual inspection confirmed that the VNS electrode 
was located around the vagus nerve and carotid artery in all VNS animals, while in 
three sVNS rats the electrode was detached from artery and nerve, although still in 
close proximity to these structures.  
In all 39 cases that were processed for immunohistochemistry the tip of the kindling 
electrode was located in the left basolateral amygdala according the rat stereotaxic 
atlas47.  
All kindled rats were fully kindled after 17 ± 4 stimuli, i.e. range of 7–10 days. Kindling 
rates did not differ significantly between VNS rats (19 ± 4 stimuli), sVNS rats (16 ± 4) 
and kindled rats (16 ± 5 stimuli). 
Anticonvulsive effect of VNS 
Animals with a greater than 25% reduction in total seizure duration after VNS 
treatment were considered responders. Responders represented 57% of VNS, 36% of 
sVNS, and 9% of kindled rats.  
Histochemistry and immunohistochemistry 
nNOS  
VNS rats showed a higher density of nNOS immunopositive cells throughout the NTS 
(Figure 6.2) and DMV (Figure 6.3) than sVNS rats, but these differences did not reach 
the level of statistical significance. VNS responders did not significantly differ from 
non-responders either. nNOS immunopositive cells were found throughout the NTS 
and DMV bilaterally in all groups. The DMV contained large nNOS immunopositive 
cells while the nNOS immunopositive cells in the NTS were smaller. The nNOS 
immunopositive cells were not evenly distributed over the whole NTS. We observed 
a high density of clustered immunopositive cells in some subnuclei, while other 
subnuclei showed few scattered nNOS immunopositive cells (Figure 6.2). There were 
no statistically significant differences in nNOS immunopositive cell density between 
VNS and sVNS animals in the cNTS (Figures 6.2 A-D), mNTS, oNTS, vlNTS, pcNTS and 
dmNTS (Figures 6.2 E-H).  
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Figure 6.2 nNOS immunopositive cells in the right central subnucleus of the NTS at bregma -13.5 mm 
(A, B, C, D) and the left dorsomedial NTS subnuclei (mediodorsal, dorsal and gelatinosous) at 
bregma -13.6 mm (E, F, G, H), at 10 x (A, C, E and G) and 40 x (B, D, F and H) magnification. 
Dotted lines indicate the cNTS (A, C) and dmNTS (E, G). Rectangles in A, C, E and G indicate 
the area of magnification in B, D, F and H. 
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Figure 6.3 nNOS immunopositive cells in the left DMV at bregma -13.3 mm at 10x (A, C) and 40x (B, D) 
magnification. Dotted lines indicate the DMV (A, C). Rectangles in A and C indicate the area 
of magnification in B and D, respectively. 
 
 
The DMV was found medioventrally to the mNTS in the caudalmost sections, and 
medially to the mNTS in the rostral sections. In both VNS and sVNS rats there was a 
high density of large nNOS immunopositive cells (Figure 6.3 A-D) and there were  no 
statistically significant differences between VNS and sVNS animals, nor between VNS 
responders and non-responders. Among both VNS and sVNS rats, nNOS 
immunopositive cell densities greater than 300 cells/mm2 were found more 
frequently in the left DMV than in the right DMV (χ2(1)=26.205, p<0.0001, Figure 6.4). 
Thus, based on the odds ratio it is 8.36 times more likely that cell density in the left 
DMV is greater than 300 cells/mm2 compared to the right DMV. There is a trend 
towards a significant association between VNS treatment and a cell density larger 
than 300 cells/mm2 in the left DMV χ2(1)=3.237, p=0.072, representing the fact that 
based on the odds ratio it is 2.37 times more likely that cell density in the left DMV of 
VNS rats is greater than 300, compared to the left DMV of sVNS rats. This trend was 
not present in the right DMV (odds ratio 1.23).  
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Figure 6.4 nNOS immunopositive cell density in the left and right dorsal motor nucleus of the vagus 
nerve (DMV). X-axis: level of investigation in mm posterior to bregma; y-axis: nNOS 
immunopositive cells (cells/mm2). Horizontal line marks the 300 cells/mm2 line. 
 
∆FosB 
In both left and right NTS, VNS rats showed a trend to a higher density of ∆FosB 
immunopositive cells than sVNS, AK and sAK rats, but this difference did not reach 
the level of statistical significance (Figure 6.5A and 6.5C and Figure 6.6A and 6.6B). 
NTS ∆FosB immunopositive cell density was highest in the rat that responded with 
the largest reduction in total seizure duration, but there was not a significant 
correlation between ∆FosB immunopositive cell density and total seizure duration 
reduction.  
In the PBN, some rats showed scattered ∆FosB immunopositive cells but most 
animals did not show any ∆FosB immunopositive cells at all. The highest density of 
∆FosB immunopositive cells was found in the right PBN of VNS rats (Figures 6.5B and 
6.5E), but this density was not significantly higher than the ∆FosB immunopositive 
cell density in the other three groups (Figures 6.6C and 6.6D). The PBN ∆FosB 
immunopositive cell density did not correlate with VNS-induced seizure duration 
reduction.  
In the LC, the highest densities of ∆FosB immunopositive cells were found on the 
right side of VNS rats (Figure 6.5B and 6.5D), but these levels were not significantly 
higher than those in the other groups (Figures 6.6E and 6.6F). Within-subject analysis 
did not reveal statistically significant differences between left and right PBN. The LC 
∆FosB immunopositive cell density did not correlate with VNS-induced seizure 
duration reduction. 
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Figure 6.5 ∆fos B immunopositive cells in the right NTS (A & C), right LC (B & D) and right PBN (B & E) of a 
VNS rat. Dotted line in 1A depicts the NTS, dotted lines in 1B depict the PBN on the right of 
the picture and LC on the left of the picture. Black arrowheads in C, D and E point at ∆fos B 
immunopositive cells.  
Discussion 
This study examined the pattern of nNOS immunoreactivity in the NTS and DMV and 
ΔfosB immunoreactivity in the NTS, DMV, PBN and LC of epileptic rats that were 
treated with acute VNS. It has been suggested that VNS is effective because changes 
are observed in these brain stem nuclei, which are structures that are connected to 
hippocampus and amygdala, where seizures originate.  
Vagus nerve afferents 
∆FosB immunohistochemistry was used to investigate activation of the afferent 
vagus nerve fibers. ∆FosB is considered to be indicative of neuronal activity42. 
Immunohistochemical detection of neuronal activity is often done using immediately 
early genes such as C-Fos, FosB or ∆FosB. C-Fos staining of the primairy projection 
nucleus of vagus nerve afferents, the NTS, immediately after VNS in non-epileptic rats 
has shown that more NTS neurons are activated immediately after VNS than after 
sVNS30,31,51. Chronic cyclic VNS additionally induces NTS ∆FosB expression31. In the 
current study epileptic rats were sacrificed 48 hours after a single train of VNS. At this 
time point, both C-Fos and FosB expression, which have their peaks at 2 and 6 hours 
after the stimulus, respectively, have returned to baseline42. In contrast, ∆FosB is a 
highly stable FosB isoform that persists in the brain for several weeks after an initial 
stimulus42. 
 Rat vagus nerve stimulation model of seizure suppression: nNOS and ∆fos B changes⏐123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Bar diagrams showing the average number of ∆FosB immunopositive cells per area in the 
NTS (A & B), PBN (C & D) and LC (E & F) per experimental group. Data are expressed as 
average ± standard deviation of 50-60 NTS sections from 5-6 animals per group, 9-18 PBN 
sections from 3-6 animals per group and 40-48 LC sections from 5-6 animals per group. The 
number of cells per square millimeter is the number on the y-axis divided by 1.5. 
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The highest density of ∆FosB ir cells was found in the NTS of VNS rats, but, in contrast 
to Cunningham et al., this level was not significantly higher than the ∆FosB density in 
the other three groups31. Several factors can account for this lack of statistically 
significant differences. First of all, the large variation in ∆FosB immunopositive cell 
density between rats, as well as the low number of rats per experimental group (five 
or six) may have contributed to this. Secondly, in comparison with Cunningham et al. 
there were important differences in stimulation protocol: we used a three-minute 
train of VNS while Cunningham et al. used three weeks of continuous cyclic 
stimulation with a duty cycle of 30s on, 5 min off. In the third place, immuno-
histochemical analysis differed with regard to the number and thickness of sections 
that were analyzed (10 sections of 10 μm thickness in the current study, versus 3 to 6 
sections of 40 μm in the study of Cunningham et al.31). In addition, previous studies 
have shown that the NTS is subdivided into several functionally and anatomically 
different subnuclei21,52. VNS-induced changes may be restricted to NTS subnuclei that 
we were unable to anatomically delineate based on the ∆FosB staining. The fact that 
we used amygdala kindled rats may have affected the ∆FosB immunopositive cell 
density in the NTS as well, because the NTS receives a direct projection from the 
central amygdala26,53, as well as from the sensorimotor54 and motor55 cortex, areas 
that have been activated daily during the experiments as a result of the generalized 
seizure. In line with this theory one would expect high ∆FosB immunopositive cell 
density in the NTS of kindled animals as well, an assumption that we could not verify 
in our study because there was no significant difference in NTS ∆FosB 
immunopositive cell density between kindled rats and shams. No studies on this 
topic are available to compare our results with.  
The PBN and LC ∆FosB studies did not reveal statistically significant differences 
between the four experimental groups either. Similarly to the NTS analysis, the 
groups were small and ∆FosB immunopositive cell density showed a large variability. 
Furthermore for technical reasons both nuclei were only analyzed in part. Despite all 
these restrictions and despite the lack of significance, when looking at Figure 6.6 it 
seems that a trend towards an effect of both kindling and VNS is present in the PBN 
and LC. These two nuclei are connected bilaterally to the NTS 24, and ipsilaterally to 
the amygdala26, and in line with these anatomical connections the left PBN and left 
LC of kindled rats contained the highest density of ∆FosB immunopositive cells, 
whereas on the right side the highest density was found in the VNS group.  
Vagus nerve efferents 
nNOS has previously been used to study the functional anatomy and connectivity of 
the NTS and DMV. These studies have revealed that nNOS is quickly upregulated 
after vagus nerve manipulations, while in healthy, untreated rats nNOS expression in 
the NTS is robust in some areas while in the DMV it is limited to a faint background 
signal37-40. We used the nNOS staining to evaluate to what extent neurons in the NTS 
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(vagal afferents) and DMV (vagal efferents) are affected by manipulation of the vagus 
nerve during implantation of the vagus nerve electrode and VNS itself.  
To minimize damage to the vagus nerve during surgical placement of the electrode 
we were as careful as possible with respect to mechanical contact with the vagus 
nerve itself during surgery. To protect the nerve from reactive gliosis and Wallerian 
degeneration that may develop as a result of surgical manipulation, we implanted 
the circular electrode around both vagus nerve and carotid artery. Although this 
technique has been used previously31,44,45, in the vast majority of experimental VNS 
studies, the vagus nerve is first prepared free from the carotid artery after which an 
electrode is wrapped around it19,25,56-62. Despite our cautious surgical technique we 
found an important effect of vagus nerve surgery because an nNOS immunopositive 
cell density of >300 cells/mm2 was found eight times more often in the left DMV than 
in the right DMV of both VNS and sVNS animals. These DMV immunopositive cells are 
motorneurons containing the cell bodies of efferent fibers traveling down the 
ipsilateral vagus nerve.  
Previous studies have shown increased nNOS expression induced by vagus nerve 
manipulations, especially lesions, between two and at least 40 days after these 
manipulations41,63. Another study52 has shown the persistence of changes in vagal 
neurons for up to 90 days. In the present study,  vagus nerve surgery had been 
performed 38 days prior to sacrifice while VNS was performed 48 hours prior to 
sacrificing the animals; a time-point at which, based on these previous findings, VNS-
induced nNOS expression can be expected as well.  
It is possible that electrical stimulation of the vagus nerve may have additionally 
contributed to the nNOS signal in the DMV the current study, since VNS rats were 2.4 
times more likely than sVNS rats to have a nNOS cell density of >300 cells/mm2 in the 
left DMV. If VNS has indeed contributed to the nNOS signal in the DMV, which is an 
efferent output nucleus of the vagus nerve, the question remains what this VNS-
induced nNOS activity illustrates: antidromic activation of vagus nerve efferents or 
non-activation related changes in cellular functioning resulting from the electrical 
stimulation.  
In the NTS, nNOS immunopositivity was present after VNS and sVNS in the various 
subnuclei as well but in contrast to the DMV, no differences in nNOS immunopositive 
cell density between the ipsilateral and contralateral NTS were observed. This 
apparently contradictory finding is most likely related to the fact that the DMV is a 
pure motor nucleus while the NTS is a sensory nucleus containing a large number of 
vagus nerve afferents. These afferents are known to express much less nNOS in 
response to vagus nerve manipulations than efferents41.  
What manipulations (surgery, electrical stimulation or both) are responsible for the 
nNOS upregulation is unclear. With regard to this last question, previous studies have 
shown that strong increases in nNOS immunopositive neurons in the NTS and DMV 
were found after vagotomy41. Furthermore, these vagotomy-induced changes in 
nNOS immunopositivity overlap with vagus nerve injury-induced changes in the 
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expression of the 27-kDA heat shock protein (Hsp27), a protein that is rapidly 
induced following oxidative and cellular metabolic stress52. Quantification of the 
nNOS immunopositive cell density in the NTS subnuclei in the current study did not 
reveal differences between treated and untreated animals, a finding contradicting 
our previous publication on VNS-treated rats34. When we presented our previous 
findings we had only analyzed 5 animals per group while in the current study we 
were able to include one animal per group more. Apparently the findings in these 
animals are responsible for the lack of significance in the current study.  
This lack of stimulation effect may be related to the fact that in previous studies 
nNOS mainly affected vagus nerve efferents41, and not afferents which are the fibers 
that most likely are responsible for the anticonvulsive effect of VNS. We therefore 
conclude that the VNS-induced effect on vagus nerve afferents can not be analyzed 
using this staining.  
Conclusion 
Vagus nerve stimulation has an anticonvulsive effect in the amygdala kindled rat. 
Independent of this anticonvulsive effect, significant changes that are indicative of 
axonal damage occur in the vagus nerve motor neurons as a result of vagus nerve 
electrode placement. Axonal damage may occur after human VNS surgery as well. 
This may contribute to two clinical observations. First of all to the lack of 
effectiveness in some of the VNS-refractory cases. Secondly it may contribute to the 
fact that in most patients, the anticonvulsive effects of VNS are not present 
immediately after VNS but rather after weeks to months and increase during the first 
year of VNS, which may be the ‘healing period’ of the nerve after having suffered 
from surgical damage. Axonal damage is likely to occur in other animal experiments 
as well, especially those in which the vagus nerve is dissected free from the carotid 
artery.  
We were unable to confirm VNS-induced neuronal activation using ΔFosB 
immunohistochemistry in the NTS, PBN and LC. Studies with large animal groups and 
a VNS stimulating protocol specifically designed for immunohistochemical detection 
of neuronal activation must be conducted in future to investigate the VNS-induced 
neuronal activation in the brain stem. 
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Abstract 
We report on the occurrence of iatrogenic Horner’s syndrome (HS) in epileptic rats after implantation of an 
electrode for vagus nerve stimulation and to describe the possible consequences of this new complication 
of carotid artery surgery in rats.  
A bipolar circular electrode was placed around the left carotid artery and vagus nerve of 31 rats. The 
incidence of HS was evaluated by visual inspection within 24 hours after surgery. 
Results: 68% of rats suffered from HS immediately after surgery. This complication did not affect 
epileptogenesis. 
The occurrence of HS in the rat is a frequent complication of vagus nerve electrode implantation, which 
does not affect epileptogenesis in this study. However, rats affected by HS may suffer from damage to the 
sympathetic innervation of the gut, due to rat-specific neuroanatomy. Therefore, caution towards other 
research questions is warranted. 
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Introduction 
Horner's syndrome (HS), or oculosympathetic palsy, is a clinical syndrome 
characterized by four symptoms: ptosis, miosis, enopthalmos and facial anhidrosis1. 
The syndrome was first described in animals in 1858 by Claude Bernhard. Eleven 
years later Johann Friedrich Horner described it in humans as well2.  
HS is caused by disruption of the oculosympathetic system. This system provides the 
sympathetic innervation of the eye and consists of a three neuron pathway (Figure 
7.1):  
1. The first order neurons originate in the posterior hypothalamus, course caudally 
through the mesencephalon and pons and terminate in the intermediolateral 
cell column of the spinal cord (the ciliospinal centre of Budge at the 
cervicothoracic junction).  
2. The second order neurons originate in the centre of Budge, leave the spinal cord 
and enter the sympathetic chain to end in the superior cervical ganglion (SCG).  
3. The third order neurons originate in the SCG and course cranially with the 
carotid artery. At the carotid bifurcation, the fibers that innervate the facial sweat 
glands follow the external carotid artery. All other sympathetic fibers adjoin the 
internal carotid artery through the carotid canal of the petrous bone, over the 
foramen lacerum and into the cavernous sinus. Here, the fibers that innervate 
the pupillodilator muscle join the ophthalmic branch of the trigeminal nerve to 
enter the orbita through the superior orbital fissure. They pass the ciliary 
ganglion and end as two ciliary nerves on the pupilodilator muscle. The fibers 
that innervate the tarsal muscle and lacrimal glands leave the cavernous sinus 
with the carotid artery, and subsequently join the opthalmic artery to enter the 
orbita through the foramen opticum. The tarsal muscles contribute to eye 
opening.   
HS can be caused by a tumor, inflammatory process, trauma or surgical procedure in 
any of the anatomical regions described above. It also has an idiopathic variant, 
which can be hereditary1. The clinical diagnosis of HS is made by darkening the 
patient’s room, which causes a normal pupil to dilate. In HS, miosis of 2-3mm will 
become apparent. Instillation of 4% cocaine in the eye causes a normal pupil to 
dilate, and can confirm the clinical diagnosis3. The partial ptosis and enophthalmos 
are caused by paralysis of the tarsal muscle. Ptosis is partial because the levator 
palpebrae muscle is unaffected.  
HS has been described before in different animals4-8, but not, to our knowledge, in 
rats. 
The oculosympathetic nervous system in rats consists of a similar three-neuron 
pathway as in humans. The localization of the SCG in rats, dorsally to the carotid 
bifurcation, is similar to that in humans as well9. There is however one important 
anatomical difference between the human SCG and the rat SCG: in humans the SCG 
consists exclusively of oculosympathetic fibers, whereas in rats a small branch of 
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sympathetic fibers leaves the SCG and courses caudally with the efferent vagus nerve 
to contribute to the sympathetic, adrenergic innervation of the small intestine10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Scheme depicting the three-neuron pathway constituting the oculosympathetic pathway.  
 The first order neurons originate in the posterior hypothalamus and course caudally to end 
in the ciliospinal centre of Budge at the level of the cervicothoracic junction. The second 
order neurons, originating in the centre of Budge, leave the spinal cord and enter the 
sympathetic chain to end in the superior cervical ganglion. Fibers in the third order neurons, 
originating in the superior cervical ganglion, course cranially with the carotid artery to reach 
their different targets. 
 
 
We think that HS can occur in rats as well. This assumption is based on the finding of 
ptosis and enophthalmos in rats that were implanted with an electrode around the 
left carotid artery and vagus nerve for vagus nerve stimulation (VNS) (Figure 7.2). VNS 
was used to treat epileptic seizures provoked by amygdala kindling (AK). Moreover, 
we hypothesize that the occurrence of HS does not influence seizure susceptibility, 
because the oculosympathetic system is not involved in epileptogenesis. 
 
The aim of the present article is, to present our series of rats in which HS occurred, 
and to describe the possible consequences of this new complication of carotid artery 
surgery in rats. 
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Figure 7.2 Rat with mild Horner’s Syndrome. Enophthalmos and 
ptosis are visible at left eye (arrow). 
Materials and Methods 
Animals 
Thirty-one male adult Sprague-Dawley rats, purchased from Harlan (Horst, The 
Netherlands) were kept under controlled conditions (21 ± 2°C ambient temperature, 
a 12 hour light/dark schedule, background noise provided by radio and food and 
water available ad libitum). The animals were allowed to adapt to the laboratory for 
one week before surgery. All experimental procedures were approved by the animal 
ethics committee of Maastricht University and complied with governmental 
legislation.  
Surgery 
All rats underwent surgery to implant two types of electrodes: one electrode for VNS 
and one set of electrodes for AK. Thirty minutes prior to surgery all rats received 
0.1ml buprenorfine (Temgesic) subcutaneously for pain relief. All surgical procedures 
were performed under general isoflurane anesthesia (5% for induction and 2.5% for 
maintenance).  
Vagus nerve electrode 
First, the left carotid artery and vagus nerve were exposed according to the following 
procedure: a 3 cm long skin incision was made on the ventral side of the neck. After 
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retracting the salivary glands and the left sternomastoid muscle laterally, the 
sternothyroid and omohyoid muscles were visualized. The sternohyoid muscle was 
left in its medial position. The carotid artery was found in the angle between the 
sternomastoid and sternohyoid muscles. The carotid sheath was carefully opened 
over a distance of approximately 7 mm. The vagus nerve was found on the lateral 
surface of the carotid artery. Subsequently, a custom made circular electrode (Figure 
7.3, developed by P. van Venrooij and V. Duysens, Medtronic Bakken Research 
Center, Maastricht, The Netherlands), was wrapped around both carotid artery and 
vagus nerve. The electrode lead was fixed to the surrounding tissue ventrally using a 
non-absorbable silk suture. The wound was closed intracutaneously using 
absorbable wire. The VNS electrode was implanted with assistance of an operating 
microscope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Vagus nerve electrode. A: lateral view; B: ventral view. After placement, the carotic artery 
and vagus nerve are both located inside the lumen of the electrode, now occupied by the 
green suture (black arrow). The two circular metal strips (white arrows) are the positive 
and negative electrodes. Scale bar illustrates the true size of the electrode. 
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Electrodes for kindling  
A second set of electrodes was implanted using a standard rat stereotact (Dual 
Manipulator Lab Standard Stereotact, Stoelting Inc., Wood Dale, Ill, USA). The 
amygdala stimulating/recording electrode was originally designed for deep brain 
stimulation in rats by the department of Instrument Development, Engineering & 
Evaluation (Maastricht University, Maastricht, The Netherlands) in collaboration with 
Dr. Y. Temel (Maastricht University Medical Center, the Netherlands)11, and consisted 
of a bipolar platinum/iridium needle (200 μm tip diameter) that was implanted in the 
left basolateral amygdala (BLA, coordinates relative to bregma: -2.5 mm posteriorly, 
4.8 mm laterally, and 9.6 mm ventrally)12. In addition, three monopolar stainless steel 
needles were implanted in the cortex at ~1 mm depth. Of these electrodes, one was 
used for recordings, one for reference, and one for ground.  
The connectors for both AK and VNS were fixed on the skull using dental acrylic 
cement (Paladur, Heraeus Kulzer GmbH, Wherheim, Germany). 
Amygdala kindling 
AK is an animal model for temporal lobe epilepsy13. It consists of electrical stimulation 
of the amygdala, twice daily. Initially, these stimuli induce afterdischarge (AD) activity 
in the amygdala, but no seizure activity. After several days of repeated stimulation, 
seizure activity becomes apparent, both on the EEG and behaviorally. Severity of the 
behavioral seizures increases with each stimulus, and is graded on a five-point 
scale14. After the rats have experienced five consecutive stage five seizures they are 
considered to be ‘fully kindled’. This fully kindled state is associated with irreversible 
changes in the brain and with irreversibly increased seizure-susceptibility. 
Ten days after surgery the afterdischarge threshold (ADT) was assessed. ADT is 
defined as the stimulus amplitude necessary to elicit a high frequent, high voltage 
discharge with a duration of two seconds, on the amygdala electrode. It is 
determined by stimulating the amygdala with a series of pulses of increasing 
intensity starting at 10 μA (50 Hz, 0.2 ms blockpulse). Stimuli were delivered through 
a WPI Accupulser A310 connected to a WPI Stimulus Isolation Unit A360 (World 
Precision Instruments, Sarasota, FL, USA). The EEG registrations from the amygdala 
and cortical electrodes were performed using a Vangard system (Vangard Systems, 
Cleveland Clinics Foundation, Cleveland, USA).    
The next day, the actual AK experiment started. The amygdala was initially 
stimulated twice daily (400 μ, 50 Hz, 0.2 ms blockpulses). After reaching the fully 
kindled state, the frequency of AK stimulation was reduced to once daily. These 
once-a-day stimulations were continued for two weeks.  
All rats were videotaped (Minolta DiMage G400, Konica Minolta Inc., Tokyo, Japan) 
during delivery of the AK stimulus and for as long as the behavioral seizure lasted. 
Seizure severity was determined offline by two blinded observers.  
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Statistical analysis 
To investigate the influence of HS on the development of epileptic seizures, ADT and 
kindling rate were compared between rats with HS and without HS by a two-tailed 
Mann-Whitney U test. Data are expressed as median (mdn). 
Results 
Nineteen of the 31 rats (61%) reached the fully kindled stage and 12 rats dropped out 
due to loss of the brain electrodes (Table 7.1). Postmortem verification of the vagus 
nerve electrode position was performed in 26 rats; it was discovered that in four of 
the rats, the electrode was no longer wrapped around the carotid artery and vagus 
nerve. Routine histochemical evaluation of 10 μm brain sections confirmed that the 
amygdala electrode was located in the amygdala in all fully kindled animals. 
Horner’s syndrome  
HS, consisting of either left-sided ptosis and enophthalmos or isolated enopthalmos, 
was noted in 68% of rats (21 of 31, see Table 7.1). In the first group of rats that was 
operated on (experimental group 1, n=12), 58% suffered from HS. In experimental 
groups 2 (n=10), 3 (n=5) and 4 (n=4) this percentage was 60, 100 and 75, respectively. 
Of the 4 rats in which  the VNS electrode was not wrapped around the carotid artery 
during postmortem examination, one had HS (25%). Of the 22 other rats, 20 had HS 
(91%).  
Epilepsy  
There was no statistically significant difference between the ADT of rats with HS 
(mdn 50.00 μA) and that of rats without HS (mdn 56.25 μA). There was no statistically 
significant difference between the kindling rate of rats with HS (mdn 17 stimulations) 
and that of rats without HS (mdn 17 stimulations) either. 
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Table 7.1 Characteristics of the rats. 
Subject  Horner’s 
syndrome 
Experimental 
group 
Loss of 
electrode 
Position of 
vagus 
electrode 
Kindling 
rate 
ADT 
(μA) 
1 + 1 + n.d. n.d. 100 
2 + 1 + correct n.d. 50 
3 + 1 + correct n.d. 50 
4 + 1 + correct n.d. 75 
5 - 1 + correct n.d. 50 
6 - 2 + correct n.d. 75 
7 + 2 - correct 20 37.5 
8 + 2 - correct 26 62.5 
9 - 2 - correct 17 62.5 
10 + 2 + correct n.d. n.d. 
11 + 2 - correct 14 125 
12 + 2 - correct 21 82.5 
13 + 3 - correct 20 50 
14 + 3 - correct 17 112.5 
15 + 3 + correct n.d. n.d. 
16 + 3 - correct 15 37.5 
17 + 4 + correct n.d. 35 
18 - 4 + correct n.d. n.d. 
19 + 4 + correct n.d. n.d. 
20 - 1 - not correct 13 75 
21 + 1 - correct 13 50 
22 - 1 - n.d. 10 50 
23 + 1 - n.d. 20 50 
24 - 1 - correct 22 75 
25 - 1 + n.d. n.d. n.d. 
26 + 1 - n.d. 19 50 
27 - 2 - not correct 17 37.5 
28 + 2 - not correct 16 37.5 
29 - 2 - not correct 20 50 
30 + 4 - correct 14 60 
31 + 3 - correct 10 87.5 
Characteristics of the rats. + = present; - = absent; n.d. = not determined; ADT = afterdischarge threshold; 
μA = micro Ampère 
 
Discussion 
In humans, 10% of non-idiopathic HS is reported to be iatrogenic15. Most of these 
cases are caused by medical interventions in the cervical area such as internal jugular 
vein cannulation16-19, thyroid surgery20,21, coronary artery bypass surgery22, tube 
thoracotomy23,24, carotid endarterectomy25, and tonsillectomy26-29. HS has also been 
reported as a complication of VNS electrode placement30; spontaneous recovery of 
symptoms occurred within 4 weeks.  
140⏐Chapter 7 
Exact data on incidence of iatrogenic HS in animals are not available. HS has been 
reported as a complication of surgery in the cervical area in dogs (anterior cervical 
spine surgery4,31), in a pig (aortic stenting5), in cats (carotid artery catheterization6) 
and in horses (intravenous injection7). 
Fourty-four studies on VNS surgery in animals have been published so far. These 
include studies on healthy animals32-51 as well as on animals that model certain 
diseases52-60, including seizures and epilepsy 8,38,39,41,61-74. In several of the above-
mentioned studies, the vagus nerve was transected before applying the electrode to 
either the proximal or distal part of the nerve. In several studies, rats were 
anaesthetized for the duration of the experiment and sacrificed immediately after.   
Only one of these studies reports HS as a complication of VNS surgery: 2 out of 10 
dogs developed HS after VNS implantation as part of a study on the safety and 
efficacy of VNS in dogs with medically refractory epilepsy. The symptoms resolved 
spontaneously within two to four weeks8. 
Two of the 44 studies mentioned other complications of VNS surgery, consisting of 
subcutaneous inflammation in 1 rat33, and unexplained death in 5 out of 57 rats54.  
 
Two of the classical symptoms of HS, enophthalmos and ptosis, were found in the 
rats described in the current study. Miosis was not evaluated because pupil size 
determination in albino rats requires dim red illumination, which could have 
interfered with the kindling process75. For the same reason the cocaine test was not 
performed. Facial anhidrosis was not evaluated either.  
We hypothesized that enophtalmos and ptosis were related to damage to the 
oculosympathetic system caused by surgery in the area of third order neuron of the 
oculosympathetic system or of the SCG. These third order neurons of the 
oculosympathetic system in rats surround the carotid artery9, while the SCG in rats is 
located immediately dorsally to the carotid artery9. Both anatomical localizations are 
similar to those in humans and other mammals. Damage to either the SCG or the 
third order neurons can occur when surgery is performed in this area, and has caused 
HS in humans and other mammals. For these reasons we conclude that carotid artery 
surgery in rats can be accompanied by HS as well. 
 
The oculosympathetic system has not been reported to be involved in 
epileptogenesis. This is supported by the findings of the current study: HS did not 
influence kindling rate or pre-kindling afterdischarge threshold.  
 
All HS-affected rats suffered from HS immediately after surgery. This indicates that 
damage to the oculosympathetic system occurred during surgery. Perhaps post-
operative edema has contributed to the symptoms as well. The finding that chronic 
placement of an electrode around the carotid artery is associated with HS in 91% of 
cases, suggests that the electrode itself may have induced secondary damage. This is 
supported by the absence of HS in 75% of rats in which the electrode was not 
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wrapped around the carotid artery anymore during postmortem examination, 
although this examination has not revealed the time point at which the detachment 
had occurred. 
More experience with the surgical technique is not associated with a lower incidence 
of HS in this study, since learning curve did not affect the occurrence of this 
complication in the current series of rats.  
 
It is unclear why HS is reported relatively frequently in humans and other mammals, 
but not in rats. Over forty papers have been published on VNS in rats. None of these 
report HS as a complication. A much larger number of rat experiments has been 
conducted in which surgery of the carotid artery took place; a pubmed search using 
the words ‘carotid artery’ and ‘surgery’ and ‘rat’, resulted in over 2000 articles.  
One of the reasons may be the fact that in many of these studies, acute experiments 
were performed, in which the rats were sacrificed immediately after finishing surgery. 
This means that HS could have been present, but was not diagnosed because the 
rat's eyes were closed throughout the experiments. Another explanation may be that 
the researchers did not recognize the symptoms as HS because they were not 
familiar with the syndrome.  
 
Based on HS symptoms, lesions of the third order neuron cannot be distinguished 
from lesions of the SCG. However, this difference may be important because if 
damage occurred at the level of the SCG, sympathetic fibers that innervate the 
intestines may have been damaged as well. This is of special importance considering 
the growing interest in the vagal control of bowel inflammation in relation to the 
cholinergic anti-inflammatory reflex76, and in the role of the vagus nerve in 
modulating inflammation and regulation of food intake and body mass32,36,48. While 
these latter studies explore the effect of the efferent, parasympathetic, vagus nerve, 
special attention has to be paid to the possibility that by stimulating the vagus nerve, 
sympathetic innervation of the bowel can be influenced as well. 
Conclusion 
HS can occur as a complication of carotid artery surgery in rats. This complication did 
not influence epileptogenesis in the current study. However, considering the 
anatomy of the SCG in the rat, HS after carotid artery surgery in rats is a complication 
that should not be overlooked because the occurrence of HS in rats may coincide 
with damage to the sympathetic innervation of the gut. 
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Pathophysiology of epilepsy 
Interleukin 1 
The pathophysiology of epilepsy has not been elucidated yet. Studies have 
repeatedly shown that febrile seizures (FS) are among the most important risk factors 
for development of epilepsy1, but also brain trauma2 and stroke3 predispose patients 
to epileptic seizures. Since all these conditions are associated with increased levels of 
the pro-inflammatory cytokine IL-1β4-6, and since IL-1β can influence neuronal 
excitability at the cellular level7-9, it is thought that IL-1β contributes to, or even 
initiates epileptogenesis10.  
The scientific evidence supporting this hypothetical key role of IL-1β was reviewed 
and summarized in CHAPTER 2 of this thesis. In all available IL-1β studies, IL-1β levels 
were detemined after seizures, often in animal models that were associated with 
neuronal damage or in brains of epilepsy patients that suffered from an underlying 
brain disease, conditions that by itself are already associated with IL-1β expression, 
also in the absence of seizures. Based on these papers we stated that it could not be 
concluded at this point that IL-1β is chronically expressed in epilepsy, nor that it is 
critically involved in epileptogenesis.  
Furthermore, if seizure-susceptibility can be attributed to IL-1β expression, the 
question is why some people develop epilepsy after FS, stroke or brain trauma, while 
the majority does not. In CHAPTER 2 we hypothesize that individual variability in IL-1 
receptor (IL-1R) upregulation may exists, possibly based on an individual balance 
between IL-1R type I and IL-1R type II expression. IL-1R type I is the actual functional 
receptor that processes the IL-1β signal whereas IL-1R type II is the decoy receptor. 
When IL-1β binds this receptor, signal transduction cannot take place because IL-1R II 
lacks an intracellular domain. Therefore we proposed that individuals that have a 
relatively high basal expression of IL-1RI might be more sensitive to IL-1β 
upregulation.    
The findings that are presented in CHAPTER 3 elaborate on the first conclusion from 
CHAPTER 2, stating that proof of chronic IL-1β expression in epileptogenesis still 
lacks. The immediate seizure-induced IL-1β expression that has been described in 
several animal models for seizures and epilepsy can have a number of sources. First 
of all, seizures induce opening of the blood-brain barrier (BBB) leading to entrance of 
circulating proteins11, while IL-1β expressing leucocytes appear to enter the CNS too 
after seizure-induced changes in the expression of vascular cell adhesion 
molecules12. Secondly IL-1β upregulation occurs when Toll-like receptors are 
activated by heath shock proteins (HSPs), and induce expression of nuclear factor 
kappa B (NFκB). Since seizures induce the activation of HSPs, NFκB could be the 
direct stimulus for IL-1β production after seizures13-15. NFκB activation is also 
associated with expression of the ceramid transfer protein (CERT, also known as the 
150⏐Chapter 8 
Goodpasture antigen binding protein16,17) a protein involved in intracellular transport 
of ceramide17.  
When these cascades are taking place, other seizure-induced processes occur 
simultaneously. One highly important phenomenon that often occurs in 
experimental epilepsy is glutamate excitotoxicity. This takes place when excessive 
amounts of glutamate are released during status epilepticus, and leads to the influx 
of relatively large amounts of calcium though the NMDA-R. When intracellular 
calcium levels reach toxic concentrations, neurons die26. When concentrations are 
high but return to normal levels before irreversible damage has taken place, 
sprouting can occur, a phenomenon that has been shown to be of high importance 
for epileptogenesis18. We therefore postulated that, in case of glutamate 
excitotoxicity, the effects of glutamate on the entrance of calcium into the cell via the 
NMDA-R are much bigger than the effects of IL-1β.   
In line with this, we investigated the degree of IL-1β expression in an animal model 
that is not associated with damage induced by glutamate excitotoxicity19-22, the 
amygdala kindled rat23 (CHAPTER 3). This model is based on daily subthreshold 
electrical stimulation of the amygdala, leading to provoked generalized seizures of 
increasing severity (stage one to five), that, after five consecutive stage five seizures 
culminate in a chronic epileptogenic state. Chronically epileptogenic animals were 
sacrificed 48 hours after the last provoked seizure.  
Apart from a number of IL-1β immunopositive cells, most likely macrophages, that 
were found in damaged cortex (where the kindling electrode pierced the cortex), we 
did not observe any IL-1β immunopositive cells in hippocampus or cortex of kindled 
rats, nor in shams (CHAPTER 3). Previous studies in the kindling model with animals 
that were sacrificed at similar phases in epileptogenesis, but at shorter intervals after 
the provoked seizure, have shown IL-1β upregulation immediately after a provoked 
generalized seizure24,25, but no other studies have been published in which IL-1β was 
determined 48 hours after a seizure.  
We subsequently hypothesized that this lack of IL-1β may have resulted from a lack 
of seizure-induced NFκB upregulation in the absence of neuronal damage, and used 
CERT immunohistochemistry as a second readout parameter for NFκB activation. The 
intensity of the CERT immunopositive signal was equal among kindled animals and 
shams (CHAPTER 3). These results suggest that kindling does not lead to NFκB 
activation at all, or that NFκB activation does take place but instead of promoting 
chronic IL-1β and CERT expression, leads to upregulation of an until now unidentified 
protein that can lower seizure thresholds and contribute to epileptogenesis in this 
model. Studies are being carried out to further unravel these possible mechanisms. 
Calcium 
In contrast to the suspective but still non-conclusive role of IL-1β in epileptogenesis, 
research over the past 20 years has clearly shown that intracellular free calcium plays 
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a key role in the process that transforms a normal brain into a hyperexcitable brain. 
As mentioned previously, intracellular calcium levels increase when glutamate is 
excessively released during a seizure, but also during other acute neurological 
conditions such as stroke or traumatic brain injury.  
Glutamate excitotoxicity occurs in all stroke or traumatic brain injury patients. A 
minority of them develops epilepsy, which implies individual variability in seizure 
thresholds.  We found individual variability in seizure thresholds in experimental 
seizures too. In CHAPTER 4 we described that kindled rats show variability in 
afterdischarge thresholds upon electrical stimulation of the amygdala and in the 
number of stimuli that is needed to develop a chronic epileptic state. Furthermore 
we described that in FS experiments of all rat pups that are exposed to hyperthermia, 
only 23% develop seizures.  
Based on the important role for calcium in epileptogenesis we subsequently 
hypothesized that genetic differences in genes related to calcium homeostasis 
contribute to the individual variability in seizure thresholds. To investigate this we 
studied the occurrence of single nucleotide polymorphisms (SNPs) in two genes: the 
CACNA1E gene encoding the α1e subunit of the voltage-gated calcium channel 
(VGCC) and the Camk2d gene that encodes the delta chain of calcium/calmodulin 
dependent kinase II (CamkII). The kindling experiments revealed an association 
between CACNA1E GG genotype and lower afterdischarge thresholds while the 
hyperthermia study showed an association between the CACNA1E G allele and 
hyperthermia-induced seizures. The Camk2d T allele appeared to be associated with 
hyperthermia-induced seizures but was not associated with kindling rate or 
afterdischargethresholds (CHAPTER 4).  
ANTICONVULSIVE EFFECTS OF VNS 
Class one evidence for the effectiveness of neuromodulation therapies in general is 
difficult to obtain, mostly because placebo controlled studies are not available. The 
effectiveness of antiepileptic treatment is classically evaluated using seizure-diaries 
that are kept by patients, parents or caregivers. The anticonvulsive effect of VNS has 
been evaluated in two randomized controlled trials in adult partial epilepsy patients 
where the effectiveness during the first three months of treatment was compared to 
‘sham’ stimulation27,28. These studies showed >50% seizure frequency reduction in 
28-31% of patients in the treatment group versus 13-15% in the placebo group. 
Long-term effectiveness was studied in an uncontrolled fashion in both adults and 
children with partial epilepsy, where mean seizure frequency at baseline was 
compared with mean seizure frequency after 6 to 18 months. In general 30-40% of 
patients reported >50% seizure frequency reduction29,30.  
Besides these long-term effects VNS has an acute effect as well. Patients that have 
auras or partial onset seizures can acutely activate the stimulator to abort the seizure. 
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This effect of VNS is only sparsely mentioned in literature, but it is estimated that 20% 
of these patients can abort a seizure this way, while placebo-activation aborts 
seizures in 10%31-33.  
Why the anticonvulsive effectiveness of VNS is limited is not known. This is related to 
the fact that the mechanism of action of VNS has not been studied in detail yet. Prior 
to its clinical use in 1997, six experimental papers, aimed at establishing the 
anticonvulsive effectiveness of VNS, had been published34-39. Only one of these 
studies study was conducted in freely moving animals suffering from experimental 
epilepsy39.  
Since then, two studies from the same group using two different seizure models 
(maximum electroshock induced seizures and PTZ seizures) have been published40,41 
to study the anticonvulsive mechanism of action on a cellular level. They showed that 
the locus coeruleus (LC) plays an important role in the anticonvulsive effect of VNS in 
the maximum electroshock model40 and that C-fiber activation is not required for the 
anticonvulsive effect of VNS in the PTZ model41. The past five years nine studies were 
published in which healthy animals were treated with VNS. These studies describe 
VNS-induced electrophysiological or immunohistochemical changes in the LC, 
thalamus, NTS, cortex and hippocampus42-50.  
Besides these animal studies, studies in humans undergoing VNS have been 
published over the years as well. These studies either used imaging techniques such 
as SPECT51 and PET52, or biochemical analysis of plasma or cerebrospinal fluid53 and 
have shown that VNS induces blood flow changes in regions connected to the 
afferent vagus nerve projection nuclei, such as the thalamus51,52, and that 
cerebrospinal fluid concentrations of GABA increase53. 
In an attempt to elucidate the mechanism of action of VNS on a cellular level we 
developed a novel animal model: the VNS-treated kindled rat, presented in CHAPTER 
5. Kindling-induced seizures mimic temporal lobe epilepsy and are often 
pharmacoresistant. Histopathological changes are similar to human temporal lobe 
epilepsy. These characterestics make the amygdala kindled rat a clinically relevant 
model. Our experimental VNS paradigm mimics the acute activation that is used to 
abort a seizure in the clinical situation. It consisted of a three-minute train of VNS. 
After one minute of VNS, the kindling stimulus was applied.  
None of the rats stopped having a seizure. Nevertheless we observed a number of 
other anticonvulsive effects: 50% of VNS treated rats versus 18% of shams showed 
>25% reduction in convulsive seizure duration; 57% of VNS treated rats versus 36% of 
shams showed >25% reduction in total seizure duration and 38% of VNS treated rats 
versus none of the shams showed >200% increase in latency. These results are in line 
with observations made by others in humans, namely that VNS affects more than 
seizure frequency alone, for instance seizure duration, duration of the post-ictal 
phase, mood and behavior54-56. The fact that the majority of patients including those 
that experience <50% seizure frequency reduction choose to have their batteries 
replaced when necessary, further illustrates these positive (side) effects of VNS.  
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All rats in our experiments were observed during VNS treatment and some of them 
coughed or scratched their necks, indicating that they felt the local stimulus. This is 
reported in human VNS literature as well27. No other stimulus-induced side effects 
were observed. As a surgical complication of VNS electrode placement we observed 
left sided Horner’s syndrome in 68% of rats (CHAPTER 7). Horner’s syndrome is a well-
known complication of neck surgery in humans (including VNS electrode 
placement57) but had not been described before in rats.  
With regard to the mechanism of action of VNS, our aim was to study surgery and 
stimulation-induced immunohistochemical changes in the primary and secondary 
projection nuclei of the afferent vagus nerve in the brain stem. These data are 
presented in CHAPTER 6. 
We used neuronal nitric oxide synthetase (nNOS) immunohistochemistry to evaluate 
to what extent neurons in the primary motor nucleus of the vagus nerve (dorsal 
motor nucleus of the vagus nerve, DMV) as well as in the primary projection nucleus 
of the vagus nerve afferents (nucleus of the solitary tract, NTS) are affected by 
manipulation of the vagus nerve during implantation, by chronic placement of the 
electrode and by VNS itself58. Despite a precise surgical technique we found an 
important effect of vagus nerve surgery and chronic electrode placement on nNOS 
immunopositive cell density in the DMV: a density of >300 cells/mm2 was found 
eight times more often in the left DMV than in the right DMV of both VNS and sVNS 
animals. We think that electrical stimulation of the vagus nerve may have 
additionally contributed to the nNOS signal in the DMV the current study, since VNS 
rats were 2.4 times more likely than sVNS rats to have a high nNOS cell density in the 
left DMV. The question remains what this VNS-induced nNOS activity in the DMV 
illustrates: antidromic activation of vagus nerve efferents or non-activation related 
changes in cellular functioning resulting from the electrical stimulation.  
A second immunohistochemical marker, ∆FosB, was used to further investigate 
activation of the afferents vagus nerve fibers. In contrast to nNOS, that merely 
indicates ‘neuronal changes’, ∆FosB is considered to be indicative of neuronal 
activity59. We were unable to confirm VNS-induced neuronal activation using ΔFosB 
immunohistochemistry in the NTS, PBN and LC. Studies with large animal groups and 
a VNS stimulating protocol specifically designed for immunohistochemical detection 
of neuronal activation, must be conducted in future to investigate the VNS-induced 
neuronal activation in the brain stem.  
Conclusions 
Regarding epilepsy, there appears to be an important pathophysiological role for the 
immune system. IL-1β may be a player, but its key role has not been established yet. 
The central question remains what the role of IL-1β would be if excitotoxic neuronal 
damage is not present, a scenario that is often the case in human epilepsy. 
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Furthermore, the action of IL-1β depends on the availability of the IL-1RI, and further 
research is needed to explore functioning of this receptor in epilepsy.  
Besides the contribution of the immune system to seizure generation, the 
epileptogenic effect of high intracellular calcium continues to play an important role 
and genetic differences, with regard to calcium homeostasis, may contribute to the 
large variability in individual seizure susceptibility.   
VNS is a well-established treatment option for refractory epilepsy with moderate 
effects on seizure frequency. A clinically relevant animal model is available now of 
which the effectiveness is comparable to the clinical situation: the VNS-treated 
kindled rat. However, the vagus nerve responds to surgical manipulation and chronic 
electrode placement by changes in brain stem nuclei. These reactions may affect the 
effectiveness of VNS in experimental epilepsy, but the effectiveness of VNS in clinical 
practice may be affected by similar changes induced by surgery or chronic electrode 
placement as well.  
The first explorative mechanistic studies in the VNS-treated kindled rat suggest that 
the VNS signal enters the brain but also that vagus nerve damage is likely to be 
present. Much more research, preferably using chronic VNS, is needed to fully 
understand the mechanism of action. This may also lead to the discovery of a more 
effective target for anticonvulsive neuromodulation therapy.  
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Summary 
Vagus nerve stimulation (VNS) is used to treat medically refractory epilepsy. Despite 
years of research it is still not clear why patients develop epileptic seizures and why 
VNS can reduce these seizures. The aims of this research were to gain more insight 
into the pathophysiology of epilepsy and into VNS. With regard to epilepsy, two 
factors that may be involved in the development of seizures were investigated: 
interleukin-1 beta (IL-1β) and calcium. With regard to VNS a clinically relevant animal 
model was developed in which the mechanism of action of VNS can be studied.  
Pathophysiology of epilepsy 
Several mechanisms appear to play a role in the pathophysiology of epilepsy. The 
role of the pro-inflammatory cytokine IL-1β is suspected to be important, but based 
on the scientific literature so far available it cannot be concluded that IL-1β is 
critically involved in epilepsy or epileptogenesis (CHAPTER 2). The suspected role of 
IL-1 is mainly based on animal studies using different models that mimic epilepsy or 
seizures. The most important findings of these studies are that IL-1β is expressed 
after a seizure and that seizures can be reduced by blocking IL-1β. In contrast to 
these studies we were unable to detect IL-1β in the brains of chronic epileptic rats 
(CHAPTER 3). The lack of IL-1β may be related to the fact that the epilepsy model we 
used, the amygdala kindled rat, is not associated with excitotoxic neuronal damage 
and associated inflammation, a phenomenon frequently encountered in the other 
epilepsy and seizure models. 
In contrast to the suspected role of IL-1β in epileptogenesis, research over the past 
20 years has clearly shown that intracellular free calcium plays a key role in this 
process that transforms a healthy brain into a hyperexcitable brain. In line with this 
important role, neurological conditions in which high intracellular free calcium levels 
are present, such as stroke and traumatic brain injury, are associated with an 
increased risk of epilepsy. It is still unclear why some of these stroke or brain trauma 
patients develop epilepsy, while the majority does not. Apparently some individuals 
are more vulnerable to seizures than others. We observed individual variability in 
seizure susceptibility in two animal models as well. We have shown in these animal 
models that polymorphisms in the calcium-related genes CACNA1E (encoding the 
α1e subunit of the voltage-gated calcium channel) and Camk2d (encoding the delta 
chain of calcium/calmodulin dependent kinase II) may contribute to the individual 
variability in seizure susceptibility (CHAPTER 4).  
Vagus nerve stimulation 
Epilepsy patients are generally treated with antiepileptic drugs. Approximately 25% 
of patients does not respond to these drugs and continues to have seizures; these 
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patients are considered to be pharmacoresitant. If curative resective neurosurgery 
(surgical removal of the part of the brain where the seizures originate) is not an 
option, patients can be treated with VNS resulting in >50% seizure frequency 
reduction in 11.7% of patients. VNS consists of continuous cyclic stimulation of the 
cervical part of the vagus nerve. For this purpose, an electrode is placed around this 
nerve and connected to a subcutaneously placed pulse generator. Besides this 
chronic effect of VNS on seizure frequency, VNS has an acute seizure suppressing 
effect in some patients as well. VNS has been applied in a number of experimental 
studies in which its anticonvulsive effectiveness has been shown. However, the 
animal models used do not mimic the clinical situation very well. Moreover, the 
experimental studies that have been conducted so far have not revealed the 
mechanism of action of VNS. In order to develop a clinically relevant animal model in 
which this mechanism of action can be studied we treated amygdala kindled rats 
with acute VNS. This treatment affected different seizure characteristics in a 
subpopulation of rats, but as in the clinical situation, not all rats responded to the 
treatment (CHAPTER 5).  
After establishing the effectiveness of VNS in this kindling model, we aimed at 
exploring the mechanism of anticonvulsive action by investigating the level of 
surgery-induced and VNS-induced changes in brain stem nuclei where vagus nerve 
efferents originate from and where afferents project to. We observed significant 
changes indicative of axonal damage in the vagus nerve motor neurons as a result of 
vagus nerve electrode placement. We were unable to confirm VNS-induced neuronal 
activation, possibly due to methodological issues (CHAPTER 6). 
In humans, side effects of VNS are common but generally mild. As a side effect of 
vagus nerve electrode placement in our rats we observed Horner’s syndrome 
(CHAPTER 7). This syndrome is well-known after surgery in the region of the carotid 
artery including after vagus nerve electrode placement, but had not been described 
before in rats.   
Conclusions 
Regarding epilepsy, there appears to be an important pathophysiological role for the 
immune system. IL-1β may be a player, but its key role has not been established yet. 
Besides the contribution of the immune system to seizure generation, the 
epileptogenic effect of high intracellular calcium plays an important role and genetic 
differences with regard to calcium homeostasis may contribute to the large 
variability in individual seizure susceptibility. VNS is a well-established treatment 
option for refractory epilepsy with moderate effects on seizure frequency. A clinically 
relevant animal model is available now in which the effectiveness is comparable to 
the clinical situation. The first explorative mechanistic studies in this model suggest 
that the VNS signal enters the brain but also that vagus nerve damage is likely to be 
present as a result of surgery and chronic electrode placement. Much more research, 
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preferably using chronic VNS, is needed. This research must provide more insight in 
VNS by understanding the mechanism of action. This may also lead to the discovery 
of a more effective target for anticonvulsive neuromodulation therapy. 
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Samenvatting 
Nervus vagus stimulatie (NVS) wordt gebruikt voor de behandeling van 
farmacotherapieresistente epilepsiepatiënten. De afgelopen tientallen jaren is er 
wetenschappelijk onderzoek gedaan naar de ontstaanswijze van epilepsie en naar 
het werkingsmechanisme van NVS. Desondanks is het nog altijd niet duidelijk 
waarom mensen epilepsie krijgen, noch waarom NVS deze aanvallen kan reduceren. 
Doel van dit onderzoek was dan ook om meer inzicht te krijgen in de pathofysiologie 
van epilepsie waarbij twee verschillende factoren onderzocht werden: interleukine 1 
beta (IL-1β) en calcium. Daarnaast werd een klinisch relevant diermodel voor NVS 
ontwikkeld, waarin het werkingsmechanisme van deze behandeling verder 
onderzocht kan worden.  
Pathofysiologie van epilepsie  
Een aantal verschillende mechanismen spelen een rol in de pathofysiologie van 
epilepsie. Het vermoeden bestaat dat de pro-inflammatoire cytokine IL-1β een 
kritieke rol speelt. Hoewel er veel epilepsiestudies zijn waarin IL-1β een belangrijke 
rol speelt, kan deze hypothese op dit moment nog niet ondersteund worden door 
direkt wetenschappelijk bewijs (HOOFDSTUK 2). De hypothetische rol van IL-1β is 
voornamelijk gebaseerd op proefdierstudies. In deze studies, waarin verschillende 
diermodellen voor epilepsie zijn gebruikt, wordt vaak verhoogde IL-1β expressie 
gevonden kort na een epileptische aanval, of wordt de aanval geblokkeerd wanneer 
Il-1β geblokkeerd wordt. In tegenstelling tot deze studies konden wij IL-1β in het 
amygdala kindling model voor epilepsie niet aantonen (HOOFDSTUK 3). 
Mogelijkerwijs komt IL-1β in onze studie niet tot expressie omdat het kindling model 
niet geassocieerd is met excitotoxiciteit, en daarmee ook niet met neuroinflammatie. 
Excitotoxiciteit en daarmee geassocieerde neuroinflammatie worden wel gezien in 
andere diermodellen voor epilepsie.  
In tegenstelling tot de vooralsnog hypothetische rol van IL-1β, is de rol van 
intracellulair vrij calcium bij het ontstaan van epilepsie de afgelopen 20 jaar duidelijk 
aangetoond. Neurologische aandoeningen waarbij hoge intracellulaire vrije 
calciumconcentraties voorkomen, zoals beroerte of traumatisch hersenletsel, zijn 
geassocieerd met een verhoogd risico op epilepsie. Het is niet duidelijk waarom 
sommige van de patiënten na een beroerte of ernstig hersentrauma epilepsie 
ontwikkelen, terwijl dit bij de meerderheid niet gebeurt. Blijkbaar zijn sommige 
individuen meer vatbaar voor het ontstaan van epileptische aanvallen dan anderen. 
In het dierexperimenteel epilepsie onderzoek worden ook individuele verschillen in 
aanvalssusceptibiliteit gezien. Polymorphismen in de twee calcium-gerelateerde 
genen CACNA1E (coderend voor een subunit van een calcium kanaal) en Camk2d 
(coderend voor een onderdeel van het calcium/calmoduline afhankelijk kinase II) 
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dragen mogelijk bij aan de individuele variabiliteit in aanvalssusceptibiliteit 
(HOOFDSTUK 4).  
Nervus vagus stimulatie 
Epilepsiepatiënten worden in eerste instantie behandeld met medicijnen. 
Uiteindelijk reageert ongeveer 25% van de patiënten niet goed op deze medicijnen 
en blijft aanvallen houden. Deze patiënten zijn ‘farmacotherapieresistent’. Als voor 
hen curatieve resectieve neurochirurgie, waarbij het epileptogene focus wordt 
verwijderd, geen optie is, kan deze groep behandeld worden met NVS. Dit resulteert 
in >50% aanvalsfrequentiereductie in 11.7% van de patiënten. NVS bestaat uit 
continu cyclische elektrische stimulatie van de linker nervus vagus in de hals. 
Hiervoor wordt een elektrode geïmplanteerd rondom deze zenuw en verbonden 
met een subcutaan geplaatste pulsgenerator. Naast een chronisch effect op 
aanvalsfrequentie kan NVS bij sommige patiënten acuut een aanval onderdrukken. 
NVS is een aantal keer toegepast in diermodellen. Doel van deze studies was 
voornamelijk de effectiviteit van NVS aan te tonen. Fundamenteel onderzoek naar 
het werkingsmechanisme van NVS is schaars. Tot nu toe is dan ook nog niet duidelijk 
waarop dit mechanisme berust. Om een klinisch relevant diermodel voor deze 
anticonvulsieve behandeling te ontwikkelen, werd de amygdala kindled rat 
behandeld met acute NVS. Dit leidde tot afname van aanvalsduur en –ernst in een 
aantal dieren (HOOFDSTUK 5). Net zoals in de klinische praktijk reageerden niet alle 
dieren op de behandeling met NVS.  
Dit klinisch relevante diermodel voor de anticonvulsieve werking van NVS werd 
vervolgens gebruikt voor het bestuderen van het werkingsmechanisme. Hiertoe 
werd een aantal hersenstamkernen onderzocht op chirurgie-gerelateerde 
veranderingen en op NVS-gerelateerde veranderingen. Deze hersenstamkernen 
bevatten ofwel de cellichamen van de efferente zenuwvezels, of ze bevatten de 
uitlopers van de afferente zenuwvezels. In de cellichamen van de efferente 
motorneuronen werden significante veranderingen gezien die mogelijk gerelateerd 
zijn aan axonale schade als gevolg van elektrodeplaatsing. Het was niet mogelijk om 
NVS-geïnduceerde neuronale activatie in een van de kernen aan te tonen, mogelijk 
omwille van methodologische redenen (HOOFDSTUK 6). 
Onder epilepsiepatiënten komen bijwerkingen van NVS frequent voor, maar over het 
algemeen zijn deze niet ernstig van aard. Horner’s syndroom is een zeldzame 
complicatie van NVS-elektrodeplaatsing in mensen. Ook bij ratten kan Horner’s 
syndroom optreden als gevolg hiervan. Dit syndroom is bekend na chirurgie in het 
gebied van de arteria carotis, maar was bij ratten nog niet eerder beschreven 
(HOOFDSTUK 7).  
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Conclusies 
Het immuunsysteem lijkt een belangrijke rol te spelen in de pathofysiologie van 
epilepsie. IL-1β zou een sleutelrol kunnen spelen, maar meer onderzoek is nodig om 
dit aan te tonen. Naast deze relatief recent geopperde bijdrage van het 
immuunsysteem, blijft een verhoogde intracellulaire calcium concentratie een 
belangrijke rol spelen in de epileptogenese, en genetische verschillen met 
betrekking tot de calcium homeostase zouden kunnen bijdragen aan de individuele 
verschillen in aanvalssusceptibiliteit.  
NVS is een geaccepteerde behandeling voor farmacotherapieresistente epilepsie met 
matig goede effecten op aanvalsfrequentie. De NVS-behandelde amygdala kindled 
rat is nu beschikbaar als klinisch relevant diermodel waarin het werkingsmechanisme 
van NVS verder onderzocht kan worden. De eerste exploratieve mechanistische 
studie suggereert dat het NVS-signaal het brein bereikt, maar ook dat schade aan de 
zenuw optreedt als gevolg van plaatsing en/of van chronische aanwezigheid van de 
elektrode. Meer onderzoek, bij voorkeur gebruik makend van chronische NVS, is 
nodig om het werkingsmechanisme volledig te kunnen begrijpen. Deze kennis zou 
ook kunnen leiden tot de ontdekking van een meer effectieve ‘target’ voor 
anticonvulsieve neuromodulatietherapie. 
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Dankwoord 
Hoewel mijn naam op de kaft van dit boekje staat en ik straks het proefschrift zal 
verdedigen zou dit boekje er helemaal niet zijn geweest zonder het initiatief, de 
begeleiding en aanwezigheid van heel veel mensen.  
 
Geachte prof. dr. J.S.H. Vles, beste Hans. Na jaren van voorbereiding was het 
uiteindelijk door jouw steun dat ik in 2006 kon beginnen aan dit onderzoek. 
Allereerst dank daarvoor. Daarnaast wil ik je bedanken voor de fijne manier waarop je 
mij de afgelopen jaren begeleid hebt. Je gaf me veel ruimte en waar nodig werd ik 
bijgestuurd. Ik heb veel van je geleerd, ook als dokter en gewoon, als mens.  
 
Geachte prof. dr. H.M.W. Steinbusch, beste Harry. Epilepsie is een aandoening die 
binnen het onderzoeksinstituut wat minder vaak aan bod komt dan de ziekte van 
Alzheimer en depressie. Desondanks heb je mij en het project altijd gesteund en heb 
je samen met Hans uiteindelijk de strakke planning bewaakt. Bedankt hiervoor. Jouw 
suggestie om Prof. dr. Hopkins bij het onderzoek te betrekken heeft het project een 
betere anatomische basis gegeven. 
 
Geachte dr. H.J.M. Majoie, beste Marian. Nadat de klinische NVS studie zoveel vragen 
had opgeworpen heb jij de daadwerkelijke stap naar het laboratorium durven 
maken. Niet veel clinici kunnen de energie en het uithoudingsvermogen hiervoor 
opbrengen. Uithoudingsvermogen heb je hier zeker voor nodig gehad, want de 
eerste keer dat wij over dit project spraken was in 2002. Bijna 10 jaar later is het 
eerste proefschrift geschreven en het tweede onderweg. Bedankt voor je steun, hulp 
bij heel veel geregel, in de gaten houden van deadlines en het altijd weer 
terugkoppelen van onze gedachtenkronkels naar de kliniek: het moet wel klinisch 
relevant zijn.  
 
Geachte dr. G. Hoogland, beste Govert. Jij was mijn dagelijks begeleider gedurende 
mijn tijd in het lab. En die had ik nodig! Wat ik enorm heb gewaardeerd is je 
aanwezigheid op cruciale momenten zoals tijdens de eerste series operaties en 
tijdens het ‘temmen’ van het EEG apparaat (of heeft hij ons getemd?). Het 
belangrijkste was misschien nog wel dat jij een deel van de gaten in mijn kennis van 
de moleculaire biologie hebt kunnen opvullen. Bovendien ben je tussen het serieuze 
onderzoeken door ook gewoon een gezellige collega. 
 
Voorzitter van de beoordelingscommissie en mijn opleider prof. dr. J.J. Van 
Overbeeke, beste Koo. Ik wil je bedanken voor het beoordelen van het manscript, 
maar vooral voor de opleiding die ik krijg op de afdeling neurochirurgie. Na jaren 
met plezier in het lab te hebben gewerkt ben ik erg blij om terug te zijn. Hopelijk 
krijg ik nog vaak de kans om met je samen te opereren want dat is een groot plezier. 
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De overige leden van de beoordelingscommissie prof. dr. F. Ramaekers, prof. dr. M. 
De Baets en prof. dr. O. Van Nieuwenhuizen wil ik bedanken voor het beoordelen van 
het manuscript en hun aanwezigheid tijdens de promotie. Dr. A. Vezzani, thank you 
very much for reading the manuscript and taking part in the corona. This is a big 
honour for me.  
 
Prof. E.A.M. Beuls, mijn dank aan u is en blijft groot. Het is door uw vertrouwen in mij 
dat ik in opleiding ben tot neurochirurg. De kiem voor mijn betrokkenheid bij dit 
onderzoeksproject ligt ook bij u, want u heeft mij in 2002 geïntroduceerd bij Dr. 
Berfelo en gesuggereerd dat ik NVS onderzoek zou kunnen gaan doen.  
 
Bedankt dr. M.W. Berfelo, Willem, voor het overdragen van jouw NVS kennis op mij. 
Je hebt me letterlijk wegwijs gemaakt, zowel in mens als in dier. Bedankt ook voor je 
kritische commentaar op de manuscripten en de leuke momenten in jullie heerlijk 
huis in Moerslag.  
 
Dear prof. dr. B.E. Leonard, dear Brian. In 2002 you gave me the opportunity to work 
in the lab in Maastricht and get experienced with several techniques and with animal 
work. Thank you for that and for your support and advice over the past 8 years.  
 
Dear prof. dr. F. Onat, dear Filiz. Thank you for having me in your lab in Istanbul in 
2004 and for teaching me the first principles of amygdala kindling.  
 
Dear prof. dr. T. Dinan, dear Ted. After a pilot in Maastricht I performed my first 
amygdala kindling experiments under your supervision in Cork. Thank you for having 
me there in 2004, and for lending us the necessary equipment later on.  
 
Beste prof. dr. D.A. Hopkins, beste David. In 2008 hebben wij kennis met elkaar 
gemaakt; mijn tijd in het lab zat er toen al bijna op. Als expert op het gebied van de 
anatomie van de nervus vagus en haar kernen in de hersenstam kwam je echter als 
geroepen! Het schrijven van een artikel hierover (hoofdstuk 6) is hierdoor overigens 
niet makkelijker geworden, maar het resultaat wordt wel veel beter. Bedankt.  
 
Paul van Venrooij, Victor Duysens and Keith Mullet at Medtronic Bakken Research 
Center provided us with excellent vagus nerve electrodes and excellent service. Your 
problem-solving skills are impressive, as was illustrated in 2004 by the almost 
overnight development and production of the ‘Narcose-Fixture’.  
Bedankt Jos Aarts, Joeri Curfs en de mannen van de werkplaats van de afdeling 
‘Instrument Development, Engineering & Evaluation’ van de Universiteit Maastricht, 
voor het leveren van de elektrodes.  
Bedankt dr. Y. Temel, Yasin, voor het mogen kopieëren van jouw elektrode ontwerp, 
maar ook voor je adviezen en steun de afgelopen jaren.  
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Bedankt dr. V. Van Kranen-Mastenbroek, Vivianne, en de afdeling Klinische 
Neurofysiologie van het Maastricht Universitair Medisch Centrum voor het EEG 
apparaat en voor de begeleiding bij het gebruik hiervan.  
Bedankt drs. Saskia Seeldrayers, Richard Frijnts en alle andere CPV medewerkers voor 
de samenwerking.  
Bedankt Hellen Steinbusch, Marjan Phillipens en alle andere analisten voor het 
beantwoorden van mijn vaak onbenullige vragen, voor de hulp en voor de 
samenwerking.  
Bedankt Tiny Wouters, voor het daadwerkelijk transformeren van een ‘manuscript’ 
tot een boekje. 
Mijn nicht(je) Els Franken wil ik bedanken voor het maken van de mooie kaft.  
Dr. A. Kessels, beste Fons, bedankt voor je fijne hulp. Je luistert goed en weet elke 
vraagstelling direkt tot haar essentie reduceren. Je hebt voor mij de statistiek 
begrijpelijk gemaakt (een beetje dan, want het blijft een vak apart).  
Bedankt Trudy Stefess, Desirée Serpenti en Marie-Thérèse Moers voor de 
administratieve en secretariële hulp.  
 
Bedankt collega’s neurochirurgen, assistenten, secretaresses, verpleegkundigen en 
OK-assistenten van de afdelingen neurochirurgie in Maastricht en Heerlen, voor de 
gestelde belangstelling in mijn onderzoek. Af en toe kwam ik tussendoor even naar 
de afdeling of de OK. Heel fijn om dan steeds maar weer de vraag te horen ‘Wanneer 
kom je nu eindelijk eens terug?’ 
 
Voor het mee lezen en schrijven aan de verschillende artikelen wil ik bedanken prof. 
dr. M. De Baets, dr. G. Kenis, C. Mencenali, dr. P. Martinez-Martinez, X. Van Wijk, O. 
Schijns en V.M. Moers-Hornikx. 
Elk jaar waren er wel een paar studenten om mij te helpen. Bedankt Benjamin Mooij, 
Daniel Keszthelyi, Julia Mescheriakova, Larissa Van Winden, Maartje Huijbers, Roos 
Kroeders, Vienna Doenni en Sandra Schipper. Niet alleen hebben jullie mij in 
praktische zin geholpen, ook hebben jullie mij scherp gehouden door steeds maar 
kritische vragen te blijven stellen.  
 
Mijn paranimfen Marlien Aalbers en Lisanne van den Hombergh. Lieve Marlien, jij 
was één van die studenten, en nu ben je ‘mijn opvolger’ in het lab. Je weet dat ik blij 
ben dat het onderzoek een vervolg krijgt. Ik ben ook blij dat jij degene bent die 
invulling geeft aan dit vervolg en ik ben trots op je als ik zie hoe je dat doet.  
Lieve Lisanne! We hebben samen al heel wat meegemaakt. Je kent mij door en door, 
staat altijd voor mij klaar en maakt mij aan het lachen. Ik ben trots op je en ben erg 
blij dat jij mijn paranimf wilt zijn.  
 
Na jaren met veel plezier in een mannen-omgeving gewerkt te hebben werd ik in het 
lab opeens omringd door allemaal lieve meisjes. Evi Lemmens, Eveline Stracks, 
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Marijke Lemmens, Rinske Vlamings, Annerieke Sierksma, Imke Van Kooten en Eva Van 
Donkelaar: bedankt voor de gezelligheid, het acrobatieken, de lunchuurtjes en 
koffiekwartiertjes, de onvergetelijke filmpjes en toneelstukjes (zie dit niet als een 
aanmoediging), en de avondjes uit die wat mij betreft nog wel even door mogen 
gaan.  
Mijn kamergenoten Lucas Ricker, Frank Dennissen, Veronique Moers en last but not 
least Ivona Brasnjevic (I wish you were here) en ik waren een vreemde combinatie 
van kolvende jonge Hollandse moeders, hard lopende en/of fietsende jonge mannen 
en a sweet and silly Serbian scientist. Hoe dan ook, het was een goede combinatie.  
Ook mijn overige collega’s in het lab wil ik bedanken voor de fijne samenwerking.  
 
Mijn lieve vriendinnen Isabelle de Kort, Maartje Van Rij, Suzanne Grooten, Katrien 
Pouls, Boukje Janssen en Claudia Vernooij: in al onze levens is in de jaren dat ik aan 
dit proefschrift werkte zo veel veranderd. Het is mooi om te zien hoe iedereen zijn 
leven leidt en om dat met elkaar te kunnen delen. Hoewel de fysieke afstand vaak 
groot is zijn jullie stuk voor stuk kleine bakens in het gewone leven geweest waaraan 
ik me van tijd tot tijd even vast kon houden. 
 
Lieve papa en mama, Amy en Wilma. Jullie zijn mijn warme nest. Toen ik jaren 
geleden uitvloog wist ik niet echt dat er neurochirurgen waren en wat promoveren 
precies inhield. Bedankt voor jullie onvoorwaardelijke liefde, hulp en steun. Daardoor 
ben ik nu waar ik nu ben. 
 
Jasper en Wouter, jullie zijn mijn basis, mijn aarde. Het is zo fijn om bij jullie thuis te 
komen elke dag.  
Liefste Jasper. Hoewel het voor mij veel belangrijker is om ‘mama’ genoemd te 
worden dan ‘dokter’ of ‘doctor’, is het heel fijn dat ik samen met jou niet hoef te 
kiezen en het allemaal kan zijn. Dankjewel.  
Liefste Wouter. Een hele grote knuffel mèt armen.  
Samen gaan we nog heel veel plezier maken en ik verheug me op de zeeën van tijd 
die we nu voor elkaar hebben. Ik hou van jullie.  
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Curriculum Vitae 
Kim Rijkers werd geboren op 8 februari 1978 in Tilburg. Na haar eindexamen VWO 
aan het Cobbenhage College te Tilburg begon ze in aan haar geneeskundestudie aan 
de Universiteit Maastricht. Na het behalen van haar artsenbul in 2002 is ze gaan 
werken als arts-assistent op de afdeling neurochirurgie van het Ziekenhuis Oost-
Limburg in Genk (B). In 2003 vervolgde ze haar arts-assistentschap neurochirurgie in 
het academisch ziekenhuis Maastricht, waar ze in 2004 aan haar opleiding tot 
neurochirurg begon (opleiders prof. E.A.M. Beuls en dr. H. Van Santbrink). Van 2006 
tot 2009 werkte ze aan het onderzoek dat geleid heeft tot dit proefschrift aan de 
‘School for Mental Health & Neuroscience’ van het Maastricht Universitair Medisch 
Centrum onder supervisie van prof. dr. J.S.H. Vles en prof. dr. H.W.M. Steinbusch. 
Samen met haar partner Jasper van Aalst kreeg zij in 2008 een zoon, Wouter. In 2009 
heeft zij haar opleiding tot neurochirurg hervat (opleider prof. dr. J.J. Van Overbeeke). 
Ze hoopt deze opleiding in 2014 af te ronden. 

